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MALARIA, THE PARASITE AND DISEASE
Malaria is a life-threatening disease caused by Plasmodium parasites that are transmitted 
from person to person by the bites of infected Anopheles mosquitoes. There are five 
Plasmodium species that can cause malaria in humans; P. falciparum, P. vivax, P. malariae, 
P. ovale and P. knowlesi [1] and two of these species, P. falciparum and P. vivax, are 
responsible for most cases of human mortality and morbidity [2]. The World Health 
Organization (WHO) report that in 2016, there were an estimated 216 million cases of 
malaria in 91 countries, an increase of 5 million cases from 2015. Malaria deaths reached 
445,000 in 2016, with a comparable number of deaths for 2015 (446,000). The WHO 
African Region carries a disproportionately high share of the global malaria burden. In 
2016, the region was accounted for 90% of malaria cases and 91% of malaria deaths [3].
The P. falciparum life-cycle
The malaria parasite is transmitted to a vertebrate host when an infected female Anopheles 
mosquito takes a blood meal and simultaneously injects sporozoites into the skin. The life-
cycle of the human malaria parasite P. falciparum is shown in Figure 1. Sporozoites migrate 
out of the skin, by locating and traversing a blood vessel whereupon they enter the blood 
stream. Sporozoites are carried to the liver where they actively invade hepatocytes; 
here, depending on the Plasmodium species, they grow and divide over 2-16 days and 
produce tens of thousands of merozoites per liver cell [4]. Merozoites exit the liver and 
enter the blood stream where they invade and multiply inside the red blood cells which 
eventually break open, allowing the parasites to infect additional red blood cells. Blood 
stage parasites continue their cycle of invading red blood cells, asexual replication, and 
then releasing newly formed merozoites repeatedly. This invasion-replication-release-
reinvasion cycle of blood stages can cause an exponential increase in infected red blood 
cells and it is the host response to parasite molecules in combination with interactions 
of infected erythrocytes with host tissue that give rise to the pathological symptoms of 
malaria. During each cycle, a small subset of asexual blood stage parasites divert from 
asexual replication and instead differentiate into male or female sexual forms, known as 
gametocytes. In the case of the human malaria parasite P. falciparum, these intracellular 
gametocytes mature and progress through stages I–V over the course of eight to ten days 
(gametocytogenesis). If taken up by a mosquito in a blood meal, the mature gametocytes 
are capable of propagating an infection in mosquitoes. Inside the mosquito midgut, male 
and female gametocytes mature into gametes (gametogenesis), with the male gametocyte 
rapidly dividing to form eight flagellated microgametes (exflagellation) and the female 
gametocyte emerges from the red blood cell and develops into a single macrogamete. 
Fertilization of a macrogamete by a microgamete results in the development of a zygote, 
which undergoes meiosis and matures into an invasive ookinete that can penetrate 
the mosquito gut wall. The ookinete forms an oocyst within which the parasite asexually 








these sporozoites travel to the salivary glands, where they can be transmitted back to 
the vertebrate host during a blood meal. 
MALARIA, THE HEALTH PROBLEM 
Nearly half of the world’s population are at risk of malaria. Most malaria cases and 
deaths occur in sub-Saharan Africa [5]. However, regions of South-East Asia, Eastern 
Mediterranean, Western Pacific, and the Americas are also at risk. In 2016, 91 countries 
had ongoing malaria transmission. Some population groups are at a considerably higher 
risk of contracting malaria and developing severe diseases than others. These include 
infants, children under 5 years of age, pregnant women and patients with HIV/AIDS, as 
Figure 1. The life-cycle of the human malaria parasite P. falciparum. P. falciparum replication and 









well as non-immune migrants, mobile populations and travelers [3]. Many prevention and 
control measures, such as the use of insecticide-treated mosquito nets, indoor spraying 
with insecticides and implementation of drug treatment programs limit both the incidence 
and spread of the infection, as well as limiting the severity of the disease. In addition, 
recent measures to improve early diagnosis and treatment of malaria has reduced disease 
and prevented deaths [6-8], and has also resulted in reducing malaria transmission. While 
these measures have contributed to a global decline in malaria, they are all under threat 
from the acquisition of development of resistance, either by Plasmodium parasites to 
antimalarial drugs or by mosquitoes to insecticides. In recent years, mosquito resistance 
to pyrethroids has emerged in many countries [9, 10] and resistance has been developed 
by the parasites against antimalarial drugs, specifically resistance against artemisinin 
which has been detected in a number of countries in South-East Asia [11, 12]. P. 
falciparum is responsible for the most severe disease and accounts for the most numbers 
of deaths and has, therefore, been the target of most antimalarial drugs and vaccine 
development efforts.
Malaria causes significant economic losses in high-burden countries. UNICEF has 
estimated that malaria costs Africa more than $12 billion annually in lost Gross Domestic 
Product (GDP), and a reduction in economic growth by more than 1% a year [13]. Malaria-
endemic countries are among the world’s most impoverished and a family can spend 
an average of over one quarter of its income on malaria treatment, as well as paying 
prevention costs and suffering loss of income [14, 15]. Despite the recent reduction in 
deaths and mortality due to malaria, it is widely believed that the most cost-effective 
means to prevent disease , and indeed disease elimination or eradication, is the mass 
administration of vaccines [16, 17]. 
MALARIA, VACCINE DEVELOPMENT
Despite major efforts over the past 70 years to develop a vaccine, there is currently no 
licensed malaria vaccine available. The most advanced malaria vaccine is the sub-unit 
vaccine RTS,S that is based on the immunodominant sporozoite surface antigen, 
circumsporozoite protein (CSP), fused to hepatitis B virus surface antigen [18]. This 
sub-unit vaccine was formulated with the potent liposomal  adjuvant  system AS01 from 
GlaxoSmithKline to target the sporozoite/liver stage of P. falciparum and has advanced to 
Phase IV clinical trials [19]. However in field studies, the efficacy of RTS,S against clinical 
malaria has been modest; between 30% and 40% in children between the ages of 5 and 
17 months [20], and vaccine efficacy rapidly declined over time [21]. Nonetheless, in 
2016 the WHO announced that the RTS,S vaccine would be rolled out in pilot projects 
in selected areas in 3 countries in sub-Saharan Africa: Ghana, Kenya and Malawi [19]. 
The limited success achieved in inducing sterile and long-lasting protective immunity 
against malaria using sub-unit vaccines has led to renewed interest in whole organism 








Whole sporozoite (wsp) vaccine approaches 
Despite three decades of testing different (recombinant) sub‐unit vaccines both in 
the clinic and the field, only modest protection against malaria infection has been achieved 
[21-24] and this has renewed an interest in whole parasite-based vaccine approaches 
[25, 26]. Sporozoite-based vaccination strategies aim at preventing the parasite’s life-
cycle progression from hepatic stages to the symptomatic blood stages of infection 
while eliciting potent pre-erythrocytic immune responses. Such whole sporozoite malaria 
(wsp) vaccination strategies are unique in their potential to induce sterile protection 
against a new infection and have led to the development of various vaccine candidates, 
currently undergoing preclinical and clinical development. It was the discovery of the pre-
erythrocytic stages of Plasmodium [7], followed by the establishment of a mouse model 
of malaria [8], that enabled the laboratory production of all stages of the parasite’s 
life-cycle [9], which eventually led to the landmark demonstration that live sporozoites 
attenuated by X-irradiation (RAS) could be used to elicit sterile protection against a new 
infection [10, 11]. This discovery was soon expanded to humans with the demonstration 
that volunteers could be protected against homologous and heterologous strains of P. 
falciparum parasites by immunization of live, attenuated sporozoites [12–14]. The success 
of these studies in both animal malaria models and humans resulted in a large number 
of subsequent studies that were aimed at optimizing sporozoite-based immunization 
and to characterize the immune responses elicited by these strategies [15–20]. However, 
the production and administration of live sporozoites attenuated by irradiation (Irr-Spz) 
was considered to be a major obstacle to the development of sporozoite vaccines at 
the end of the 20th century and efforts focused more on the characterization of sub-unit 
vaccine that targeted different points of the parasite life-cycle. However, as the reduced 
efficacy of sub-unit vaccines became increasingly evident, at the beginning of the new 
century, a renewed call for the development of sporozoite-based immunization strategies 
took place. In the early part of this century malaria research entered the genomic era, with 
genome sequences of various Plasmodium parasite species becoming available, as well 
as transcriptomic and proteomic datasets from different parasite developmental stages 
[42–48]. This information was used to identify genes that play essential roles in distinct 
points of the parasite’s life-cycle, and these were targeted for deletion using increasingly 
sophisticated methodologies for stable transfection of Plasmodium parasites [49–55]. 
This in turn, resulted in the generation of genetically attenuated parasites (GAPs), whose 
liver-stage development is arrested by deletion of specific gene(s). Studies in rodents 
demonstrated that GAPs, like irradiated sporozoites, were able to elicit a strong immune 
protection [56–58]. Informed by GAP studies performed in rodent models, the first P. 
falciparum GAPs were developed, with some now entering into clinical development as 








Improving wsp vaccine approaches: the aim of the studies described in 
this thesis
A number of studies have shown that Irr-Spz can generate strong protective immunity in 
humans [27-29]. However, in order to achieve sterile immunity, multiple immunizations 
with high numbers of attenuated sporozoites are required [27, 30]. These high numbers of 
sporozoites has cost-of-goods implications and increases the burden on the complicated 
sporozoite production procedure, which can result in limitations in the practical mass 
administration of such vaccines in malaria-endemic countries.
The major challenge for sporozoite-based vaccines is to produce a highly immunogenic 
live-attenuated vaccine, which requires the fewest attenuated sporozoites per dose and 
the fewest doses in order to induce sustained sterile protection against malaria in the field. 
In rodent models of malaria it has been shown that immunization with sporozoites of 
GAPs can induce similar, or even better, levels of protective immunity compared to Irr-Spz 
[31-34]. Genetic attenuation of sporozoites has been achieved through the deletion of 
one or more genes that play a critical role during liver stage development, resulting in 
complete arrest of parasite growth in the liver, thereby preventing a blood stage infection 
after immunization with GAP sporozoites. An advantage of GAP compared to Irr-Spz 
vaccination, is that GAP sporozoites are genetically homogenous with defined genetic 
identity and attenuation phenotype, and GAPs can be further modified to induce optimal 
protective immunity.
GAPs have additional advantages over Irr-spz, in particular in manufacturing. GAP 
sporozoites do not need to be irradiated before they are vialed and their production poses 
little risk to the individuals who produce the vaccine as, GAP sporozoites are unable to 
establish a pathogenic blood stage infection [32-34]. 
GAP studies performed in rodent malaria models have been critical for the creation 
of several P. falciparum GAP vaccines, which are undergoing clinical evaluation [35-39]. 
Studies in rodents have also been used to identify the immunological basis of GAP-induced 
immune responses and to improve GAP immunogenicity [33, 34, 37]. While the precise 
mechanisms of protection mediated by immunization with attenuated sporozoites remain 
unknown, T cells appear to be critical for protection and in particular CD8+ T cells are 
thought to play a major role in eliminating infected hepatocytes. Early rodent studies 
using Irr-Spz have demonstrated a vital role for CD8+ T cells [40, 41]. Recent mechanistic 
investigations into protective immune responses induced by immunization with attenuated 
sporozoites have demonstrated diverse and robust immune responses that encompasses 
both CD8+ and CD4+ T cells, as well as a significant contribution from antibodies [42, 
43]. Nonetheless, CD8+ T cells are considered to be the main effector cells in eliciting 
protection after sporozoites immunization [44].
In this thesis we describe a set of studies performed in rodent models of malaria to 
improve malaria vaccines, in particular GAP vaccines. We attempted to increase GAP 








encoding putative immunomodulatory proteins in the GAP genome to create ‘self-
adjuvanting’ parasites; (iii) generating GAPs that arrest late into liver-stage development 
(LA-GAP) to increase antigen load and diversity during immunization; and (iv) exploring 
possibilities to genetically modify parasite to express vaccine antigens from different life-
cycle stages, in order to test the ability of parasites to induce immune responses against 
multiple life-cycle stages and to inform the creation of a ‘multi-stage’ GAP vaccine.
Outlined below is the rationale for choosing the different adjuvants, putative 
immunomodulatory proteins, the different approaches to generate LA-GAPs and parasites 
engineered to express additional vaccine candidate antigens. We have used well 
established rodent malaria models [31, 45, 46] in combination with standard and adapted 
protocols for immunization [46, 47] in order to evaluation of protective immune responses 
induced by the different GAPs and immunization approaches.
Transgenic parasites and malaria vaccine research (Chapter 2)
Chapter 2 reviews the use of transgenic malaria parasites in vaccine research. Genetic 
modification of rodent and human malaria parasites have been critical for generation of 
GAPs that arrest in the liver and transgenic rodent malaria parasites have been extensively 
used for testing the safety and immunogenicity of GAPs [33, 34, 37]. Many gene-deletion 
rodent parasites have been tested in mice to examine growth and arrest in the liver and 
for their capacity to induce potent protective immune responses. Many GAPs have been 
created in transgenic reporter lines that express fluorescent and/or luminescent proteins, 
which permits an in vivo, real-time, evaluation of both their arrest characteristics and 
protective efficacy. In order to generate completely safe GAP vaccines, GAPs must be 
generated that completely arrests in the liver. Consequently, multiple gene deletions in 
the same GAP are considered necessary, each governing independent, but essential, 
processes during liver-stage development. Therefore, in order to generate and test 
a P. falciparum GAP in human test subjects, large-scale screening of single and multiple 
gene-deletion mutants in rodents is necessary to identify suitable genes for deletion in P. 
falciparum.
In this thesis we use a variety of well-established and genetic modification technologies 
to create a variety of (transgenic) rodent malaria parasite mutants. Specifically, we have 
generated transgenic ‘self-adjuvanted’ GAPs (Chapter 4), gene-deletion late-arresting 
GAPs (Chapter 5) and transgenic parasites expressing additional Plasmodium vaccine 
antigens (Chapter 6). In studies where we examined if exogenous adjuvants could improve 
GAP immunogenicity (Chapter 3) as well as in the studies in Chapters 4 & 5, we made 
use of transgenic parasites that express luminescent and fluorescent reporter proteins to 








Improving GAP immunization by the addition of immunostimulatory 
molecules (Chapter 3)
Protection against a malaria infection can be achieved by immunization with live-
attenuated Plasmodium sporozoites. While the precise mechanisms of protection remain 
unknown, T cell responses are thought to be critical in the elimination of infected liver 
cells. Only a limited number of studies have been performed on the effect of adjuvants 
on protective immunity induced by whole sporozoite immunization. In particular, the use 
of the glycolipid α-galactosylceramide (α-GalCer) [48] and its analog 7DW8-5 have been 
analyzed [49]. Co-administration of these molecules with sporozoites resulted in enhanced 
recruitment and activation/maturation of dendritic cells in lymph nodes draining the site 
of vaccine administration and thereby enhancing parasite-specific T cell immunogenicity. 
Recently, cancer immunotherapies have employed antibodies that target proteins on 
the surface of T cells, as treatment with these antibodies have been shown to restore, 
expand and enhance the function of tumour-reactive T cells. The antagonistic antibodies 
targeting CTLA-4 and PD-1 have been used to block inhibitory signals to T cells [50, 
51], while agonistic antibodies targeting CD27, OX40 and 4-1BB on CD4+ and CD8+ T 
cells have been used to increase costimulatory signals [52-54]. These immunostimulatory 
antibodies have been shown to improve the control of tumors and this was associated 
with an increase in tumor-specific T cell function [55]. In Chapter 3, we describe studies 
that examine if agonistic OX40 monoclonal antibody (OX40 mAb) treatment improved 
protective immunity in mice, induced by immunization with a late-arresting GAP. We 
immunized BALB/c mice using sporozoites of a P. yoelii GAP, an established rodent model 
to evaluate GAP vaccination [31]. In addition, we describe the development of a GAP 
immunization protocol in BALB/c mice that permits a rapid screening and evaluation of 
different approaches to enhance GAP protective immunity in BALB/c mice.
Improving GAP immunogenicity by creating ‘self-adjuvanting’ parasites 
that also express putative immunomodulatory molecules (Chapter 4)
As described in Chapter 3, GAP immunization in combination with exogenous adjuvants 
provides useful information about mechanisms underlying protective immunity. However, 
the use of such adjuvants in populations where malaria is endemic may be difficult due 
to cost-of-goods, applicability or side-effects. Further, induction of protective immune 
responses by GAP immunization is dependent on sporozoites migrating to the liver and 
invading hepatocytes. The administration of adjuvants at the site of GAP injection will 
result in systemic distribution of the adjuvant which will therefore be considerably diluted 
at the sites where parasite antigens are taken up by antigen presenting cells (APCs), i.e. 
the liver, spleen or proximal lymph nodes [56]. In order to maximize the adjuvant effect, 
i.e. the increase of antigen uptake by APCs and providing stimulatory signals to enhance 
APC function, it is important to maximize the adjuvant effect at the point of antigen uptake 








Due to the limitations of co-injecting adjuvants with attenuated sporozoites, we 
explored in Chapter 4 the possibility of creating GAPs that express immunomodulatory 
proteins in sporozoites and liver stages, so-called adjuvant GAPs [58-61]. Self-adjuvanting 
vaccines, in which the antigenic and adjuvanting moieties of the vaccines are present in 
the same molecule, have been developed for sub-unit vaccines targeting cancer cells, 
viruses [62, 63], nematodes [64] and bacteria [65, 66], for example by conjugation of 
lipopeptide-based Toll-like receptor (TLR) agonists to the target protein [61]. In vaccine 
development against malaria, the vaccine candidate antigen CSP has been fused to 
bacterial flagellin [67], a protein which is a potent TLR5 agonist [68]. However, to the best of 
our knowledge, no sporozoite-based vaccine has been reported that expresses additional 
immunomodulatory/adjuvant molecules [33, 37].
We selected four TLR agonists that can increase adaptive immune responses and have 
the ability to improve cross-presentation of antigens as has been demonstrated in other 
animal and/or human studies. The selected adjuvant proteins are: (i) nontoxic cholera toxin 
B sub-unit from Vibrio cholerae (CTB) [69, 70]; (ii) heat shock protein Gp96 of mice (Gp96) 
[71-73]; (iii) heat shock protein X from Mycobacterium tuberculosis (HspX) [74, 75]; and 
(iv) the TLR5 binding region of Salmonella typhimurium flagellin (amino acids 89–96; FliC) 
[68, 76, 77].
To facilitate the generation of multiple ‘self-adjuvanting’ lines in P. yoelii LA-GAP, we 
generated a GIMO locus in the P. yoelii fabb/f gene locus, thereby creating a novel P. 
yoelii GIMO GAP mother line. This line was used for the rapid introduction of the adjuvant 
fusion-transgenes into the P. yoelii genome without retention of a drug selectable marker 
(SM). The genes encoding the ‘adjuvant’ proteins were fused to a Plasmodium gene 
expressed in liver stages, uis4 (PY17X_0502200). UIS4 is located at the parasitophorous 
vacuole membrane (PVM) in infected hepatocytes [78]. We fused the adjuvant proteins 
to a PVM protein as it has been shown that ovalbumin (OVA) fused to proteins located in 
the PV/PVM induce stronger T cell responses than ovalbumin expressed in the cytoplasm 
of transgenic parasites [79, 80]. The fusion genes were introduced by GIMO transfection 
[81, 82] into the novel GIMO GAP mother line. The four adjuvant GAP were analyzed for 
protective immunity using the P. yoelii-BALB/c screening model for assessing protective 
immunity after GAP immunization [45]. This model is described in Chapter 3, where we 
describe analyses on protective immunity induced by immunization of GAP in combination 
with the exogenous adjuvant OX40. 
The generation and characterization of novel late-arresting GAPs (LA-
GAPs) (Chapter 5) 
It has been shown that immunization of mice with GAP that arrest late during liver stage 
development can induce higher levels of protective immunity compared to immunization 
with GAP that arrest early after invasion of hepatocytes. Specifically, it has been shown 
that late-arresting GAP (LA-GAP) induce greater numbers of a broader range of CD8+ 








immunization with early-arresting GAPs [31], most probably due to a greater number and 
repertoire of antigens expressed by LA-GAP. This may also explain the high degree of 
protection observed when humans are immunized by fully infectious sporozoites under 
chemoprophylactic treatment with chloroquine [83, 84]. In this immunization approach, 
liver stage development progresses normally but the merozoites that are released 
from the liver and infect erythrocytes are killed by chloroquine. This whole sporozoite 
vaccination approach induces sterile protection against parasite challenge, but requires 
approximately 60-fold- fewer cumulative sporozoites than immunization with Irr-Spz that 
arrest early during liver stage development [85].
A prerequisite for a GAP vaccine for human use is that the GAP sporozoites are unable 
to establish a potentially pathogenic blood stage infection and therefore parasites must 
completely arrest during development in the liver. Consequently, multiple gene deletions 
in the same GAP are considered necessary, each governing independent but essential 
processes during liver-stage development. Currently, three P. falciparum GAPs have been 
developed for clinical evaluation and all are early-arresting GAPs, that arrest development 
soon after hepatocyte invasion. In these GAPs either two or three genes have been 
deleted, which encode proteins that play a vital role in early liver stage development. 
Three of the selected proteins, P52, P36 and B9, are all members of the so-called 6-Cys 
gene family and all participate in the formation/maintenance of the parasitophorous 
vacuole (PV) inside the infected hepatocyte [86, 87]. The fourth protein, SLARP/SAP1, 
is involved in regulation of parasite gene expression [88, 89]. In contrast to the creation 
of early arresting-GAPs, the generation of safe LA-GAPs have been challenging. Several 
genes have been identified that encode proteins that play an important role during late 
liver stage development but deletion of those genes did not result in complete growth 
arrest in rodent models of malaria. Examples include multiple proteins involved in type 
II fatty acid synthesis pathways (FAS II, i.e. Fab proteins) [90, 91], a transcription factor 
with AP2 domain(s) (AP2-L) [92], biotin-protein ligase 1 (HCS1) [93] and proteins involved 
in formation and egress of merozoites from liver schizonts, i.e. liver merozoite formation 
protein (PALM) [94], putative liver stage protein 1 (LISP1) [95, 96], sequestrin or liver-specific 
protein 2 (LISP2) [86] and ZIP domain-containing protein (ZIPCO) [97]. Only the deletion of 
the genes encoding FabB/F [90] and MEI2-like RNA-binding protein (PlasMei2) [98] have 
been reported to result in complete growth arrest in the rodent parasite P. yoelii. However, 
studies in P. falciparum have shown that parasites lacking FabB/F expression are unable to 
complete mosquito stage development [99]. 
In order to create an LA-GAP that completely arrests late into liver stage development 
and cannot establish a blood infection, we describe in Chapter 5 studies where we create 
double gene deletion mutants using combinations of different genes that have a role 
in late liver stage development and could synergize to create fully arrested GAPs. We 
describe attenuation evaluation studies as well as immunogenicity testing of LA-GAPs to 








Generation of transgenic parasites expressing antigens from other life-
cycle stages (Chapter 6)
The creation of GAPs expressing vaccine antigens from either different parasite life-
cycle stages or strains could improve GAP vaccine potency by providing stage and strain 
transcending immunity, respectively. In order to establish if transgenic parasites can 
express additional proteins and if these antigens are able to provoke immune responses, 
we examined if P. berghei parasite could be used to express the P. falciparum transmission 
blocking vaccine candidate antigen, Pfs48/45. We expressed Pfs48/45 in P. berghei blood 
stages, as they are easier to produce than sporozoites, and next we examined if these 
blood stage parasites could be used to provoke antibody responses against Pfs48/45. 
Efficient and conformationally-accurate expression of Plasmodium proteins in 
heterologous systems, such as yeast or bacteria, is frequently problematic resulting in 
misfolded or incorrectly modified proteins, which are often poorly expressed [100, 101]. 
This hampers the screening of Plasmodium antigens in immunization studies for their 
suitability as vaccine candidate antigens. Preclinical evaluation of Plasmodium antigens 
often involves immunizing rodents with recombinant Plasmodium proteins followed by an 
examination of induced immune responses, either in vivo using rodent models of malaria 
or in vitro by performing functional assays with human malaria parasites incubated with 
immune sera [46]. Transgenic rodent malaria parasites (RMP) expressing human malaria 
parasite (HMP) antigens are increasingly used to evaluate and rank the order of candidate 
malaria vaccines before investing in scalable manufacture to support advancement to 
clinical testing [46]. 
We reasoned that the use of transgenic RMP expressing HMP proteins for production 
of HMP proteins would circumvent the above-mentioned problems associated with 
expression in heterologous expression systems including peculiarities of post-translational 
modifications and Plasmodium-specific domains involved in protein trafficking and cellular 
location. As a proof of concept we explored in Chapter 6 the possibility of expressing an 
antigen, Pfs48/45 of gametocytes of the human malaria parasite P. falciparum in blood 
stages of the rodent parasite P. berghei. Expression of Pfs48/45 for transmission blocking 
immunization studies has been problematic in most commonly used expression systems, 
mainly due to incorrect or insufficient protein folding, which is dependent on the correct 
formation of disulfide bridges in this cysteine-rich protein [102, 103]. 
The creation of transgenic parasites that express antigens from multiple life-cycles that 
can induce potent immune responses is also of interest to the development of whole 
organism vaccines [32]. GAPs could be further modified to induce immune responses 
against multiple life-cycle stages by expression in GAPs blood- or transmission-stage 
antigens to produce a multi-stage GAP vaccine. In Chapter 6 we describe studies 
analyzing expression of Pfs48/45 in P. berghei blood stages and the immunogenicity of 
P. berghei expressed Pfs48/45 by performing assays to measure transmission-reducing 









In Chapter 7 the results of the studies described in Chapters 2-6 are summarized 
and discussed, including a discussion on the composition of the ‘next generation’ GAP 
vaccine and challenges of creating a GAP vaccine that needs to induce strong, sustained 
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Transgenic malaria parasites expressing foreign genes, for example fluorescent and 
luminescent proteins, are used extensively to interrogate parasite biology and host-
parasite interactions associated with malaria pathology. Increasingly transgenic parasites 
are also exploited to advance malaria vaccine development. 
Areas Covered
We review how transgenic malaria parasites are used, in vitro and in vivo, to determine 
protective efficacy of different antigens and vaccination strategies and to determine 
immunological correlates of protection. We describe how chimeric rodent parasites 
expressing P. falciparum or P. vivax antigens are being used to directly evaluate and rank 
order human malaria vaccines before their advancement to clinical testing. In addition, we 
describe how transgenic human and rodent parasites are used to develop and evaluate 
live (genetically) attenuated vaccines. 
Expert Commentary
Transgenic rodent and human malaria parasites are being used to both identify vaccine 
candidate antigens and to evaluate both sub-unit and whole organism vaccines before they 
are advanced into clinical testing. Transgenic parasites combined with in vivo pre-clinical 
testing models (e.g. mice) are used to evaluate vaccine safety, potency and the durability 










In the mid-nineties genetic modification to create permanent modifications in malaria 
parasite genomes was first described in the rodent malaria parasite Plasmodium berghei[1]. 
This technology was extended to other Plasmodium species, including the human 
malaria parasite P. falciparum, and was initially used for loss-of-function analyses to 
uncover the function of Plasmodium genes, including genes encoding potential vaccine 
candidate antigens (reviewed in[2, 3]). In addition to gene-disruption and gene-mutation, 
methodologies have been developed to create malaria parasites that express ‘foreign’ 
genes from other organisms, so called transgenic parasites. Amongst the first transgene 
mutants were rodent malaria parasites that expressed fluorescent and luminescent 
reporter proteins. These parasites have been used to visualize and analyze parasite growth 
and development in vitro and in vivo and have been valuable tools to analyze cellular 
and molecular features of malaria parasite biology (reviewed in [4, 5, 6, 7]). Transgenic 
rodent parasites have also been used to provide mechanistic insights into host-parasite 
interactions that regulate host (immune) responses to infection or those that mediate 
malarial pathology [8, 9, 10, 11, 12, 13]. 
Transgenic parasites expressing fluorescent or luminescent reporter proteins have 
been created in rodent malaria species, the human parasite P. falciparum and the primate 
parasite P. cynomolgi. These parasites have been exploited in screening assays to measure 
(inhibition of) parasite growth at different points of the parasite life-cycle. Fluorescent 
and luminescent P. falciparum parasites have been used in vitro to examine the effect of 
drugs and other inhibitors on blood stage growth and on gametocytes[6, 14, 15, 16, 17]
and fluorescent P. cynomolgi parasites have been generated to screen for compounds that 
target the hypnozoite stage in the liver[18]. Transgenic fluorescent and luminescent rodent 
parasites have been used in in vitro screening assays to test inhibitors that target parasite 
development in the blood and liver [6, 19, 20, 21, 22].  
In addition to measuring growth inhibition in vitro, transgenic rodent parasites have 
been used to examine the impact of drug or vaccine interventions in vivo, where inhibition 
of parasite development is measured as the reduction of reporter signal(mostly luminescent) 
in organs of the treated (compared to unimmunized/untreated) rodent host[6, 17, 19, 22, 
23]. As the life-cycle and basic biology of rodent and human Plasmodium parasites are 
very similar and since the vast majority of genes within their genomes are conserved [24], 
transgenic rodent parasites are frequently used to evaluate protective immunity against 
candidate Plasmodium antigens in vivo and are used to assess different vaccine delivery 
platforms and vaccination regiments. Several of these studies have been conducted 
in different inbred mice strains that exhibit different, often polarized, immunological 
responses to infection. Transgenic rodent parasites have been used in preclinical studies 
to examine protective immune responses to pre-erythrocytic (sporozoite and liver stage) 








More recently transgenic rodent parasites have been generated that express proteins 
of the human Plasmodium species P. falciparum and P. vivax. These so-called ‘chimeric’ 
parasites have been used to evaluate the (in vivo) action of drugs against human 
Plasmodium protein targets [25, 26], to study malaria pathology during pregnancy, in vivo 
[27] and to evaluate the protective efficacy of vaccines that target human Plasmodium 
antigens (reviewed in [28, 29, 30] and see Table 1). In these vaccine studies, mice are 
immunized with P. falciparum or P. vivax antigens and subsequently challenged with 
chimeric rodent parasites expressing the cognate P. falciparum or P. vivax antigens. Such 
chimeric parasites permit an in vivo immunological evaluation of novel target Plasmodium 
antigens and vaccination strategies and can indicate the magnitude and type of protective 
immune response induced. This knowledge can be used to down-select from candidate 
antigens under consideration before proceeding to clinical studies [31].
Lastly, genetic modification of rodent and human malaria parasites has also been used 
to generate parasites that arrest in the liver. These parasites can provoke strong protective 
immune responses in the host and are therefore being evaluated as live, attenuated vaccines 
[32, 33, 34].Many gene-deletion rodent parasites have been tested in rodents for growth-
arrest in the liver and for their capacity to induce potent protective immune responses. 
These so called genetically attenuated parasites (GAPs) have been created in transgenic 
reporter lines, which simplifies the in vivo evaluation of both their safety and protective 
efficacy. In order to generate completely safe GAP vaccines, GAPs must be generated that 
completely arrests in the liver. Consequently, multiple gene-deletions in the same GAP 
are considered necessary, each governing independent but essential processes during 
liver stage development. Therefore, in order to generate and test a P. falciparum GAP in 
human test subjects, large scale screening of single and multiple gene-deletion mutants in 
rodents is necessary to identify suitable genes for deletion in P. falciparum. 
In this review we describe the use of transgenic malaria parasites and their use as 
preclinical evaluation tools to measure vaccine efficacy and immune responses after 
vaccination. We describe: (i) transgenic rodent and human parasites that express reporter 
proteins that have been used to evaluate immunogenicity of vaccine antigens and vaccine 
efficacy; (ii) the use of transgenic chimeric rodent parasites, expressing antigens of P. 
falciparum or P. vivax, to compare immunogenicity of vaccines and vaccine strategies; 
and (iii) the use of transgenic parasites to identify and evaluate genetically attenuated 
parasite(GAP) vaccines and to examine immunological correlates of protection after 
vaccination in vivo.
TRANSGENIC PARASITES EXPRESSING REPORTER 
PROTEINS
Transgenic rodent and human malaria parasites that express fluorescent and luminescent 
reporter proteins have been used in screening assays to efficiently and rapidly measure 








Table 1. Transgenic rodent and human malaria parasites used in malaria vaccine research





A number of RMP expressing different fluorescent reporter proteins have been used 
to quantify parasite growth of different life cycle stages and to analyze interactions 




A number of different luminescent reporter RMP have been generated that have 
been used to quantify parasite growth of different life cycle stages, both in vitro 
and in vivo (see Sections2and 4 for references)a
Ovalbumin 
(OVA)
Several  OVA-expressing RMP have been used to analyze interactions of 
the parasite with the host immune system (see Sections2and 4 for references)a
Transgenic P. falciparum parasites expressing reporter proteins
Reporter Remarks
GFP GFP-expressing P. falciparum parasites have been used in GAI assays [16]
Luciferase Luminescent P. falciparum parasites have been used to quantify inhibition of oocyst 
production in SMFA assays [14]




P. vivax gene Remarks
RMgm 
ID Ref
PfLSA-1 PF3D7_1036400 Additional copy; Pf (NF54) gene under the control 
of Pbuis4 promoter; in Pb (ANKA)
#1314 [31]
PfLSA-3 PF3D7_0220000 Additional copy; Pf (NF54) gene under the control 
of Pbuis4 promoter; in Pb (ANKA)
#1315 [31]
PfCelTOS PF3D7_1216600 Additional copy; Pf (NF54) gene under the control 




PF3D7_1302200 Additional copy; Pf (NF54) gene under the control 
of Pbuis4 promoter; inPb (ANKA)
#1311 [31]
PfLSAP1 PF3D7_1201300 Additional copy; Pf (NF54) gene under the control 
of Pbuis4 promoter; inPb (ANKA)
#1308 [31]
PfLSAP2 PF3D7_0202100 Additional copy; Pf (NF54) gene under the control 
of Pbuis4 promoter; inPb (ANKA)
#1312 [31]
PfETRAMP5 PF3D7_0532100 Additional copy; Pf (NF54) gene under the control 
of Pbuis4 promoter; inPb (ANKA)
#1309 [31]
PfFalstatin PF3D7_0911900 Additional copy; Pf (NF54) gene under the control 
of Pbuis4 promoter; inPb (ANKA)
#1313 [31]
PfCSP PF3D7_0304600 Additional copy; Pf (NF54) gene under the control 
of Pbuis4 promoter; inPb (ANKA)
#1316 [31]
PfTRAP PF3D7_1335900 Additional copy; Pf (NF54) gene under the control 
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P. vivax gene Remarks
RMgm 
ID Ref
PfCSP PF3D7_0304600 Replacement copy; Pb (ANKA)csp replaced 
by Pf(Wellcome strain) csp, full-length Pbcsp 
promoter & 302bp Pbcsp3’UTR.
Reduced sporozoite production
#69 [73]
PfCSP PF3D7_0304600 Replacement copy; Pb (ANKA) csp replaced by 
Pf(NF54) csp under control of endogenous Pbcsp 
promoter and 3’UTR; No drug selectable marker.
Normal sporozoite production and infectivity
#4110
PfCSP PF3D7_0304600 Replacement copy;Py (17XNL) csp replaced with 
Pf (3D7) csp. Human DHFR selectable marker. 
Pbhsp70 3’UTR
Normal sporozoite production and infectivity
#1442 [96]
PfTRAP PF3D7_1335900 Replacement copy;Pb (ANKA)trap replaced by 
Pf(NF54)  trap  under control of endogenous 
Pbtrap  promoter and 3’UTR; No drug selectable 
marker
Normal sporozoite production and infectivity
#4112
PvTRAP PVP01_1218700 Replacement copy;Pb (ANKA) trap replaced with 
Pv (Sal-1) trap. No selectable marker. 
Normal sporozoite production and infectivity
#1103 [97]
Pv25 PVX_111175 Replacement copy; Pb25 and Pb28 replaced with 
Pv  25; in Pb (ANKA)
#222 [49]
Pf25 PF3D7_1031000 Replacement copy; Pb25 and Pb28 replaced with 
Pf25; in Pb (ANKA)
#273 [50]
PfCelTOS PF3D7_1216600 Replacement copy; Pb (ANKA) celtos replaced 
by Pf (NF54) celtos under control of endogenous 
Pbceltos promoter and 3’UTR; No drug selectable 
marker




PVX_119355 Replacement copy; Pb (ANKA) csp replaced by 
PvVK210 csp under control of endogenous Pbcsp 
promoter and 3’UTR; No drug selectable marker




PVX_119355 Replacement copy; Pb (ANKA) csp replaced by 
Pv VK247 csp under control of endogenous Pbcsp 
promoter and 3’UTR; No drug selectable marker
Normal sporozoite production and infectivity
[77]
PvCelTOS PVX_123510 Replacement copy; Pb (ANKA) celtos replaced by 
Pvceltos under control of endogenous Pbceltos 
promoter and 3’UTR; No drug selectable marker 
Normal sporozoite production and infectivity
#4111 [75]
Rodent malaria parasites expressing HMP-RMP fusion proteinsb
CSP PF3D7_0304600 The repeat region of Pb(NK65) csp is replaced 













P. vivax gene Remarks
RMgm 
ID Ref
MSP1 PF3D7_0930300 The Pb (ANKA) msp-1_19 C-terminal replaced 
with the Pf (D10)  msp-1_19 C-terminal
#201 [78]
MSP1 PF3D7_0930300 ThePb(ANKA)  msp-119 C-terminal replaced with 
the Pf (FCC1/HN)  msp-1_19 C-terminal
#330 [99]
CSP (VK210) PVX_119355 The repeat region of Pb (ANKA) csp is replaced 
with the  Pv (210) csp repeat region. 
#906 [100]
CSP (VK210) PVX_119355 The repeat region ofPb (ANKA) csp is replaced 
with (part of) Pv (210) csp gene
#1104 [47]
CSP (VK247) PVX_119355 The majority of Pb (ANKA) csp gene is replaced 
with Pv (247) csp; the fusion gene retains Pb signal 
sequence (1-20aa) and Pb GPI anchor sequence 
(372-395aa) 
#1443 [101]
P25 PVX_111175 The Pb (ANKA)25 and 28 genes replaced with 
a fusion of Pv25 and Pb 25
#223 [49]
VAR2CSA PF3D7_1200600 A synthetic Pf 3D7 DBL1X-6ε gene (var2csa) fused 
to Pb (ANKA) fam-a
#1436 [27]
Genetically Attenuated Parasites (GAPs)
See Section 4 for details (and references) of transgenic parasites used to generate and test  
GAP vaccines
aFor full list of transgenic reporter parasites generated in RMP see the RMgm Database www.pberghei.eu
bPlasmodium species abbreviations: Pf - P. falciparum; Pv- P. vivax; Pb- P. berghei; Py- P. yoelii
These assays have been used to identify and characterize anti-Plasmodium drugs and 
small molecule inhibitors, as well as vaccines targeting parasite development at different 
points of the life-cycle. Transgenic parasites expressing fluorescent or luminescent 
proteins have been generated in three rodent malaria parasites (RMP), P. berghei, P. 
yoelii and P. chabaudi. For P. berghei and P. yoelii a number of transgenic lines exist that 
express different reporter proteins such as GFP, mCherry or luciferase (or fusions thereof). 
Most of these lines express these proteins under control of Plasmodium promoters of 
constitutively expressed Plasmodium genes (often housekeeping genes), which creates 
parasites that can be visualized and quantified throughout the complete life cycle 
(Figure 1A,B). Frequently used promoter regions of RMP genes include elongation factor 
1-apha (eef1α), dihydrofolatereductase-thymidylate synthase (dhfr-ts) or heat shock 
protein 70 (hsp70). Information on all published RMP transgenic lines can be found in 
the RMgm database of genetically modified rodent parasites (www.pberghei.eu).
Different assays have been developed to quantify parasite growth using reporter 
parasites. To test the effect of inhibitors on blood and liver stage growth, simple and rapid 
assays exist that can quantify parasite numbers in blood samples, infected hepatocytes 








positive parasite-infected red blood cells [20, 36, 37] (Figure 1A) or quantification of 
luminescence signals to determine parasite numbers or parasite loads in blood, liver 
or other organs [19, 21](Figure 1B). Infecting mice with defined numbers of luciferase 
expressing parasites and subsequent quantifying parasite loads (luminescence signal) in 
the liver by real time imaging of live mice is frequently used to establish the in vivo effect of 
either inhibitors and vaccines on liver stage development [6, 17, 22, 23]. Bioluminescence 
imaging is simple to execute and can be used to monitor the course of an infection without 
sacrificing the animal [19] (Figure 1B). This reduces the number of animals required for 
experimentation because multiple measurements can be made in the same animal over 
time that also minimizes the effects of biological variation. In addition, since imaged 
mice do not have to be sacrificed, additional features of parasite development can be 
established, for example characteristics of the ensuing blood stage infection such as 
the prepatent period, i.e. the duration between sporozoite infection and a microscopically 
detectable blood infection. Bio-luminescence imaging is a proven and sensitive method 
to measure parasite liver loads in mice, even after infection with low sporozoite doses. It 
has been shown that parasite liver loads can still be determined even after inoculation of 
1-10 sporozoites and that in vivo imaging quantification of parasite loads correlates very 
Figure 1. The use of transgenic reporter parasites in malaria vaccine research. (A) Representative 
fluorescent images of different life cycle stages of P. falciparum and P. berghei (mCherry and GFP) 
reporter parasites. Blood stage trophozoites (Tr); schizonts (Sc); dissected infected mosquito midguts 
(Mid) with mature oocysts (Oo); salivary gland sporozoites (Spz); P. berghei liver stage schizont (LS). 
Host and parasite DNA are stained with Hoechst or DAPI (blue). (B) Representative rainbow images of 
luminescence intensity in blood (upper panels) or liver (bottom panels) of live mice either uninfected 
(U) or infected (I) with luminescent reporter parasites. Parasite density (luminescence intensity) can 
also be determined in extracted tissue (ex vivo); lungs (lg), kidney (K), adipose/fat tissue (F), liver 
(Lv), spleen (S), brain (B) and heart (H). Bottom panel shows luminescence in extracted livers of 
infected and uninfected mice, 48 h after infection with sporozoites. (C) Schematic representations 
showing the use of transgenic reporter parasites in assays to determine efficacy of erythrocytic, 
transmission blocking (TB) and pre-erythrocytic (sporozoite and liver stage) vaccines. Erythrocytic 
Vaccines: The inhibitory activity of sera from (semi) immune individuals or purified immunoglobulins 
from vaccinated animals/people on parasite invasion and growth in red blood cells are frequently 
determined in Growth Inhibition Assays (GIA). GFP expressing P. falciparum parasites have been 
used in GIA where inhibition of parasite growth was determined by measuring parasitemia by flow 
cytometry. Transmission Blocking Vaccines: The standard membrane-feeding assay (SMFA) is a well-
established method to evaluate the activity of antibodies/serum against human malaria parasites 
in the mosquito, mainly quantified by determination of oocyst production. A transgenic reporter 
P. falciparum line expressing luciferase have been used in SMFA to quantify oocyst production in 
mosquitoes, thus eliminating the need for mosquito dissections. Pre-erythrocytic (sporozoite and liver 
stage) Vaccines: Assays employing luciferase-expressing RMP have been developed to visualize and 
quantify liver stage development. Quantification of parasite liver loads by real time imaging has 
been performed in vaccinated and unvaccinated mice that have been challenged with luminescent 
parasites that either only express luciferase (e.g. in GAP studies; Section 4) or also express human 








well with qPCR quantification methods [38]. The sporozoite doses used in different studies 
vary according to the vaccines being tested. Specifically, when examining potential GAP 








to establish if these parasites completely arrest in the liver, an essential and critical safety 
requirement of a live-attenuated vaccine. In addition, mice immunized with GAP parasites 
(see below) are often challenged with relatively high doses of WT parasites (i.e. 1x104), in 
order to test the protective efficacy of different GAP vaccines and vaccination regiments. 
In sub-unit vaccine studies mice are usually challenged with lower doses of sporozoites 
(1-3 x 103), a dose reflective of 1-5 mosquito bites, after which parasite liver loads 
are established.
As well as transgenic RMP lines, reporter parasites have been generated for the human 
parasite P. falciparum. Transgenic P. falciparum parasites expressing fluorescent or 
luminescent proteins have been used to quantify blood stage growth in vitro in standard 
growth inhibition assays(see below),to quantify parasite development in the mosquito 
in standard membrane feeding assays to measure transmission-blocking (TB) activity 
and in high-throughput screening of TB compounds against P. falciparum gametocytes 
(see below). For the TB assays against mosquito stages and gametocytes, transgenic P. 
falciparum (NF54 strain)parasite lines have been generated that express a GFP-luciferase 
fusion protein under control of the strong constitutive hsp70 [39] or the gametocyte 
specific pfs16 promoter [40]. 
In addition to RMP expressing fluorescent and luminescent proteins for vaccine 
studies, multiple transgenic RMP lines expressing the model antigen ovalbumin (OVA) 
as an immunological reporter have been created to study immune responses after 
vaccination. Transgenic Plasmodium parasites expressing OVA have been exploited to 
examine parasite-specific CD8+ T cell responses during both blood and liver infections 
[9, 10, 41, 42, 43]. For example, intravital two-photon microscopy of livers of mice 
infected with P. berghei parasites that express OVA and GFP in their cytoplasm showed 
that transferred OVA-specific CD8+ T cells recognize and forms clusters around infected 
hepatocytes, leading to the elimination of the intra-hepatic parasites [41]. In addition, 
analysis of liver stage parasites expressing OVA, either in their cytoplasm or exported to 
the parasitophorous vacuole membrane, in conjunction with OVA-specific CD8+ and CD4+ 
OVA T cells demonstrated that export of parasite proteins into the infected hepatocytes 
enhanced immunogenicity and CD8+ T cell based protection[10]. 
Below we describe the use of transgenic Plasmodium reporter parasites in preclinical 
assays to evaluate different Plasmodium vaccines and vaccination approaches, that target 
the3 major points of the parasite life-cycle: erythrocytic vaccines, transmission blocking 
vaccines and pre-erythrocytic vaccines.
Erythrocytic Vaccines
Although a number of RMP transgenic reporter parasites have been used in screening 
assays to evaluate drugs or other inhibitors, not many studies have reported the use of 
these parasites in assays to assess blood stage vaccines.  The inhibitory activity of sera 








or people is mostly evaluated in P. falciparum using in vitro erythrocyte reinvasion and 
growth inhibition activity assays (GIA assays). These assays are used to quantitatively 
measure antibody-mediated effects on parasite invasion and growth, often in small scale 
synchronized cultures of blood stage parasites that are maintained in microtiter plates for 
1-2 cycles in the presence or absence of antibodies. Determination of inhibition of invasion 
and growth in these assays is mainly performed by (automatic and high-throughput) 
microscopic, enzymatic or flow cytometric assays using wild type P. falciparum parasites 
[30, 44, 45, 46].In one study, a flow cytometric assay was developed that used transgenic 
P. falciparum parasites expressing GFP [16]. In this study P. falciparum parasites of the D10 
strain were genetically modified to express GFP under control of the constitutive Pfhsp86 
promoter and inhibition of parasite growth by inhibitory antibodies and human serum 
was determined by measuring parasitemia by flow cytometry. This assay was superior to 
microscopy based approaches and comparable to DNA-staining based techniques to 
quantify growth inhibition (Figure 1C).
Transmission Blocking Vaccines
Mutant RMP are frequently used in (loss-of-function) studies that aim to identify and 
characterize Plasmodium proteins essential for parasite development in mosquitoes, 
which may be suitable targets for TB vaccine strategies. Often these deletion mutants 
have been created in transgenic RMP that express fluorescent or luminescent reporters, 
under control of constitutive stage specific promoters permitting a detailed examination 
of parasite development in the mosquito, for example enabling easier quantification 
of gametocyte development, fertilization and oocyst or sporozoite production. While 
the use of transgenic RMP in TB vaccine studies is limited, chimeric RMP lines expressing 
the ookinete surface protein P25 of P. vivax and P. falciparum have been used in direct 
mosquito feeding (DMF) assays for evaluation of the efficacy of vaccines targeting P25 
of P. vivax and P. falciparum. In these assays immunized mice were challenged with 
the chimeric RMP parasites expressing the human antigen, followed by determination 
of oocyst reduction in mosquitoes that were fed on the immunized and challenged 
mice [44, 47, 48, 49, 50].  
The standard membrane-feeding assay (SMFA) is a well-established and recognized 
method to evaluate TB activity of antibodies/serum against human malaria parasites [51]. 
This assay has been utilized widely to assess the TB activity of purified antibodies and 
serum, both in preclinical and clinical vaccine studies. TB activity in the SMFA is defined 
by the reduction in oocyst numbers in mosquitoes that have been fed with infected blood 
containing gametocytes in the presence of antibodies/serum compared to no(or control) 
antibodies (Figure 1B).Often oocyst production is measured by a microscopic analysis of 
dissected mosquito midguts. Recently, a transgenic reporter P. falciparum line expressing 
luciferase has been used in SMFA to quantify oocyst production in mosquitoes, thus 








of the P. falciparum NF54 strain and expresses a fusion protein of GFP and luciferase which 
is under control of the constitutive Pfhsp70 promoter and parasites of this line do not 
express a drug-selectable marker. This novel dissection-free luminescence-based SMFA 
method, using a transgenic P. falciparum reporter parasite which is not resistance to known 
antimalarials, makes this assay much more amenable to high-throughput screening for 
both TB drugs and vaccines. 
Pre-erythrocytic Vaccines
Transgenic RMP are frequently used in preclinical sporozoite and liver stage vaccine 
studies. Simple and sensitive in vitro and in vivo assays employing luciferase-expressing 
P. berghei and P. yoelii parasites have been developed to visualize and quantify liver 
stage development [19, 22]. In these assays, parasite hepatic development is determined 
by bioluminescence measurement of cultured liver stages or by real-time imaging of 
luminescence emanating from the liver of live mice. These measurements correlate well 
with established (but more laborious) quantitative RT-PCR methods [38, 52]. Both in 
vitro and in vivo luminescence imaging assays have been used to screen inhibitors and 
vaccines against liver stages (Figure 1C; [23, 29, 31, 53, 54]).The simplicity and speed 
of quantitative analysis of parasite liver loads by real-time imaging and the possibility to 
analyze parasite development in live mice without surgery, greatly enhances the analysis 
of the effect of individual vaccines or vaccine strategies that target pre-erythrocytic 
stages. Quantification of parasite liver loads by real time imaging has been performed 
in mice that have been first vaccinated with human Plasmodium sub-unit vaccines and 
then challenged with luminescent chimeric RMP that express human parasite antigens 
(see Section 3) or in mice that have been immunized with genetically attenuated parasites 
and subsequently challenged with luminescent RMP(see Section 4). In addition, imaging 
of luminescent parasites in mice has been successfully used to examining host factors 
regulating liver infections[55]and to analyze the impact of immune responses on inhibition 
of liver stage development[23, 56, 57, 58]. Such studies have revealed the importance of 
adaptive and innate immune responses in protective immunity after vaccination. In these 
studies passively or actively immunized mice (including immunological compromised 
mice) were challenged with luciferase-expressing parasites to monitor reduction in 
parasite liver loads. In addition to the use of luminescent RMP, transgenic RMP expressing 
fluorescent proteins have been used to provide insight into interactions of sporozoites 
with cells in lymph nodes and with dermal tissue and blood vessels, and their interactions 
specifically with cells of the innate and adaptive immune system [59, 60, 61, 62, 63, 64]. 
Using fluorescent P. berghei sporozoites it was demonstrated that fewer sporozoites enter 
the blood and reach the liver in sporozoite-immunized mice than naïve mice. Specifically, 
high circumsporozoite protein (CSP) antibody titers were shown affect sporozoite motility 
in the skin, preventing immobilized sporozoites of entering dermal blood vessels [65].
No assays have yet been reported to analyze P. Falciparum liver stage development in 








either cultured in hepatocytes (primary human or HC-O4 hepatocytes) or in chimeric mice 
with human liver tissue, have used wild type parasites that were analyzed by RT-PCR or 
by microscopy of fixed and stained cells. One study reported the use of transgenic P. 
falciparum parasites that express luciferase to study liver infection in immune compromised 
mice engrafted with human liver tissue [57]. This FRG huHep mouse is susceptible to 
a P. falciparum sporozoite infection and supports complete liver stage development. 
The reporter P. falciparum (NF54) parasites express a gfp-luciferase fusion gene under 
theconstitutivePfeef1a promoter and the reporter expression cassette is introduced into 
the pf47 locus [66]. In this study [57]a clear effect could be detected on infection of livers 
of FRG huHep mice by passively transferred antibodies against CSP and parasite liver 
loads in these mice were analyzed using bioluminescence imaging 6 days after infection 
with sporozoites (i.e.at the peak of liver-stage luciferase activity).
CHIMERIC RODENT PARASITES EXPRESSING HUMAN 
PLASMODIUM  PROTEINS
In addition to transgenic reporter parasites, rodent parasites expressing human malaria 
parasite proteins (HMP; P. falciparum and P. vivax) have been used in vaccine studies. 
These ‘chimeric’ RMP are used both to analyze immune responses against HMP antigens 
and to evaluate in vivo protective efficacy of vaccines that target HMP antigens (reviewed 
in [28, 29] and see Table 1). The preclinical evaluation of protective immunity involves 
mice being immunized with vaccines targeting different P. falciparum or P. vivax antigens 
followed by challenge with chimeric rodent parasites that express the corresponding 
HMP antigen. Mainly chimeric RMP expressing pre-erythrocytic HMP antigens have been 
generated (Table 1). Chimeric parasites have also been used to study immunogenicity and 
protective efficacy of transmission blocking HMP vaccine antigens, i.e. P. falciparum and P. 
vivax P25 [47, 49, 50]and blood stage vaccine antigens, i.e. P. falciparum MSP1 (Table 1).
Generation of chimeric parasites have been performed using standard methods of RMP 
transfection [67]by introducing HMP genes into the RMP genome, either as additional gene 
copies or by replacing the complete RMP with its HMP ortholog [29]. In addition, chimeric 
parasites have been generated that express fusions of the RMP and HMP orthologous 
genes (Table 1). The recently described GIMO (Gene Insertion-Marker Out) transfection 
method [68] greatly simplifies and speeds up the generation of transgenic parasites 
expressing heterologous proteins, which are free of drug-selection marker genes. Using 
this method two principle types of chimeric RMP expressing HMP proteins have been 
created ([29]; Figure 2A). The first type are ‘additional copy mutants’; here the HMP gene 
is introduced as an additional gene copy into a silent/neutral locus of the GIMO mother-
line and the HMP gene is under the control of a constitutive or stage-specific RMP gene 
promoter. This strategy is often used when an ortholog of the HMP gene is absent from 
the RMP genome. The second type of chimeric parasites are ‘replacement mutants’; here 








HMP gene. This method creates chimeric parasites expressing the HMP gene under control 
of the endogenous RMP gene promoter and transcriptional terminator. The absence of 
a drug-selectable marker in both the additional copy and replacement mutants makes it 
possible to rapidly introduce additional genetic modifications in these chimeric parasites, 
e.g. introduction of additional HMP genes or fluorescent/ luminescent reporter genes.
Chimeric parasites have been used in vaccine studies for a number of reasons. While 
a high level of genetic orthology exists between genes of RMP and HMP, critical differences 
often exist in the sequence and structure of the encoded proteins [24]. In addition, HMP 
express a number of genes encoding vaccine candidates that are absent from RMP 
[24, 31].These differences complicate the analysis of immunogenicity and protective 
efficacy of HMP antigens in rodent models and compromise the effective translation of 
findings into a human malaria vaccine. Therefore ‘humanizing’ RMP by introducing HMP 
genes into rodent parasite genomes can help to circumvent some of these problems. 
HMP cannot readily infect small animals and testing of P. falciparum parasites in rodents 
is expensive as it is largely restricted to immune-deficient mice (i.e. DRAG or FRG) 
transplanted with human hematopoietic stem cells and/or liver tissue [69, 70]. While it is 
possible to test both pre-erythrocytic and blood stage P. falciparum vaccine candidates 
directly in human subjects, these studies are expensive and laborious to perform and 
therefore less suitable for larger screening studies[71]. Preclinical screening studies using 
chimeric RMP make it possible to rapidly evaluate and compare the protective efficacy 
of novel target antigens and vaccination strategies in order to down select candidate 
antigens and strategies that can proceed into clinical studies.
Recently 10 pre-erythrocytic P. falciparum vaccine candidate antigens were tested for 
their protective efficacy using chimeric parasites [31]. The antigens were selected based 
on published literature, immuno-profiling and expression studies. Mice, immunized with 
viral-vectored vaccines expressing the HMP antigens, were challenged with chimeric 
parasites for evaluation of protective immune responses and characterization of 
the immune responses (see Figure 2B for the immunization/challenge protocol). In this 
study two antigens, PfLSA1 and PfLSAP2, generated better protective efficacy than two 
leading pre-erythrocytic P. falciparum vaccine antigens, PfCSP or PfTRAP, in both inbred 
BALB/c and outbred CD-1 mice. The chimeric parasites used in this study had the HMP 
gene introduced as an additional gene copy as a number of the selected genes did not 
have an ortholog in the P. berghei genome, thereby excluding the possibility to make 
replacement mutants. A number of other chimeric RMP have been used, which express 
a HMP ortholog in place of their own RMP gene (Table 1), for example chimeric parasites 
expressing pre-erythrocytic vaccine candidates such as P. vivax and P. falciparum CSP and 
CelTOS ([72, 73, 74, 75]; Table 1). 
Chimeric parasites have also been used to evaluate immunogenicity of antigens against 
other lifecycle stages (i.e. TB vaccines see Figure 2C) as well as being used to evaluate 
different vaccine delivery platforms and to optimize the vaccination strategy and schedule. 








Figure 2. The use of chimeric RMP expressing human malaria parasite (HMP) proteins in malaria 
vaccine research. (A) Additional Copy Mutants have the HMP gene (e.g. the P. falciparum gene coding 
sequence; Pf CDS) introduced as an additional gene copy into a silent/neutral locus of the RMP; 
the HMP gene is under the control of a constitutive or stage-specific RMP gene promoter. Replacement 
Mutants have the RMP coding sequence (Pb CDS) replaced by the orthologous HMP CDS. This often 
2 step replacement method, employing the methods of GIMO transfection, creates chimeric parasites 
expressing the HMP gene under control of the endogenous RMP gene promoter and transcriptional 
terminator. (B) Vaccine immunogenicity and protective efficacy measured in mice immunized with 
HMP liver stage sub-unit vaccines or rodent GAPs. Immunized (and naïve) mice are challenged either 
with luminescent chimeric RMP expressing the cognate HMP antigen or with luminescent ‘wild-type’ 








UIS3, showed that combination of two vaccines expressing these antigens could protect 
100% of immunized mice, despite these antigens demonstrating only modest protective 
immunity when administered as a single antigen formulation [76]. This synergistic effect 
was only evident when the two vaccines were mixed and administered into two legs. 
Another study, testing different vaccine delivery platforms targeting P. vivax CSP using 
chimeric RMP that expressed P. vivax CSP, demonstrated that superior immunogenicity 
was generated by virus like particles (VLP) expressing P. vivax CSP compared to other 
formulations, including viral-vectored vaccines or protein plus adjuvant [77].
Chimeric parasites expressing either full length HMP proteins or fusions of HMP-RMP 
proteins can be instructive in determining critical immunological determinants of 
the protective immune responses after vaccination, for example in GIA using material 
obtained from immunized humans or animals [78, 79, 80]. However, the mechanisms of 
protection after vaccination can be lost in in vitro assays if only individual components of 
the adaptive immune response are examined in isolation. For example, responses that 
require both antibody and cell-mediated responses, either acting independently or when 
they work in concert such as in antibody-dependent cell-mediated cytotoxicity responses 
[81]. Ultimately, however, even positive results generated using chimeric parasites in 
rodents or in vitro assays will need to be validated in human vaccine trials.
ATTENUATED PARASITE VACCINES
Transgenic parasites have not only been used for development and evaluation of 
immunogenicity of antigens and protective immunity of subunit vaccines, they have also 
been used to develop and evaluate whole organism vaccines consisting of (genetically) 
attenuated parasites. Vaccination with live, attenuated, sporozoites has been shown to 
induce strong protective immune responses both in rodents and in humans (reviewed in 
[32]). Sporozoite attenuation has been performed by radiation or by genetic modification 
of parasites (reviewed in [32, 33, 34, 82, 83]). A prerequisite for induction of protective 
immunity is that the attenuated sporozoites enter the liver, since heat-killed or over-irradiated 
sporozoites that do not invade hepatocytes do not efficiently confer protection [33, 84]. 
These so-called genetically attenuated parasites (GAPs) have genes encoding proteins 
essential for parasite development in the liver removed, thereby producing parasites 
that arrest in the liver. For both GAPs and radiation-attenuated parasites immunogenicity 
real time imaging of the liver of live mice at 44-48 h after challenge with sporozoites (in vivo imaging 
of luminescence) and/or measuring the time to establish a detectable blood stage infection (pre-
patent period; % survival). (C) Vaccine efficacy of HMP transmission blocking vaccines determined 
in a direct mosquito feeding assay (DMFA) in mosquitoes. In these assays mice are immunized with 
the HMP transmission blocking vaccine. Immunized  and naïve mice are then infected with chimeric 
RMP parasites expressing the cognate HMP antigen. The infected mice are used to feed mosquitoes 
and (reduction in) oocyst production in mosquitoes is quantified 8-10 days after feeding in order to 








(protective efficacy) and safety are critical factors for further clinical development as whole 
organism vaccines. Transgenic rodent parasites have been used extensively in preclinical 
evaluation studies to establish the safety profile of GAPs, i.e. absence of a blood stage 
infection in mice after inoculation with high numbers of GAPs[34]. A number of different 
GAP vaccine candidates have been generated in rodent parasites, by deletion of either 
single or multiple genes. These have been analyzed in mice to ensure they completely 
arrest in the liver and therefore meet the necessary safety profile for translation into human 
GAP. Introducing genes encoding fluorescent and luminescent genes into the genomes of 
GAPs has permitted a detailed analysis on the timing and magnitude of arrest in the liver 
[85, 86] (Figure 1B). Based on studies on growth arrest and safety of rodent GAPs, three 
multiple gene-deletion P. falciparum GAPs have been developed that have advanced into 
clinical evaluation [87, 88, 89]. 
In addition to examining the safety profile of a GAP, transgenic RMP have also been 
used to evaluate the protective immunity induced by attenuated sporozoites, both 
radiation-attenuated sporozoites and GAPs. In multiple studies, mice immunized with 
attenuated parasites have been challenged with fully infectious sporozoites that express 
luciferase to determine liver loads by real time imaging, similar to what has been described 
above for evaluation of protective immunity of sub-unit vaccines (Section 2 and 3; 
Figure 2B). Quantification of parasite liver loads and the pre-patent period provide a direct 
measurement of protective immunity induced by different immunization regimens. 
Rodent GAPs expressing luciferase have also been used to investigate different 
attenuated sporozoite administration strategies [90, 91]. These studies demonstrated 
that the route and dose of administration of attenuated sporozoites are critical factors in 
inducing protective immunity.  Intradermal, subcutaneous and intramuscular administration 
of attenuated sporozoites resulted in reduced parasite liver loads when compared to 
the same number of sporozoites introduced intravenously. Lower parasite liver loads 
after intradermal delivery was associated with reduced protective efficacy compared to 
intravenous immunization. Transgenic fluorescent rodent GAPs have been used to analyze 
direct interactions of lymphocytes with infected hepatocytes using intravital imaging of 
mice that had previously been immunized with attenuated sporozoites [13, 41, 92, 93]. 
These studies have revealed the importance of CD8+ T cell mediated killing and elimination 
of infected hepatocytes in mice immunized with attenuated sporozoites. Further, using 
transgenic RMP expressing the immunological reporter protein ovalbumin, it has been 
possible to analyze direct interactions and effects of antigen specific CD8+ T cell mediated 
immune responses in the liver of mice immunized with attenuated sporozoites ([10, 41]; 
see also Section 2).
EXPERT COMMENTARY
The ability to genetically manipulate the malaria parasite by deleting, mutating genes 








the molecular and cellular biology of malaria parasites for the last 20 years. Genetic 
modification has been central to the functional characterization of genes including genes 
encoding putative vaccine candidate antigens. The generation of reporter parasites with 
additional genes in their genome has resulted in the increased use of transgenic parasites in 
translation-oriented research, for example in preclinical studies evaluating immunogenicity 
and protective efficacy of novel antigens and vaccines. These studies involve transgenic 
parasites of both rodent and human malaria species. Two examples of transgenic human 
parasites are luminescent P. falciparum parasites that have been used in high-throughput 
assays to quantify transmission blocking activity and the use of luminescent P. falciparum 
parasites to analyze the effects of (passively transferred) immune sera on liver infection 
in mice engrafted with human liver tissue (Section 2). These assays are used to generate 
insights into the immunogenicity of putative vaccine candidate antigens, knowledge which 
in turn can be used to improve vaccine strategies that target transmission blocking stages 
and pre-erythrocytic stages, respectively.  
Compared to transgenic P. falciparum parasites, transgenic rodent malaria parasites 
have been more widely applied in experimental vaccine studies, especially in the evaluation 
of pre-erythrocytic antigens and to assess different pre-erythrocytic vaccination strategies. 
For example, luminescent parasites are frequently used to challenge immunized mice in 
standard assays that measure the reduction in parasite liver load as a consequence of 
the protective immune responses induced by different antigens or vaccine strategies. 
Another example is the application of intravital imaging using fluorescent parasites in 
immunized mice, which has revealed critical insights into the immune response targeting 
sporozoites and infected liver cells (Section 2). Such in vivo assays to analyze crucial 
protective immune responses after vaccination and to evaluate protective immunity are 
valuable tools to improve pre-erythrocytic vaccines. 
In addition to reporter rodent parasites, chimeric rodent parasites expressing proteins 
of the human malaria parasites P. falciparum and P. vivax are now being increasingly used in 
vaccine studies. Chimeric RMP expressing HMP proteins are used to determine protective 
efficacy in mice immunized with different sub-unit vaccines expressing P. falciparum 
and P. vivax antigens (Section 3). These studies have been used to select novel vaccine 
candidate antigens for advancement into clinical trials. Chimeric RMP can not only support 
identification of novel antigens, but also contribute to the in vivo evaluation of novel 
delivery platforms and vaccine strategies, both for vaccines targeting pre-erythrocytic 
parasites and transmission blocking vaccines (Section 3). The use of chimeric rodent 
parasites to evaluate protective immunity or transmission blocking immunity is not without 
its limitations. First, the use of chimeric RMP still relies on a murine model, often inbred 
mice strains, and encounter issues related to restriction of MHC epitopes and marked 
immune-dominance of certain epitopes [94]. Outbred mice can possibly be used to more 
accurately reflect what may be seen in humans but it is possible that some antigens 
identified as poorly immunogenic in these studies may in fact be immunogenic in humans. 








dependent on the RMP promoter used, which is unlikely to exactly mimic the timing and 
magnitude of the expression of the HMP protein in the HMP. In studies where multiple 
vaccine antigens are examined the chimeric parasites will express the different HMP 
antigens at the same level, which is unlikely to be the case in wild-type HMP. Therefore, 
where possible, it would be useful to also compare protective vaccine efficacy in mice 
using a chimeric RMP parasite where the HMP antigen expression matches its expression 
in the HMP, both in timing and magnitude. Despite these limitations, chimeric RMP allow 
for rapid vaccine (rank-order) screening in vivo and can provide critical insights into both 
the importance of the vaccine target and the mechanism of protection. Indeed data from 
chimeric RMP is being used to justify the selection of novel HMP antigen vaccines (and 
delivery platforms) to advance into clinical testing.
In addition to the role of transgenic parasites in the development of subunit vaccines, 
transgenic parasites have played a central role in the development and evaluation of whole 
organism vaccines consisting of attenuated sporozoites. Studies in rodent malaria models 
on the safety and immunogenicity of GAPs has formed the basis of the development 
of different (multiple gene deletion) P. falciparum GAPs that have now advanced into 
clinical trials (see Section 4). Given the data from rodents studies with both GAPs and 
irradiated sporozoites and from data emerging from irradiated sporozoite vaccine research 
in humans it is anticipated that further improvements can be made to increase GAP 
potency. Here again transgenic RMP can play an important role, for example to optimize 
the routes of attenuated parasite vaccine administration (e.g. studies with devices to 
improve intradermal or intramuscular delivery, use of adjuvants etc) and in development 
of the so-called ‘next generation’ GAP vaccines with increased potency requiring fewer 
sporozoites per dose and fewer vaccination doses to achieve sustained sterile protection 
(e.g. GAPs which arrest late into liver stage development). 
Transgenic parasites used in conjunction with ‘humanized’ animal models or in 
sophisticated in vitro assays are designed to aid and speed up malaria vaccine design, 
specifically to suggest potential priorities for expensive and time-consuming clinical 
trials. As mentioned above, however, the predictive power of these assays can only be 
determined after human trials have been performed and lessons learnt from the success 
and discrepancies that will arise. In addition, over-reliance on a single experimental model 
may result in putative valid vaccine targets not being advanced further, as they did not 
generate sufficient immunity in the testing platform (e.g. in mice).   
FIVE-YEAR VIEW
Despite considerable effort, over decades, a highly effective vaccine against malaria still 
does not exist. This is in part due to the limited number of antigens and methods of 
immunization that have advanced into clinical testing. Most vaccine studies have focused 
on a limited number of antigens but for a broad acting, highly durable and potent malaria 








Therefore, in order to create multi-antigen and multi-stage vaccines many more antigens 
and improved vaccine delivery platforms will need to be investigated and evaluated as 
a priority in the next 5 years. In addition, the critical host and parasite factors mediating 
protective immunity and those that are necessary for maintaining durable protection 
need also further investigation in the upcoming years. The use of transgenic parasites in 
conjunction with other enabling technologies (e.g. genetic modification of mice or human 
cell lines, advances in imaging etc) has opened up new possibilities and will be used to 
contribute to a more rapid preclinical evaluation of vaccines, vaccination strategies and 
identification of critical factors of protective immune responses. Transgenic P. falciparum 
parasites expressing luminescent reporter proteins are currently valuable tools to assess 
drugs and inhibitors against the parasite in high-throughput assays and are now also 
being used to test the immunogenicity of (novel) transmission blocking antigens and will 
continue to be used to evaluate novel transmission blocking vaccine strategies. In addition, 
the recent availability of luminescent P. falciparum parasites that express luciferase under 
strong promoters (i.e. constitutive, sporozoite or liver-stage specific) will act as a bridge 
between rodent and clinical studies. They will be increasingly used in assays to evaluate 
the effects of (human) immune serum, cells and factors on P. falciparum blood and liver 
cell infection, both in cultured cells and in humanized mice with human hematopoietic 
and human liver cells. Such assays will contribute to generate essential insights into 
the immunogenicity of (in particular pre-erythrocytic) antigens and vaccination strategies. 
Both reporter RMP expressing fluorescent and luminescent proteins as well as chimeric 
RMP expressing HMP antigens will contribute to these studies examining protective 
immune responses in particular of vaccine strategies targeting pre-erythrocytic  vaccines. 
The use of transgenic parasites may not only help to rank order existing candidates but 
also help to reveal novel vaccine candidate antigens and vaccination strategies. Loss of 
function and protein-tagging mutants often reveal parasite proteins that have critical roles 
in parasite development or, for example, are located on the surface of extracellular forms 
of the parasite and may therefore be vulnerable to antibody-based vaccines. Uncovering 
critical protective immune responses and efforts to establish correlates of protection after 
vaccination may be greatly aided by the use of both transgenic parasites and humanized 
mice, which could be used to examine both the induction and recall of immune responses 
in different organs. Transgenic RMP will continue to play an important role in preclinical 
evaluation of novel attenuated sporozoite vaccines both in studies to develop GAPs that 
are more immunogenic and in studies to improve vaccination strategies (e.g. optimizing 
the route of administration). In particular, next generation P. falciparum GAPs that have 
been further modified to express multi-stage and antigens from multiple strains.
KEY ISSUES
•	 Most vaccine studies have focused on a limited number of antigens but for a broad 








insufficient to provide the protection required. Multi-stage, multiple-antigen sub-unit 
or genetically attenuated parasite vaccines may provide a solution.
•	 Transgenic (human and rodent) malaria parasites expressing ‘foreign’ proteins, 
for example fluorescent and luminescent proteins, have been used to determine 
the protective efficacy of different antigens and to evaluate vaccination platforms/
strategies. 
•	 Transgenic parasites (e.g. expressing OVA) are being used to understand the critical 
determinants of protection after vaccination; specifically to examine the  induction and 
recall of protective immune responses in the blood and the liver 
•	 Luminescent rodent parasites are now increasingly used to challenge vaccinated 
mice, and non-invasive measurements of parasite liver load permits examination of 
both the protective responses generated by different antigens and to evaluate novel 
vaccine strategies.
•	 Luminescent P. falciparum parasites are being used both in high-throughput assays to 
quantify transmission blocking activity and to analyze the effects of human immune 
sera/immunoglobulins on parasite development in the liver of humanized mice. 
•	 Chimeric rodent parasites, expressing P. falciparum or P. vivax antigens, are being 
used to directly evaluate and rank-order human malaria vaccine candidates and 
determination of the most suitable for clinical testing. 
•	 Chimeric rodent parasites permit an in vivo comparison of different P. falciparum/vivax 
vaccine delivery platforms and vaccination strategies; they are being used to determine 
the best combination of antigens, delivery system and immunization protocol to move 
forward into clinical testing.
•	 Transgenic parasites play a central role in the development and evaluation of whole 
organism vaccines consisting of attenuated sporozoites. Both in evaluation of safety 
and in assessing protective efficacy. Improvements in genetically attenuated parasite 
vaccines and strategies for vaccination (i.e. optimizing the route of administration) will 
continue to require the use of transgenic parasites.
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Protection against a malaria infection can be achieved by immunization with live-attenuated 
Plasmodium sporozoites and while the precise mechanisms of protection remain unknown, 
T cell responses are thought to be critical in the elimination of infected liver cells. In cancer 
immunotherapies, agonistic antibodies that target T cell surface proteins, such as CD27, 
OX40 (CD134) and 4-1BB (CD137), have been used to enhance T cell function by increasing 
co-stimulation. In this study, we have analyzed the effect of agonistic OX40 monoclonal 
antibody treatment on protective immunity induced in mice immunized with genetically 
attenuated parasites (GAPs). OX40 stimulation enhanced protective immunity after 
vaccination as shown by an increase in the number of protected mice and delay to blood-
stage infection after challenge with wild-type sporozoites. Consistent with the enhanced 
protective immunity enforced OX40 stimulation resulted in an increased expansion of 
antigen-experienced effector (CD11ahiCD44hi) CD8+ and CD4+ T cells in the liver and 
spleen and also increased IFN-γ and TNF producing CD4+ T cells in the liver and spleen. 
In addition, GAP immunization plus α-OX40 treatment significantly increased sporozoite-
specific IgG responses. Thus, we demonstrate that targeting T cell costimulatory receptors 












Malaria remains a major threat to the lives of more than 3 billion people world-wide and 
there remains a pressing but unmet need for an effective vaccine, which can provide 
sustained protection against either infection or disease. Despite three decades of clinical 
testing different (recombinant) sub‐unit vaccines, only modest protection has been 
reported so far [1-4] and this has renewed an interest in whole parasite-based vaccine 
approaches [5, 6]. It was first shown in rodent models of malaria that complete protection 
against infection can be obtained by vaccination using live attenuated sporozoites [7, 8]. 
Sterile protection against a malaria infection was also demonstrated in humans after 
immunization with Plasmodium falciparum sporozoites, either attenuated by radiation or 
administered under chemoprophylaxis [9-11]. A prerequisite for induction of protective 
immunity using sporozoite-based vaccines is that sporozoites retain their capacity to 
invade liver cells after their administration. The most advanced live-attenuated vaccine 
is based on radiation-attenuated sporozoites (PfSPZ-Vaccine), which is currently being 
evaluated both in the clinic and in field trials [12, 13]. In rodent models, immunization with 
sporozoites of genetically-attenuated parasites (GAP) can induce similar or even better 
levels of protective immunity compared to  irradiated sporozoites (Irr-Spz) [14, 15] . Rodent 
GAP studies have been critical in the creation of two P. falciparum GAP-based vaccines 
that are currently undergoing clinical evaluation [16-18]. 
A number of studies from both the clinic and the field have shown that Irr-Spz can 
generate strong protective immunity in humans [13, 19, 20]. However, in order to achieve 
high level protective immunity multiple immunizations with high doses of attenuated 
sporozoites are required [9, 13]. The high numbers of sporozoites required for vaccination 
increases the costs of sporozoite-based vaccines and complicates the production and 
application of such vaccines for mass administration in malaria-endemic countries. 
The major challenge is to produce a highly immunogenic live-attenuated vaccine, which 
requires the fewest attenuated sporozoites per dose and the fewest doses to induce 
sustained sterile protection against a malaria infection.
While the precise mechanisms of protection mediated by immunization with attenuated 
sporozoites remain unknown, T cells appear to be critical for protection and in particular 
CD8+ T cells are thought to play a major role in eliminating infected hepatocytes. Early 
rodent studies using Irr-Spz have demonstrated a vital role for CD8+ T cells [21, 22]. Recent 
mechanistic investigations into protective immune responses induced by immunization 
with attenuated sporozoites have demonstrated diverse and robust immune responses 
that encompasses both CD8+ and CD4+ T cells, as well as a significant contribution from 
antibodies [23, 24]. Nonetheless, CD8+ T cells are considered to be the main effector cells 
in eliciting protection after sporozoites immunization [25].
Recently, cancer immunotherapies have employed antibodies that target proteins on 
the surface of T cells, as treatment with these antibodies have been shown to restore, 











targeting CTLA-4 and PD-1 have been used to block inhibitory signals to T cells [26, 
27], while agonistic antibodies targeting CD27, OX40 and 4-1BB on CD4+ and CD8+ T 
cells have been used to increase costimulatory signals [28-30]. These immunostimulatory 
antibodies have been shown to improve the control of tumors and this was associated with 
an increase in tumor-specific T cell function [31].In this study, we have analyzed the effect 
of agonistic OX40 monoclonal antibody (OX40 mAb) treatment on protective immunity 
induced in mice by immunization with GAP sporozoites. We immunized BALB/c mice using 
sporozoites of a P. yoelii GAP, an established rodent model to evaluate GAP vaccination 
[14]. We found that OX40 mAb (α-OX40) treatment enhanced protective immunity, which 
was correlated with an expansion effector CD4+ and CD8+ T cell subsets, in both the liver 
and the spleen. In addition α-OX40 treatment induced the production of effector cytokine-
producing T cells in the liver and spleen. Our results indicate that targeting costimulatory 
receptors on T cells can be used to improve sporozoite-based vaccine potency and in 
turn could be used to improve GAP vaccine implementation by reducing the numbers of 
sporozoites required to induce protective immunity.
MATERIALS AND METHODS
Experimental animals and parasites
Female BALB/cByJ mice (6-7 weeks; Charles River, NL and Harlan, Bicester, UK) were used. 
All animal experiments of this study were approved by the Animal Experiments Committee 
of the Leiden University Medical Center (DEC 13132 and 14307). The Dutch Experiments 
on Animal Act is established under European guidelines (EU directive no. 86/609/EEC 
regarding the Protection of Animals used for Experimental and Other Scientific Purposes). 
All experiments were performed in accordance with relevant guidelines and regulations. 
Two P. yoelii (Py) lines were used: i) the reference ‘wild type’ Py17XNL parasite line 1971cl1 
(PyWT; PyGFP-luccon; line RMgm-689; www.pberghei.eu [32]; which contains the fusion 
gene gfp-luc gene under control of the constitutive eef1α promoter integrated into 
the silent 230p gene locus (PY17X_0306600) and does not contain a drug-selectable 
marker and ii) the ‘genetically attenuated parasite’ Py17XNL mutant that lacks the gene 
fabb/f  (3-oxoacyl-acyl-carrier protein synthase; PY17X_1126500). This mutant (ΔPyFabBF-
GFP-Luccon; PyΔfabb/f; mutant RMgm-4109; www.pberghei.eu) was generated in 
the reference line 1971cl1 [33] by standard methods of transfection using a DNA construct 
that targets the fabb/f gene containing hdhfr/fcu selectable marker cassette by double 
cross-over integration. 
Mosquito infection, analysis of oocysts and preparation and injection of 
sporozoites
Sporozoites were obtained by manual dissection of the salivary glands of infected female 
Anopheles stephensi mosquitoes 14 days after feeding on infected mice. Mosquitoes were 
kept at a temperature of 24.5°C and 80% humidity. Salivary glands were collected in RPMI 











sporozoites were counted in a Bürker counting chamber using phase-contrast microscopy. 
For intravenous (IV) administration sporozoites were suspended in RPMI medium and per 
mouse 200 μl was injected into the tail vein. Oocyst numbers in dissected midguts from 
infected mosquitoes were established 8 days after feeding using light-microscopy.
Determination of parasite liver load by real time in vivo imaging
Parasite liver loads in live mice after immunization and after challenge were quantified 
by real time in vivo imaging as previously described [34]. Liver stages were visualized 
and liver loads quantified by measuring luciferase activity of parasites in whole bodies 
of mice at 44 h after injection of sporozoites using the IVIS Lumina II Imaging System 
(Perkin Elmer Life Sciences, Waltham, USA). During measurements mice were anesthetized 
using the isofluorane-anesthesia system (XGI-8, Caliper Life Sciences, Hopkinton, USA). 
D-luciferin was dissolved in PBS (100 mg/kg; Caliper Life Sciences, USA) and injected 
subcutaneously in the neck. Measurements were performed within 8 min after the injection 
of D-luciferin. Quantitative analysis of bioluminescence of whole bodies was performed by 
measuring the luminescence signal intensity using the ROI (region of interest) settings of 
the Living Image® 4.4 software.
Immunization protocol and determination of prepatent period after challenge
For the immunization experiments mice were immunized using isolated PyΔfabb/f 
sporozoites according to the immunization protocols described in the Results section. 
Blood of immunized mice was analyzed for possible breakthrough blood infections by 
Giemsa-stained blood smears one day before challenge with PyWT sporozoites. Immunized 
mice and naïve controls were challenged 14 days after the last immunization with 3000 
(i.e. 3 × 103) PyWT sporozoites. Challenged mice were monitored for blood-stage infections 
by Giemsa-stained blood smears made at day 4 to 14 after challenge. The prepatent 
period (measured in days after sporozoites challenge) is defined as the day when a blood 
stage infection with a parasitemia of 0.5–2% is observed [35]. Organs (and serum) used for 
immunological analysis were collected from the mice at day 7 after immunization or at 7 
days after challenge.
OX40 monoclonal antibody (mAb) treatment
Mice were treated with 200 µg of OX40 mAb (clone RM134L; Bio X Cell, West Lebanon, 
NH, United States) in 200 µl PBS and administrated by intraperitoneal injection (IP) either 
at day 0 or one day after prime or boost immunization. 
Treatment with ARTC2-blocking nanobodies
Immunized mice and naïve controls were treated with 50 µg ARTC2-blocking nanobodies 
(Biolegend) in 200 µl PBS administered by IP injection 30 min before sacrificing mice for 











Liver perfusion and purification of liver and spleen cells
Mice were perfused under anesthesia by intracardiac injection of 20 ml PBS (B. Braun, 
Oss, NL). Perfused livers were minced in small pieces and digested for 30 min at 37°C 
in Dulbecco’s Modified Eagle Medium (Thermo Fisher Scientific, Breda, NL) containing 
250 U/ml collagenase and 20 µg/ml DNase. Hepatic leukocytes was obtained by passing 
the digested tissue through a 70 µM cell-strainer (BD Biosciences. San Diego, CA) and 
Percoll gradient. For spleens,  splenocytes were harvested by mincing the tissue through 
a 70 μm cell strainer.
Cell surface staining, intracellular staining, and flow cytometry
For cell surface staining, hepatic leukocytes and splenocytes were resuspended in staining 
buffer (PBS, 2% FCS. 0.05% sodium azide) and incubated with fluorescent conjugated Abs 
for 30 min at 4°C. For intracellular cytokine staining, hepatic leukocytes and splenocytes 
were re-stimulated in vitro with medium containing 5 × 104  PyWT sporozoites for 24 h 
in 96-well flat-bottom plates (1.5 × 106 hepatic leukocytes and splenocytes per well) as 
described [36]. In order to improve re-stimulation and to increase the number of antigen-
presenting cells, 1.5 × 105 of splenocytes were added at the start of the cultures to all 
wells. Twenty hours after incubation 1 μg/ml brefeldin A (Golgiplug; BD Pharmingen) 
was added to all wells. After re-stimulation, cells were transferred to U-bottom 96-well 
plates, and the cell surface stained with fluorescent conjugated Abs at 4°C for 30 min in 
staining buffer. After washing, cells were fixed with 0.5% paraformaldehyde at 4°C for 
30 min, followed by intracellular staining for cytokines at 4°C for 30 min in Perm/Wash 
buffer (BD Biosciences). After washing and resuspending in staining buffer, cells were 
acquired using a BD LSRII flow cytometer and data were analyzed using FlowJo software 
(Tree Star). Fluorochrome-conjugated mAbs specific for CD3, CD4, CD8, CD44, CD11a, 
KLRG1, CD134, IFN-γ, IL-2, and TNF were purchased from BD Biosciences or eBioscience 
(San Diego, CA).
ELISA
Enzyme-linked immunosorbent assay (ELISA) plates (Corning,Inc.) were coated overnight 
at 4°C by adding 1 × 104 PyΔfabb/f sporozoite lysate diluted in 100 µl NaHCO3 buffer 
(pH 9,6) per well. Plates were washed three times with PBS-T (0.05% Tween 20 in 1×PBS) 
prior to blocking for 2 h in blocking buffer (1% BSA in PBS-T). Next, sera was diluted 
in blocking buffer at 1:100 for sporozoite lysate per well. Plates were incubated for 3 
h at room temperature before washing as described above. Next, 100 µl of a 1:5000 
dilution of horseradish peroxidase (HRP) conjugated anti-mouse IgG (Jackson Immuno-
Research) was added and incubated for an additional 1 h at room temperature. Finally, 
plates were washed again and 100 µl of TMB Substrate solution (Thermo Scientific) was 
added for 5 min. The reaction was stopped by addition of 50 µl of 0.5 N sulfuric acid 













All data are calculated using the GraphPad Prism software package 5.04 (GraphPad 
Software, Inc). For ELISA, cell surface and intracellular staining analysis, statistical analysis 
was performed using the unpaired Student’s t-test. For the survival analysis, statistical 
analyzes to determine differences in protection after challenge were performed using 
a Kaplan–Meier survival plot, and survival curves were compared using the log-rank 
(Mantel-Cox) test. Survival was considered as the complete absence of parasites in blood. 
The significance threshold were 0.05 in all analysis.
RESULTS 
Establishing a GAP Sporozoite-BALB/c immunization-challenge protocol 
to investigate strategies to improve GAP immunization
The P. yoelii-BALB/c parasite-mouse combination is a well-established model used to 
analyze vaccines that target sporozoites or liver-stage parasites. To analyze protective 
immunity induced after GAP immunization, we used sporozoites of P. yoelli Δfabb/f GAP 
parasites. The PyΔfabb/f parasites (GAP) lacks the fabb/f gene (PY17X_1126500) and 
arrest late into liver stage development [33, 37]. This GAP produces oocysts and salivary 
gland sporozoites comparable to the wild-type parent P. yoelii 17XNL PyGFP-luccon line 
(PyWT) (Figure S1A). Both GAP and PyWT sporozoites express the fusion protein GFP-
Luciferase under control of the constitutive eef1a promoter, permitting the determination 
of parasite liver loads in live mice by real time bioluminescence imaging [33]. The GAP 
sporozoites exhibit levels of in vivo liver infection that are comparable to PyWT sporozoites 
(Figure S1B), however, these  GAP sporozoites are unable to initiate a blood infection 
(Table S1). 
Protective immunity in immunized mice after challenge with WT sporozoites is defined 
either by the number of mice that are completely protected from infection or by the delay 
in time taken to establish a blood stage infection, i.e. the prepatent period (time-to-
event analysis) [38]. In this study the prepatent period is defined as the number of days 
to reach a 0.5-2% parasitemia after PyWT sporozoites challenge as previously described 
[17]. Previously we had established that a primary immunization followed by boost 
immunization with 1 × 104  GAP sporozoites induced sterile protection in more than 90% 
of BALB/c mice against challenge with 1 × 104  PyWT sporozoites [33]. To examine putative 
enhancing protective immunity of treatment with adjuvants/immunomodulatory molecules 
we attempted to identify a ‘sub-saturating’ immunization regiment by immunizing mice 
with only a single dose of GAP parasites. Mice were immunized with either 1, 2.5 or 5 × 
104 GAP sporozoites and then challenged 14 days later with 3 × 103 PyWT sporozoites 
(Figure 1A). A single immunization with all three doses resulted in none of the mice being 
completely protected. We observed a maximum of one day delay in prepatent period in 
immunized mice compared to naïve mice. Since the blood stage multiplication rate is 10× 











reduction in the infection in the liver [39]. The immunization with 2.5 and 5 × 104 GAP 
sporozoites resulted in a significance longer prepatent period (‘survival’; p = 0.014 and 
p = 0.025,  respectively) compared to naïve mice after challenge with PyWT sporozoites. 
Since we did not observe a major difference between the dose of 2.5 and 5 × 104, we 
Figure 1. Suboptimal protection after GAP immunization and effect of α-OX40 treatment on prepatent 
period after infecting mice with wild type (PyWT) sporozoites. (A) Protection assays performed in 
groups of BALB/c mice (n=5 per group) immunized with as single dose of 1, 2.5 or 5 × 104
 
GAP 
sporozoites and challenged 14 days later with 3 × 103 PyWT sporozoites. Challenged mice were 
monitored for blood-stage infections. The Kaplan-Meier curves illustrate the prepatent period (day 
at which a parasitemia of 0.5–2% is observed). Immunization with 2.5 and 5 × 104
 
GAP sporozoites 
resulted in a significant longer prepatent period compared to control, non-immunized mice (Log-Rank 
(Mantel-Cox) test; p = 0.014 and  p = 0.025; respectively). (B) Effect of α-OX40 treatment on parasite 
development in liver and blood. BALB/c mice were treated with α-OX40 on day 0 and infected with 
3.0 × 103 PyWT sporozoites 13 days later.  Infected mice were monitored for blood-stage infections. 
The Kaplan-Meier curves illustrate that there was no significant differences were observed in prepatent 











choose the protocol of 2.5 × 104 GAP immunization followed by 3 × 103 PyWT sporozoites 
challenge, to analyze the effect of α-OX40 treatment on protective immunity.
In addition, we performed an experiment to analyze the possible effect of treatment 
with α-OX40 in naive mice on liver and/or blood stage infection.  Naïve mice treated with 
200 µg of α-OX40 in 200 µl PBS by intraperitoneal injection (IP) and non-treated mice were 
challenged with PyWT sporozoites 14 days after treatment. No differences in prepatent 
period were observed between treated and untreated mice (Figure 1B), indicating that 
α-OX40 treatment has no effect on growth/multiplication of PyWT parasites in both 
the liver and blood in non-immunized mice.
α-OX40 treatment increases the protective immunity in mice immunized 
with a single GAP immunization
To determine whether OX40 is expressed on activated T cells in mice immunized with 
2.5 × 104 P. yoelii fabb/f GAP sporozoites, we determined the OX40 cell surface expression 
at day 3 post-immunization. OX40 expression was clearly detected on activated (CD44hi) 
CD4+ and CD8+ T cells in the liver (Figure 2A). In the spleen, the expression of OX40 on 
activated CD4+ T cells was also observed, albeit at lower levels compared to activated liver 
CD4+ T cells whereas OX40 expression on activated splenic CD8+ T cells was not detected 
(Figure 2A). These data show that GAP immunization is associated with the upregulation of 
co-stimulatory OX40 receptor on CD4+ and CD8+ T cells. Therefore to  examine if α-OX40 
treatment enhances protective immune responses after GAP vaccination, we treated mice 
with α-OX40 one day after they were immunized with a single dose of 2.5 × 104 GAP 
sporozoites as described above (Figure 2B). As expression of OX40 is upregulated after 
antigen recognition, we scheduled α-OX40 administration 1 day after the immunization 
[40]. Immunized mice were injected intraperitoneally with 200 µg α-OX40 in 200 µl PBS 
by IP injection. In two experiments we observed an increase in protective immunity in 
GAP-immunized plus α-OX40 mice (Figure 2C). In the control groups of mice, naïve and 
GAP-immunized but not OX40 treated, none of the mice were protected against PyWT 
sporozoites challenge and all mice became patent at day 5 or 6 in two experiments. In 
contrast, in the two groups of GAP-immunized plus α-OX40 treated mice, a total of 4 out 
of 15 (26.7%) mice were completely protected and in 9 of the remaining 11 mice (60%) 
PyWT parasites emerged in the blood one day later than GAP-immunized mice and naive 
mice (Figure 2C). The vaccination of GAP with α-OX40 induced a significant increase 
in protection compared to immunization with only GAP parasites in both independent 
experiments (*p = 0.011 and **p = 0.0017). 
α-OX40 treatment after a single GAP immunization results in an increase 
of effector (CD44hi CD11ahi) CD4+ T cells in both  liver and spleen
One week after immunization, organs and blood were collected from mice that were 











treatment (Figure 3A). In all immunized mice we observed a significant and strong increase 
in total white blood cells (WBCs) and CD4+/CD8+ T cells compared to the naïve control 
mice. Strikingly, we observed only in the GAP-immunized plus α-OX40 treated mice 
a significant increase (**p =0.0023) in CD4+ T cell numbers in the liver compared to GAP-
immunized mice (Figure 3B). We analyzed the phenotype of the antigen-experienced 
Figure 2. α-OX40 treatment increases the protective immunity in mice that received a single GAP 
immunization. (A) OX40 expression on activated CD44hi CD4+ and CD44hi CD8+ T cells in 
the spleen and liver at day 3 after immunization. Flow cytometric histograms indicate OX40 
expression (red) and fluorescence minus-one (FMO) controls (blue). (B) The time line shows 
immunization of BALB/c mice with GAP sporozoites (2.5 × 104), α-OX40 treatment and challenge with 
wild type (PyWT) sporozoites (3 × 103). Challenged mice were monitored for blood-stage infections 
from day 18 onwards to determine the prepatent period. (C) The Kaplan-Meier curves illustrate 
the prepatent period (day at which a parasitemia of 0.5–2% is observed). Data show representative 
from 2 independent experiments with (i) 5 and (ii) 10 mice per group: Naïve vs GAP not significant 
(n.s.); GAP + α-OX40 vs GAP  p = 0.011 and p = 0.0017; GAP + α-OX40 vs Naïve, p = 0.008 and 











Figure 3. α-OX40 treatment after a single GAP immunization results in an increase of effector 
(CD44hiCD11ahi) CD4+ T cells in both liver and spleen. (A) The time line showing immunization of 2 
groups of BALB/c mice with GAP sporozoites (2.5 × 104) that were treated or not treated with α-OX40 
one day after immunization. T cells were collected from the liver and spleen at day 7 and analyzed for 
phenotype analysis at day 7 or for cytokine expression at day 8 after in vitro re-stimulation with whole 
sporozoites. (B) The total number of WBC, CD8+ and CD4+ T cells in liver and spleen of different 
groups of mice. Significant differences in total WBC (*p = 0.03) and CD4+  T cells (**p = 0.0023) were 
observed between the livers of α-OX40 treated and non-treated mice. Representative data is shown 
from 2 independent experiments with 6 mice per group. (C) The upper panel shows the percentages 
of (CD44hiCD11ahi) T cells of total CD8+ and CD4+ T cells in liver and spleen in the different groups 
of mice. The lower panel shows the total number of (CD44hiCD11ahi) CD8+ and (CD44hiCD11ahi) CD4+ 
T cells in liver and spleen. A significant increase of (CD44hiCD11ahi) CD4+ cells was observed in both 
liver and spleen of mice immunized with GAP plus α-OX40 compared to only GAP-immunized mice 
(***p =0.0004  and *p =0.044, respectively). Representative data is shown from 2 independent 
experiments with 6 mice per group. Significant difference by unpaired t-test is indicated by not 











effector T cells using CD44 and CD11a as markers [41-43]. When we compared effector 
(CD44hiCD11ahi) CD8+ and CD4+ T cells we found that in both the spleen and the liver 
of GAP-immunized plus α-OX40 treated mice the number of (CD44hiCD11ahi) CD4+ T 
cells were significantly increased (*p = 0.044 and ***p = 0.0004; respectively), compared 
to GAP-immunized mice. No significant differences were observed in (CD44hiCD11ahi) 
CD8+ T cells in α-OX40 treated or untreated GAP-immunized mice, either in the liver or 
spleen (Figure 3C). Combined these results show that the administration of α-OX40 after 
a priming  GAP immunization  enhances the number of antigen-experienced effector CD4+ 
T cells in both the liver and spleen.
Increased effector T cell formation by α-OX40 treatment after  
prime-boost GAP immunization
In order to examine the effect of α-OX40 treatment on both the formation and recall 
of the adaptive immune response after GAP vaccination, we adopted a prime-boost 
immunization strategy. Specifically, we immunized mice initially with a 2.5 × 104 GAP 
sporozoites followed 2 weeks later by a boost with 2.5 × 104 GAP sporozoites (Figure 4). 
This GAP immunization schedule provides 90-100% sterile protective immunity in BALB/c 
mice [14].  α-OX40 treatment, as described above, was performed 1 day after the boost 
immunization as described for a vaccination protocol against mouse cytomegalovirus 
infection [44], and organs and blood collected one week after the boost immunization. 
In GAP-immunized plus α-OX40 treated mice we observed a strong significant increase 
in total WBCs in both the spleen (**p = 0.001) and liver (*p = 0.035) compared to GAP-
immunized mice (Figure 4). We also observed an increase in total CD4+ and CD8+ T cells 
in GAP-immunized plus α-OX40 mice in the liver (p = 0.0625, *p =  0.043 respectively). In 
the spleen we only observed a significant increase in total CD4+ T cells (*p = 0.019) but 
not in the CD8+ T cells in GAP-immunized plus α-OX40 treated mice compared to GAP-
immunized mice.  In both the spleen and the liver of GAP-immunized plus α-OX40 treated 
mice the number of (CD44hiCD11ahi) CD4+ (**p = 0.0014 and **p = 0.0045; respectively) 
and CD8+  (**p = 0.0073 and *p = 0.0357; respectively) T cells were significantly increased 
compared to GAP-immunized mice (Figure 5A). Also, when we compared activated 
effector-type (CD44hiKLRG1hi) CD4+ and CD8+ T cells, we found that in the spleens of GAP-
immunized plus α-OX40 mice the number of (CD44hiKLRG1hi) CD4+ T cells were significantly 
increased (*p = 0.043) compared to GAP-immunized mice (Figure 5B). Combined these 
results suggest that enforced OX40 stimulation after a prime-boost immunization does 
not only impact the expansion of antigen-experienced effector CD4+ T cells, as was shown 
after a single immunization, but also expands the pool of antigen-experienced effector 











α-OX40 treatment increases IFN-γ and TNF producing CD4+ T cells in 
both liver and spleen and increases the amount of sporozoite-specific 
antibodies after prime-boost GAP immunization 
In order to study the impact of the α-OX40 treatment on the cytokine production of 
the CD4+ and CD8+ T cells after prime-boost immunization, we performed intracellular 
staining for IFN-γ and TNF of hepatic leucocytes and splenocytes isolated 7 days after 
the final immunization. Before staining cells were stimulated in vitro for a period of 24 h 
with sporozoites.  It has been reported that treatment with anti-ARTC2 antibodies can 
improve T cell survival and recovery after in vitro stimulation  consequently mice were 
Figure 4. Prime-boost GAP immunization plus α-OX40 during the boost provokes the expansion of 
total WBC, CD8+ and CD4+ T cell numbers in the liver and spleen. (A) Time line showing immunization 
of 2 groups of BALB/c mice with GAP sporozoites (2.5 × 104). Both groups received a prime (day 0) 
and boost (day 14) immunization, and were either treated or not treated with α-OX40 one day after 
the boost immunization. T cells were collected from the liver and spleen at day 7 for phenotype 
analysis at day 7 or for cytokine expression at day 8 after in vitro re-stimulation with whole sporozoites. 
(B) The total number of WBC, CD8+ and CD4+ T cells in liver and spleen of different groups of mice. 
Significant differences were observed between total WBC (*p = 0.035 and **p = 0.001) and  CD4+ 
T cells (*p = 0.0625 and *p = 0.019) collected from the liver and spleen of treated and untreated 
mice. In addition, a significant difference in total CD8+ T cells  (*p = 0.019) was observed between 
livers of treated and untreated mice. Representative data is shown from 2 independent experiments 
with 6 mice per group. Significant difference by unpaired t-test is indicated as not significant (n.s.) or 











treated with ARTC2 nanobodies 30 min before collection of the organs [45]. We observed 
a significant increase in IFN-γ producing CD4+ (**p = 0.0065) and CD8+ (**p = 0.0018) 
T cells in the spleens of GAP-immunized plus α-OX40 treated mice compared to GAP-
immunized mice. In the liver of GAP-immunized plus α-OX40 treated mice, there was an 
increase of IFN-γ producing CD4+ T cells (p = 0.0506) but not of CD8+ T cells. Further, we 
observed a significant increase in TNF producing CD4+ T cells in both liver (*p = 0.0398) 
and spleen (**p = 0.0068) of GAP-immunized plus α-OX40 treated mice compared to 
GAP-immunized mice but TNF production in CD8+ T cells was not significantly different 
in either the liver or spleen (Figure 6A). Taken together, these results show that α-OX40 
treatment after a prime-boost GAP immunization elicits a significant increase in IFN-γ 
and TNF producing CD4+ T cells in both liver and spleen of GAP-immunized plus α-OX40 
treated mice compared to GAP-immunized mice. 
In addition to collecting organs at day 7 after the final immunization, we also collected 
serum from these mice to perform ELISA analysis with P. yoelii sporozoite lysate to quantify 
parasite-specific IgG responses. This analysis revealed that mice immunized with GAP 
sporozoites generate sporozoite-specific antibody responses and that there is a significant 
(*p=0.02, Student’s t-test) increase in the total IgG produced in mice immunized with GAP 
plus α-OX40 treatment compared to mice immunized with only GAP (Figure 6B).      
DISCUSSION
Vaccination with live attenuated sporozoites can induce protective immunity in humans but 
induction of sterile protection requires immunization with multiple doses and each dose 
consisting of relatively high numbers of sporozoites [1, 6]. Enhancing the immunogenicity 
of whole sporozoite (wsp) vaccines, for example by adding adjuvants, can be used to both 
reduce the number of sporozoites per dose and the number of vaccine doses, as well as 
directing the adaptive immune response. We show in this study that treatment of mice 
Figure 5. Increased effector T cell formation by α-OX40 treatment after prime-boost GAP 
immunization. (A) See Figure 4  for the time line of immunization and collection of T cells. The upper 
panel shows the percentages of (CD44hiCD11ahi) CD8+ and CD4+ T cells in liver and spleen. The lower 
panel shows the total number of (CD44hiCD11ahi) CD8+ and (CD44hiCD11ahi) CD4+ T cells in liver 
and spleen. A significant increase of (CD44hiCD11ahi) CD8+ cells (*p = 0.0357 and **p = 0.0073) and 
(CD44hiCD11ahi) CD4+ (**p = 0.0045 and **p = 0.0014) was observed in both liver and spleen,  in 
mice immunized with GAP plus α-OX40 compared to only GAP-immunized mice. Representative data 
is shown from 2 independent experiments with 6 mice per group. Significant difference by unpaired 
t-test is indicated by not significant (n.s.) and significant; * p<0.05 or ** p<0.01, ***p<0.001. (B) 
The upper panel shows percentages of (CD44hiKLRG1hi) CD8+ and CD4+ T cells in liver and spleen in 
the different groups of mice. The lower panel shows the total number of (CD44hiKLRG1hi) CD8+ and 
(CD44hiKLRG1hi) CD4+ T cells. A significant increase of  (CD44hiKLRG1hi) CD4+ T cells was observed 
in spleens of mice immunized with GAP plus α-OX40 compared to only GAP-immunized mice 
(*p =0.043, respectively). Representative data is shown from 2 independent experiments with 6 mice 
per group. Significant difference by unpaired t-test is indicated by not significant (n.s.) and significant; 











with an agonistic antibody against the T cell costimulatory molecule OX40, a member of 
the tumor necrosis factor receptor (TNFR) superfamily [46], enhances protective immunity 
after immunization with GAP sporozoites.
Previously it has been shown that targeting OX40 increases the magnitude of T cell 
responses and improves T cell functionality [47, 48]. OX40 is transiently expressed on 
T cells following cognate interactions between T cell receptors (TCRs) and antigen-major 











is expressed on both activated CD4+ and CD8+ T cells, OX40 expression on CD4+ T cells 
is greater than CD8+ T cells and consequently α-OX40 treatment is expected to exert its 
greatest effect on CD4+ T cells [46, 48, 49]. OX40 signaling promotes T cell proliferation 
and survival, influences CD4+ T cell differentiation into T helper subsets [50-53] and is 
reported to reverse CD4+ T cell hypo-responsiveness [54]. While it has been previously 
described that OX40 is expressed on activated human and rodent CD4 T cells after 
a malaria blood stage infection [55, 56] no data had been reported on the expression 
of OX40 on T cells after a sporozoite/liver stage Plasmodium infection/immunization. 
We demonstrate in this study that after GAP-sporozoite immunization OX40 expression 
was observed on activated (CD44hi) CD4+ and CD8+ T cells in the liver. Similarly OX40 
expression was upregulated on activated CD4+ T cells in the spleen but not observed 
on activated CD8+ T cells. We therefore hypothesized that therapeutic ligation of OX40 
during immunization with attenuated Plasmodium sporozoites would increase  parasite-
specific CD4+ and CD8+ T cell activity, limit the degree of T cell exhaustion and improve T 
cell effector-memory formation, all resulting in increased clearance of PyWT sporozoites/
liver stages.
To analyze the effect of adjuvants on wsp vaccination approaches we first developed 
a model with a sub-saturating immunization regiment,  which we could use to measure 
enhancement of protective immunity through the application of adjuvants. In this study we 
demonstrate that a single immunization with 2.5 and 5 × 104 sporozoites induces partial 
protection as determined by an absence of sterile protection after PyWT sporozoites 
challenge but a 1 day delay in the emergence of parasites in the blood (prepatent period). 
A 1 day delay in prepatent period has been correlated with a 10× reduction in parasites 
released from the liver [39], indicating a 10× increase in protective immunity compared to 
unimmunized mice. 
Figure 6. α-OX40 treatment increases IFN-γ and TNF producing CD4+ T cells in both  liver and spleen 
and increases the amount of sporozoite-specific antibodies after prime-boost GAP immunization. 
(A) See Figure 4  for the time line of immunization and collection of T cells. The upper panel shows 
percentage of IFN-γ and TNF cytokine producer CD8+ and CD4+ T cells in liver and spleen after in 
vitro sporozoite re-stimulation. The second panel shown the total number of IFN-γ and TNF cytokine 
producer CD8+ and CD4+ T cells in liver and spleen. Significant differences in both IFN-γ cytokine 
producer CD8+ and CD4+ T cells (**p = 0.0018 and **p = 0.0065, respectively) were observed between 
spleens of α-OX40 treated and untreated mice. In addition, an increase in  IFN-γ cytokine producer 
CD4+ T cells (p = 0.0506) was observed in livers of treated mice compared to livers of untreated 
mice. Further, a significant differences of TNF producing CD4+ T cells in both liver and spleen 
(*p = 0.0398 and **p = 0.0068, respectively) were observed between α-OX40 treated and untreated 
mice. Representative data is shown from 2 independent experiments with 6 mice per group. 
Significant difference by unpaired t-test is indicated by not significant (n.s.) and significant; * p<0.05 
or ** p<0.01, ***p<0.001. (B) Quantification by ELISA of P. yoelii WT sporozoite-specific IgG obtained 
from naïve and prime-boost immunized mice with P. yoelii GAP (with or without α-OX40 treatment). 
The concentration of the total IgG in the ELISA was quantified using the values for each sample based 
on the standard curve obtained with defined concentrations of polyclonal antibodies against PyCSP 











In cytomegalovirus (CMV) vaccination studies it was found that the increase in vaccine 
potency can be achieved by α-OX40 treatment through the expansion of both antigen-
specific CD4+ and CD8+ T cells [44]. A marked upregulation of OX40 is observed on 
Plasmodium specific CD4+ T cells that are generated in both human and rodent malaria 
blood stage infections and, in rodent studies, α-OX40 treatment was shown to increase 
parasite-specific memory CD4+ T cells resulting in a reduced blood-stage infection [55-57]. 
However, prior to this study the effects of OX40 treatment on immune responses induced 
by wsp vaccination have not been described.  
Our analyzes of T cell responses in mice immunized with a single dose of GAP parasites, 
showed an increase in total WBC numbers in the livers and an increase in CD4+ effector 











untreated mice. It has been reported by Cooney et al. that T cells with a CD44hiCD11ahi 
phenotype are indicative of antigen-experienced effector cells in GAP-immunized 
BALB/c mice [42]. While protective immunity after wsp immunization is thought to largely 
dependent on the killing infected hepatocytes by CD8+ T cells and IFN-γ [16, 58, 59], 
adoptive transfer of CD4+ T cells from GAP-immunized C57BL/6 mice was able to provide 
sterile protection to 50% of naïve animals against a WT infection, indicating an important 
role for CD4+ T cells in GAP induced immunity [58]. In addition, protective immunity induced 
by sporozoites of a P. yoelii GAP, similar to the one used in our study, was dependent not 
only on CD8+ T cells but also CD4+ T cells [60]. Immune responses induced by P. yoelii 
GAPs that arrest late into liver development [14] are reported to involve both the cellular 
and humoral arm of the adaptive immune response. Indeed, Keitany et al. showed that 
functional antibodies are induced after immunization with P. yoelii GAPs, which can inhibit 
sporozoite invasion of liver cells and reduce intrahepatic parasite development [61-63]. 
Since enhancement of CD4+ T cell responses by OX40 stimulation may lead to an increase 
in humoral immunity we examined total IgG responses generated in mice after prime-
boost GAP immunization, either with or without α-OX40 treatment. These studies revealed 
that anti-sporozoite antibodies were generated after GAP immunization and significantly 
more IgG was generated in mice immunized with GAP plus α-OX40 treatment compared 
to mice immunized with only GAP. This observation indicates that the increase in CD4+ T 
cells after α-OX40 treatment may be directly contributing to B cell maturation/activation.  
We further examined the effect of α-OX40 treatment on adaptive immune responses 
by analyzing immune responses in mice that had received a boost immunization after 
the prime immunization. After this prime-boost strategy we observed an increase in total 
WBC numbers in livers and spleens of both GAP-immunized plus α-OX40 and GAP-only 
immunized mice. However, we observed a significant increase in effector (CD44hiCD11ahi) 
CD4+ and CD8+ T cells in liver and spleen of GAP-immunized plus α-OX40 treated mice 
compared to GAP-only immunized mice. This is in contrast to the single prime strategy 
where we only observed a significant in increase only in effector (CD44hiCD11ahi) splenic 
and liver CD4+ T cells in GAP-immunized plus α-OX40 treated mice. When we examined 
the activation phenotype (CD44hiKLRG1hi) of these T cells in liver and spleen, α-OX40 
treatment significantly increased only the number of activated CD4+ T cells and only those 
present in the spleen. Additionally, we observed a significant increase in IFN-γ producing 
CD4+ and CD8+ T cells in the spleen but not in the liver [60]. We also observed a significant 
increase in TNF producing CD4+ T cells, but not CD8+ T cells, in the liver and spleens of 
GAP-immunized plus α-OX40 treated mice. Therefore CD4+ T cells in the spleen may 
contribute to protective immunity either by enhancing humoral responses targeting 
sporozoites invasion [62] or by enhancing CD8+ T cell responses that target infected 
hepatocytes. Recently it was reported, in mice that liver resident CD8+ T cells induced 
by wsp vaccination may be primed in the spleen and their conversion occurring after 
reencountering parasite antigen in the liver [64]. Our results indicate that the increased 











via enhanced CD4+ T cell responses in the spleen. It is known that CD4+ T cell help is 
necessary for an effective CD8+ T cell memory response against non-inflammatory antigens, 
such as tumor cells and certain pathogens that may not carry sufficient danger signals 
[65]. Mice depleted of CD4+ T cells during immunization with sporozoites failed to exhibit 
a robust CD8+ T cell expansion and were not protected against challenge [66, 67]. Murray et 
al. found that CD4+ T cell help was also necessary to induce protection after immunization 
with GAP sporozoites [60]. OX40, in addition to being a costimulatory receptor that 
potentiates proliferation, survival, memory formation, and effector function of CD4+ and 
CD8+ T cells, can also overcome the suppressive activity of regulatory T cells (Tregs) [68]. 
Overcoming immune suppression effects could also benefit the generation of protective 
immunity after wsp vaccination as it has been recently shown that wsp immunization, 
in particular after GAP administered via the skin, can induce regulatory responses [33]. 
Together, our results indicate that improving CD4+ T cell activation enhances protective 
immunity against malaria.  Whether this CD4+ T cell stimulation acts primarily by improving 
humoral responses targeting sporozoites or by increasing CD8+ T cell responses against 
infected liver cells and how these responses may contribute to formation of immunological 
memory and duration of protection requires further investigation. 
A limited number of other studies have been performed on the effect of adjuvants on 
protective immunity induced by wsp immunization. In particular the use of the glycolipid 
α-galactosylceramide (α-GalCer) [69] and its analog 7DW8-5 have been analyzed [70]. 
Co-administration of these molecules with sporozoites resulted in enhanced recruitment 
and activation/maturation of dendritic cells in lymph nodes draining the site of vaccine 
administration and thereby enhancing parasite-specific T cell immunogenicity. Although 
the possible use of certain adjuvants in human vaccination studies may be difficult due 
to costs, applicability or side-effects, these pre-clinical studies provide useful information 
of the largely unknown mechanisms underlying protective immunity. Although α-OX40 
treatment is currently in clinical trials for cancer immunotherapy, the use of antibody-based 
α-OX40 treatment may, for vaccines for the developing world, be unrealistic as they are 
likely to be too expensive. Other (protein based) agents that can stimulate costimulatory 
responses, including agonists of OX40 are being developed as potential adjuvants 
in vaccine development. For example, combination therapy using the protein ligand 
of OX40, OX40L, fused to a cancer vaccine have been shown to reduce breast cancer 
metastasis, by enhancing antigen specific CD4+ and CD8+ T cell responses and inhibiting 
immunosuppressive Treg responses [71]. The co-administration of proteins like OX40L 
which are likely to be cheaper and easier to produce, may therefore be more practical 
and feasible approaches to pursue. In conclusion, this study demonstrates how specific 
immune response to vaccination coupled with activation of costimulatory molecules on 
the surface of T cells, can enhance protective immunity after wsp immunization and merits 
further investigation to see if such approaches not only increase the magnitude but also 
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Supplementary Figure S1. Phenotype features of P. yoelii GAP (GAP) parasites compared to P. yoelii 
wildtype (PyWT) parasites. (A) No significant differences in oocyst and sporozoite production in 
Anopheles stephensi mosquitoes between PyWT and GAP were observed. Oocysts and sporozoites 
were counted at day 8 and day 14 after the mosquito feeding, respectively. (B) No significant 
differences in parasite liver load between mice infected with 1 × 104 GAP sporozoites and mice 
infected with 1 × 104 PyWT sporozoites IV at 44 h post infection, were observed. Parasite liver load in 
mice was determined by measuring in vivo luciferase activity and depicted as relative light units (RLU). 
The right panel shows representative images of real time in vivo imaging of luciferase expressing liver 
stage parasites in mice at 44 h after injection of PyWT and GAP sporozoites.
Supplementary Table S1. Breakthrough blood infections and prepatent period in mice after intravenous 
injection of different doses of PyWT and GAP  sporozoites.
Parasites Dose Breakthrough/Infected animalsa Prepatency (days)
PyWT 3 × 103 6/6 5
GAP 1 × 104 0/4 -
2.5 × 104 0/40 -
5 × 104 0/4 -
a Number of mice showing breakthrough infections of the total number of infected mice
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In this study we created genetically attenuated rodent malaria parasites (GAPs) that express 
putative immunomodulatory proteins to increase GAP immunogenicity. Four different 
proteins were selected with known adjuvant activity: nontoxic cholera toxin B (CTB) 
subunit, mouse heat shock protein Gp96, Mycobacterium heat shock protein X (HspX) and 
Salmonella flagellin (FliC). These proteins were C- terminally tagged to UIS4, a protein 
expressed in liver stages where it is located on the parasitophorous vacuole membrane 
(PVM). The genes encoding the fusion proteins, were introduced into the genome of 
a Plasmodium yoelii GAP and were expressed under control of the P. yoelii uis4 promoter. 
To create the adjuvant GAPs, we first developed a P. yoelii GAP GIMO parent line 
(GIMOPyGAP-fabb/f) for rapid introduction of the adjuvant fusion-transgenes into the genome 
without retention of a drug selectable marker (SM). Specifically, in this GIMO parent line 
the hdhfr::yfcu positive::negative SM is introduced into the fabb/f gene, creating a GAP 
that arrests during late liver-stage development. The four adjuvant-expression cassettes 
were introduced into the fabb/f locus of GIMOPyGAP-fabb/f by performing GIMO transfection 
and negative selection. Adjuvant GAP-immunogenicity was determined by analysis of 
protective immunity induced by sporozoite immunization of BALB/c mice. When compared 
to immunization performed with non-adjuvanted P. yoelii  fabb/f GAP, we were unable 
to observe a significant enhancement  in protection  (>10×) against wild type P. yoelii 















Complete protection against a malaria infection can be obtained after immunization with 
live attenuated sporozoites, both in rodent models of malaria and in humans [1-3]. Sterile 
protection against a malaria infection has been achieved in humans after immunization 
with Plasmodium falciparum sporozoites, that have either been attenuated by radiation 
or administered under chemoprophylaxis [4-6]. A prerequisite for induction of protective 
immunity by sporozoite-based vaccines is that sporozoites retain their capacity to invade 
liver cells after their administration. The most advanced live-attenuated vaccine is based 
on radiation-attenuated sporozoites (PfSPZ-Vaccine), which is currently being evaluated 
both in the clinic and in field trials [2, 7]. In rodent models of malaria, immunization with 
sporozoites of genetically-attenuated parasites (GAP) can induce similar, or even better, 
levels of protective immunity compared to irradiated sporozoites (Irr-Spz) [1, 8-10]. These 
rodent GAP studies have been critical in the creation of two P. falciparum GAP vaccines, 
which are currently undergoing clinical evaluation [11-13].
A number of studies from both the clinic and the field have shown that Irr-Spz can 
generate strong protective immunity in humans [7, 14, 15]. However, in order to achieve high 
levels of protection, multiple immunizations with high doses of attenuated sporozoites are 
required [4, 7]. Immunization with high sporozoite doses increases the costs of sporozoite-
based vaccines and complicates their production, compromising mass administration 
in malaria-endemic countries. A major challenge is to produce a highly immunogenic 
live-attenuated vaccine, which requires the fewest attenuated sporozoites per dose and 
the fewest doses to induce sustained sterile protection against a malaria infection.
While the precise mechanisms of protection mediated by immunization with attenuated 
sporozoites remain unknown, T cells, in particular CD8+ T cells, appear to be critical for 
protective immunity as they are thought to play a major role in eliminating infected 
hepatocytes [16, 17]. Recent mechanistic investigations into immune responses induced by 
sporozoite-based immunization have shown that protective immune responses encompass 
diverse and robust immune responses that include not only CD8+ but also CD4+ T cells, 
and a significant contribution from antibodies [17, 18].
Rodent models of malaria have been used to explore different approaches to 
enhance immunogenicity of vaccines consisting of attenuated sporozoites [9, 10, 19]. 
For example, it has been shown that immunization of mice with GAP that arrest growth 
late during liver stage development induce higher levels of protective immunity than 
GAP that arrest early after invasion of hepatocytes [8]. In a limited number of studies, 
adjuvants have been co-administered with attenuated sporozoites to enhance protective 
immune responses after immunization. It has been shown that the co-administration of 
the glycolipid α-galactosylceramide (α-GalCer) and its analog 7DW8-5 with sporozoites 
can enhance the recruitment and activation/maturation of dendritic cells in draining 
lymph nodes at the site of sporozoite administration, thereby enhancing parasite-














with attenuated sporozoites in combination with treatment with agonistic antibodies, 
targeting the costimulatory receptor on activated T–cells, OX40, can enhance protective 
immunity [22].
Although these preclinical studies provide useful information about the mechanisms 
underlying protective immunity, the use of adjuvants in human vaccination studies may be 
hampered by cost, applicability or side-effects. Further, induction of protective immune 
responses by GAP immunization is dependent on sporozoites migrating to the liver and 
invading hepatocytes. The administration of adjuvants at the site of GAP injection will 
result in systemic distribution of the adjuvant which will therefore be considerably diluted 
at the sites where parasite antigens are taken up by antigen presenting cells (APCs), i.e. 
the liver, spleen or proximal lymph nodes [23]. In order to maximize the adjuvant effect 
(i.e. increase antigen uptake by APCs and/or provide stimulatory signals to enhance APC 
function) it is important to maximize the adjuvant effect at the point of antigen uptake and 
processing [23, 24].    
Due to the limitations of co-injecting adjuvants with attenuated sporozoites, we 
explored the possibility of creating GAPs that express immunomodulatory proteins 
in sporozoites and/or liver stages, so called adjuvant GAPs [25-28] . Self-adjuvanting 
vaccines, in which the antigenic and adjuvanting moieties of the vaccines are present 
in the same molecule, have been developed for subunit vaccines targeting cancer cells, 
viruses [29, 30], nematodes [31] and bacteria [32, 33], for example by conjugation of 
lipopeptide-based Toll-like receptor (TLR) agonists to the target protein [28]. In vaccine 
development against malaria, the vaccine candidate antigen CSP has been fused to 
bacterial flagellin [34], a protein which is a potent TLR5 agonist [35]. However, to the best of 
our knowledge, no sporozoite-based vaccine has been reported that expresses additional 
immunomodulatory/adjuvant molecules [9, 10, 19].
We selected four TLR agonists that can increase adaptive immune responses and have 
the ability to improve cross-presentation of antigens, as has been demonstrated in other 
animal and/or human studies. The selected adjuvant proteins are: (i) nontoxic cholera 
toxin B subunit from Vibrio cholerae (CTB)[36, 37]; (ii) heat shock protein Gp96 of mice 
(Gp96)[38-40]; (iii) heat shock protein X from Mycobacterium tuberculosis (HspX) [41, 42]; 
and (iv) the TLR5 binding region of Salmonella typhimurium flagellin (amino acids 89–96; 
FliC)  [35, 43, 44]. The genes encoding these proteins were fused to a Plasmodium protein 
expressed in liver stages, UIS4 (PY17X_0502200), which is located at the parasitophorous 
vacuole membrane (PVM) in infected hepatocytes. We fused these proteins to a PVM 
protein as it has been shown that ovalbumin (OVA) fused to proteins located in the PV/
PVM induce stronger T cell responses than ovalbumin expressed in the cytoplasm of 
transgenic parasites [45, 46]. The fusion genes were introduced by GIMO transfection 
[47, 48] into a novel GIMO GAP parasite line (GIMOPyGAP-fabb/f) whose growth is arrested 
late during liver stage development. The four adjuvant GAP were analyzed using the P. 
yoelli-BALB/c screening model for assessing protective immunity after GAP immunization 














induced by immunization with these adjuvant GAPs compared to the non-adjuvanted P. 
yoelii Δfabb/f GAP.
MATERIALS AND METHODS
Experimental animals and wild type and transgenic P. yoelii lines
Female OF1 and BALB/cByJ mice (6-7 weeks; Charles River) were used. All animal 
experiments of this study were approved by the Animal Experiments Committee of 
the Leiden University Medical Center (DEC 12042 and 14207).  All experiments were 
performed in accordance with relevant guidelines and regulations. Two P. yoelii (Py) lines 
were used: (i) the reference ‘wild type’ Py17X parasite line 1971cl1 (Py-GFP-Luccon; line 
RMgm-689; www.pberghei.eu) which contains the fusion gene gfp-luc gene under control 
of the eef1α promoter integrated into the silent 230p gene locus (PY17X_0306600) and 
does not contain a drug-selectable marker and (ii) a Py17X mutant that lacks the gene 
fabb/f (3-oxoacyl-acyl-carrier protein synthase; PY17X_1126500). This mutant (2251cl3; 
PyGAP; ΔPyFabb/f-GFP-Luccon; mutant RMgm-4109; www.pberghei.eu) was generated in 
the reference line 1971cl1 by replacing the fabb/f gene by the hdhfr::fcu selectable marker 
(SM) cassette.
Generation of transgenic P. yoelii parasite lines
i) Generation of a P. yoelii GAP GIMO parent line (GIMOPyGAP-fabb/f) for 
introduction of transgenes
The GIMO GAP parent line (GIMOPyGAP-fabb/f; 2668cl1) was generated in line 1971cl1 by 
standard methods of transfection [50] using a DNA construct (pL2138) that targets the fabb/f 
gene (PY17X_1126500) by double cross-over integration and contains the hdhfr::yfcu 
SM driven by the P. yoelii hsp70 promoter (PY17X_0712100). To generate GIMOPyGAP-fabb/f 
we constructed DNA plasmid pL2138 using the basic gene insertion construct pL0034, 
which contains the hdhfr::yfcu selectable marker (SM) cassette under the control of the P. 
berghei eef1α promoter with 3’ terminal sequence of pbdhfr/ts. The P. berghei eef1α 
promoter was replaced by the P. yoelii hsp70 promoter (PY17X_0712100) using PstI and 
NcoI digestion resulting in construct pL2137. The P. yoelii hsp70 promoter was amplified 
from genomic P. yoelii  DNA using primers 8080 and 8081 (1078 bp)(see Table S1 for all 
primer sequences). Next, we used an existing construct (pL1980) that have been used 
to generate P. yoelii GAP GIMO (pL1980) [49], which contains 5’ and 3’ fabb/f  targeting 
regions, the hdhfr::yfcu selectable marker (SM) cassette under the control of the eef1α 
promoter with 3’ terminal sequence of pbdhfr/ts. We  replaced the eef1α-hdhfr::yfcu 
selectable marker (SM) cassette from pL1980 with the hsp70-hdhfr::yfcu cassette from 
pL2137 by digestion of the plasmids with PstI and  AgeI. This final construct (pL2138) 
was analyzed by restriction digestion to confirm correct assembly. Before transfection, 
the construct pL2138 was linearized by digesting with HindIII/EcoRI. Parasites of line 














technologies and transformed parasites selected by positive selection with pyrimethamine 
[50]. Selected parasites were cloned by limiting dilution and mutant 2668cl1 was used 
for genotype and phenotype analysis. Correct integration of the hdhfr::yfcu SM in 
the fabb/f gene in 2668cl1 of gene was verified by Southern analyses of Pulsed Field 
Gel (PFG)-separated chromosomes and diagnostic PCR analysis [50]. PFG-separated 
chromosomes were hybridized with a mixture of two probes: a probe of the hdhfr gene 
and a ~800 bp fragment of the 5′UTR of PBANKA_0508000 located on chromosome 5 
[48]. PCR primers used to confirm correct integration of the construct are listed in Table S1. 
ii) Introducing an mCherry::uis4 expression cassette in GIMOPyGAP-fabb/f 
Parasites of GIMOPyGAP-fabb/f were transfected with a construct that contains a mCherry::uis4 
expression cassette. This construct (pL2154) aims at replacing the hdhfr::yfcu SM in 
the fabb/f locus of GIMOPyGAP-fabb/f. The pL2154 plasmid  contains the P. yoelii uis4 
(PY17X_0502200) CDS fused to an mCherry cassette under the control of the P. yoelii uis4 
promoter with 3’ terminal sequence of the P. yoelii uis4.
Plasmid pL2154 was generated by three cloning steps. In the first step, we amplified 
the uis4 coding sequence (CDS) together with its 5’-UTR promoter region (1764 bp) from 
P. yoelii genomic DNA using 8130 and 8131 primers.  Next, we replaced the hdhfr::yfcu 
selectable marker cassette (SM) of plasmid pL1980 ([49] and described above) with 
the PCR amplified uis4 CDS and 5’-UTR using PstI and KpnI digestion. In the second step, 
the 3’-UTR (938 bp)of P. yoelii uis4 was amplified from genomic DNA using primers 8132 
and 8133 primers. This PCR-amplified cassette was cloned into the intermediate plasmid 
which contains the 5’ and 3’ fabb/f  targeting regions and the uis4 CDS and 5’-UTR cassette 
using XhoI and KpnI, resulting in construct pL2148. Next, the mCherry CDS was amplified 
from plasmid pL1628 [47] using primers 8148 and 7739 and cloned into pL2148 using XhoI 
and SpeI. This final construct (pL2154) was analyzed was analyzed by restriction digestion 
to confirm correct assembly. Before transfection, the construct pL2138 was linearized by 
digesting with HindIII/EcoRI.
Transfection (exp. 2696), negative selection with 5-FC, cloning and genotyping of 
transformed parasites was performed using standard  methods [47, 50]. Correct integration 
of the mCherry::uis4 expression cassette in the fabb/f gene in 2696cl1 was verified was 
verified by Southern analyses of Pulsed Field Gel (PFG)-separated chromosomes and 
diagnostic PCR analysis as described above.  
iii) Generation of four transgenic GAP expressing putative 
immunomodulatory proteins fused to UIS4
Parasites of GIMOPyGAP-fabb/f were transfected with four different constructs that contain an 
expression cassette with uis4 fused to the the following genes: ) nontoxic cholera toxin B 
subunit from Vibrio cholerae (CTB) [36, 37]; (ii) heat shock protein Gp96 of mice (Gp96) 
[38-40]; (iii) Heat shock protein X from Mycobacterium tuberculosis (HspX) [41, 42] and 














[35, 43, 44]. These constructs aims at replacing the hdhfr::yfcu SM in the fabb/f locus of 
GIMOPyGAP-fabb/f. The complete CDS of the ctb gene was amplified from plasmid pUC57-CTB 
(synthesized by GenScript HK Limited) using primers 8189 and 8190 (394 bp) and cloned into 
pL2148 (see above) using XhoI and SpeI, resulting in construct 2165. The complete CDS of 
the gp96 gene was amplified from plasmid pCMV-mouse Hsp90b1 cDNA purchased from 
Dharmacon (Catalog number: MMM4769-202763350) using primers 8146 and 8147 (2428 
bp) and cloned into pL2148 using SacI and MfeI, resulting in construct 2156. The complete 
CDS of the hspx gene was amplified from Mycobacterium tuberculosis H37Rv DNA (kindly 
provided by K. Franken, Department of Infectious Diseases, Leiden University Medical 
Center, Leiden, The Netherlands) using primers 8144 and 8145 (460 bp) and cloned into 
pL2148 using XhoI and SpeI, resulting in construct 2152. The flic sequence (89 to 96 aa) 
gene was amplified from cDNA of Salmonella enteritidis (ATCC line 13076; kindly provided 
by Dr. J. J. Verweij, Leiden University Medical Center, Leiden, The Netherlands) using 
primers 8152 and 8153 (145 bp) and cloned into pL2148 using XhoI and SpeI, resulting 
in construct 2155. All amplified sequences are fused the to the P. yoelii uis4 gene and 
these fusion genes are under control of the uis4 5’-UTR regulatory sequences. The final 
DNA constructs were linearized with HindIII/EcoRI before transfection. Transfections (exp 
2690 with pL2165; 2692 with pL2156; 2694 with pL2152; 2698 with pL2155), negative 
selection with 5-FC, cloning and genotyping  of transformed parasites was performed 
using standard methods [47, 50]. Correct integration of the constructs in the fabb/f gene 
in the transgenic GAP lines, CTB::UIS4 (2690cl1); Gp96::UIS4 (2692cl2), HspX::UIS4 
(2694cl1), FliC::UIS4 (2698cl2)  was verified was verified by Southern analyses of Pulsed 
Field Gel (PFG)-separated chromosomes and diagnostic PCR analysis as described above.
iv) Generation of the GIMO P. yoelii 17X line GIMOPys1
The GIMOPys1 (2828cl2) was generated in line 1971cl1 (see above) by standard methods 
of transfection [50] using a DNA construct (pL2203) that targets the neutral s1 gene 
locus (PY17X_1210000) by double cross-over integration and contains the hdhfr::yfcu SM 
driven by the P. yoelii hsp70 promoter (PY17X_0712100). We used plasmid pL2200 that 
contains the hdhfr::yfcu selectable marker (SM) cassette under the control of the P. yoelii 
hsp70 5’-UTR promoter and the 3’ terminal sequence of pbdhfr/ts. In this plasmid we 
replaced the existing targeting 5’-UTR and 3’-UTR regions of gene PBANKA_1122300 
with the 5’-UTR and 3’-UTR regions of s1 gene. These regions were  amplified from P. 
yoelii genomic DNA using primer sets 8450/8451 (1040 bp) and 8452/8453 (937 bp), 
respectively. First, the 5’UTR-targeting region (1040 bp) of s1 was cloned into pL2200 
plasmid using HindIII and PstI. Next, the 3’-UTR targeting region (937 bp) of s1 was 
cloned into the intermediate plasmid using KpnI and NotI, resulting in the final GIMO 
s1 plasmid (pL2203). This construct was linearized with HindIII/EcoRI before transfection. 
Transfection (exp 2828), positive selection with pyrimethamine, cloning and genotyping of 














of the hdhfr::yfcu SM in the fabb/f gene in 2828cl2 of gene was verified was verified by 
Southern analyses of Pulsed Field Gel (PFG)-separated chromosomes and diagnostic PCR 
analysis as described above.  
v) Introducing an gp96@lisp2 expression cassette in GIMOPys1 
Parasites of GIMOPys1  were transfected with a pL2221 construct that contains an expression 
cassette where the gp96 gene (see above) is under control of the 5’-UTR promoter region 
of lisp2  (PY17X_1004400). This construct (pL2221) aims at replacing the hdhfr::yfcu SM 
in the s1 locus of GIMOPys1. First we generated an intermediate plasmid which contains 
an expression cassette where the gp96 gene (see above) is under control of the 5’-UTR 
promoter region (1060 bp) of lisp2  (PY17X_1004400).  First, we amplified the lisp2 
promoter region from genomic DNA using primers 8507 and 8508. The amplified fragment 
was cloned into the plasmid pL2156 (described above) to replace the 5’fabb/f targeting 
region, uis4 CDS and and 5’-UTR cassette using PspOMI and SacI. Next, the 3’-UTR 
(883 bp) of lisp2 was amplified by PCR from genomic DNA using primers 8509 and 8510 
primers and cloned using MfeI and NotI restriction enzymes into the intermediate plasmid 
to replace 3’-UTR uis4 and 3’-UTR fabb/f targeting region. This resulted in a construct 
where the gp96 gene is under control of the lisp2 promoter region and the 3’-UTR of 
the lisp2. Next, by using the GIMO s1 plasmid (pL2203; described above), the hdhfr::yfcu 
SM cassette was replaced with the gp96 gene and the 5’-UTR and 3’-UTRl sequence using 
XmaI enzyme. The final DNA construct (pL2221) was linearized with PspOMI and NotI 
before transfection. Transfection (exp 2866), negative selection with 5-FC, cloning and 
genotyping of transformed parasites was performed using standard methods [47, 50]. 
Correct integration of the gp96@lisp2 expression cassette in the s1 gene in 2866cl1 was 
verified by Southern analyses of Pulsed Field Gel (PFG)-separated chromosomes and 
diagnostic PCR analysis as described above.
vi) Generation of transgenic GAP expressing Gp96 and FliC  fused to 
HEP17/EXP1
We generated two constructs that target the fabb/f gene and that contains an expression 
cassette with the gp96 gene (see above) or the flic sequence (see above) fused to HEP17/
EXP1 (PY17X_0928700). These constructs aims at replacing the hdhfr::yfcu SM in the fabb/f 
locus. First, the 5’UTR promoter region of hep17 (1380 kb upstream of the start codon) 
and the signal peptide (SP) sequence of hep17 (bp 1 to 81) were amplified from wild-type 
P. yoelii DNA using primers 7838 and 7839 (1481 bp) and this fragment was subcloned into 
plasmid pL1980 ([49]; described above). Second, the remaining sequence of the hep17 
CDS after the SP (bp 82 to 785), along with the 3’-UTR region (806 bp) was amplified 
using primers 7840 and 7841 (1539 bp) and cloned into this vector. Third, we cloned 
into this vector the mCherry CDS, resulting in plasmid pL2100. This vector was used to 














the flic sequence (amplified from pL2155 using 7947 and 7948 primers) and the gp96 
sequence (amplified from pL2156 using 7955 and 7956 primers). The resulting final vectors 
with flic and gp96 fused to hep17 were pL2114 and pL2115, respectively. The final DNA 
constructs were linearized with PspOMI/NotI before transfection. Transfection, negative 
selection with 5-FC, cloning and genotyping  of transformed parasites was performed 
using standard  methods [47, 50]. Correct integration of the construct in the fabb/f gene 
in the transgenic GAP line FliC::hep17/exp1 (2587m1cl1) was verified was verified by 
Southern analyses of Pulsed Field Gel (PFG)-separated chromosomes and diagnostic PCR 
analysis as described above.  
Mosquito infection, analysis of oocysts and preparation and injection of 
sporozoites
Sporozoites were obtained by manual dissection of the salivary glands of infected A. 
stephensi mosquitoes 14 days after feeding on infected mice as described [22]. For 
intravenous (IV) administration sporozoites were suspended in RPMI1640 medium and per 
mouse 200 μl was injected into the tail vein. Oocyst numbers in dissected midguts from 
infected mosquitoes were established 8 days after feeding using light-microscopy.
Determination of parasite liver load and prepatent period after infection, 
immunization or challenge
Parasite liver loads in live mice quantified by real time in vivo imaging as previously 
described [51]. Mice were monitored for blood-stage infections by Giemsa-stained blood 
smears made at day 4-14 after infection or challenge. The prepatent period  is defined as 
the day when a blood stage infection with a parasitemia of 0.5–2% is observed [48].
In vitro hepatocyte cultures and analysis of parasite development
The human hepatocyte cell line HepG2-CD81 was used for in vitro cultures of liver stages 
as described [52]. Isolated sporozoites (5×104 ) were added to monolayers of HepG2-
CD81 cells on coverslips in 24 well plates. At 40 hours after infection, nuclei were stained 
with Hoechst 33342 at a final concentration of 10 µM and live imaging of parasites was 
performed using a DM RA Leica fluorescence microscope (40×). Images analysis was done 
with the Leica LAS X software.
Statistics
All data were analyzed using the GraphPad Prism software package 5.04 (GraphPad 
Software, Inc). For oocysts/sporozoite number and in-vivo imaging (RLU) analysis, 
statistical analysis was performed using the unpaired Student’s t-test. Survival analysis 
were performed using Kaplan–Meier survival plots and survival curves were compared 
using the log-rank (Mantel-Cox) test. Survival was considered as the complete absence of 















Generation of a P. yoelii GAP GIMO parent line (GIMOPyGAP-fabb/f) to 
introduce transgenes
In order to introduce adjuvant transgenes into the genome of a non-lethal P. yoelii (17X) 
GAP, we created a ‘GIMO GAP motherline’. This line was created for the following reasons: 
(i) P. yoelii 17X in combination with BALB/c mice is a standard combination used to analyse 
protective immune responses induced by GAP immunization [53]; (ii) the insertion of 
the positive/negative selectable marker (i.e. creation of the GIMO locus) into P. yoelii fabb/f 
gene (PY17X_1126500) creates a late-arresting P. yoelii GAP, therefore making it possible 
for adjuvant transgene expression to be maintained late into liver stage development 
[8, 49]; and (iii) the GIMO-locus in a P. yoelii GAP can be used to insert adjuvant-expression 
cassettes rapidly using GIMO transfection, yielding drug-resistance marker free adjuvant-
GAPs [47, 48].
In the GIMO-transfection protocol, transgene-expression cassettes replace 
the positive-negative hdhfr::yfcu selection marker (SM), which is present in the genome 
of a standard GIMO mother line, resulting in SM-free transgenic parasites [47]. Recently, 
a P. yoelii 17X fabb/f GAP (line 2251cl3) has been created in a line that constitutively 
expresses GFP and luciferase (1971cl1) by introducing the hdhfr::yfcu SM into the fabb/f 
locus [49]. The presence of the fusion gene gfp-luciferase under control of the constitutive 
eef1a  promoter permits quantification of parasite liver loads by in vivo imaging after 
sporozoite administration [48, 54]. We initially used this line as a GAP GIMO parent line 
for introduction of transgene-expression cassettes. However we encountered problems 
selecting for the desired transgenic GAP. After transfection and the application of 
negative drug selection in mice, we repeatedly selected for parasite populations in which 
the majority of the parasites still had the genotype of the GAP GIMO parental line without 
the transgene-expression cassettes (data not shown). Since these parasites still contained 
the hdhfr::yfcu SM we reasoned that expression of the negative marker yfcu in parasites 
of line 2251cl3 was not sufficient to kill parasites by the 5-FC treatment. In this parental 
GIMO line the hdhfr::yfcu SM expression is controlled by the eef1a P. berghei promoter 
which may be less effective in driving transgene expression in P. yoelii than in P. berghei. 
We therefore decided to generate a new GIMO P. yoelii 17X fabb/f GAP parent line, where 
the hdhfr::yfcu SM is under control of the strong hsp70  promoter of P. yoelii [55].
This new GIMO GAP parent line (GIMOPyGAP-fabb/f; 2668cl1) was also generated in 
the parent 1971cl1 line by standard methods of transfection. A DNA construct was used 
that targets the fabb/f gene to introduce the hdhfr::yfcu SM driven by the P. yoelii hsp70 
promoter by double cross-over integration (Figure 1A). Transfection followed by positive 
selection with pyrimethamine, cloning and genotyping of transformed parasites was 
performed using standard technologies [50]. Correct integration of the hdhfr::yfcu SM in 
the fabb/f gene was verified by Southern blot analyses of Pulsed Field Gel (PFG)-separated 














Figure 1. Generation and genotype analysis of the P. yoelii GAP GIMO parent line (GIMOPyGAP-fabb/f) 
for introduction of adjuvant-expression cassettes. (A) Schematic representation of the introduction of 
the hdhfr-yfcu selectable marker (SM) cassette into the fabb/f gene locus of the parent P. yoelii parasite 
(line 1971cl1). Construct pL2138 contains the hdhfr-yfcu SM flanked by the hsp70 promoter region and 
the 3’ pbdhfr UTR. This construct is integrated into the fabb/f locus by double cross-over homologous 
recombination at the fabb/f homology regions (HR1, HR2). Positive selection with pyrimethamine 
selects for parasites that have the fabb/f coding sequence replaced by the SM cassette, thereby 
creating a GAP GIMO line (2668cl1) for introduction of adjuvant expression cassettes. Location of 
primers used for PCR analysis and sizes of PCR products are shown. (B) Diagnostic PCR (left panel) 
and Southern analysis of PFG-separated chromosomes (right panel) confirm correct integration of 
construct pL2138 in parasites of line 2668cl1. PCR shows the presence of the hdhfr::yfcu marker. 
5’ integration PCR (5’-int; primers p1/p2), 3’ integration PCR (3’-int; primers p5/p6), hdhfr::yfcu 
(primers p3/p4). Primer locations and product sizes are shown in A and primer sequences in Table 
S1). Hybridization of PFG-separated chromosomes with a mixture of two probes (the hdhfr probe and 
a control probe recognizing p25 gene on chromosome 5) shows the presence of the SM cassette 














type blood stage growth as determined during the cloning procedure (data not shown). 
This GIMOPyGAP-fabb/f line was used as the parental GIMO GAP line to introduce the different 
adjuvant transgenes as described in the next sections.  
Introduction of the mCherry::uis4 fusion gene into GIMOPyGAP-fabb/f and 
analysis of mCherry::UIS4 expression in sporozoites and liver stages
To express putative adjuvants, we fused the adjuvant proteins to P. yoelii UIS4 
(PY17X_0502200; up-regulated in infective sporozoites, ETRAMP10.3) and placed 
the fusion genes under control of the 5’-promoter and 3’-transcriptional terminator 
sequences of P. yoelii uis4. UIS4 is a protein of the parasitophorous vacuole membrane 
(PVM) that surrounds the parasites in infected hepatocytes [56]. We fuses the adjuvant 
proteins to a PVM protein as it has been previously shown that ovalbumin (OVA) fused 
to PVM proteins induces stronger T cell responses than OVA located in the cytoplasm of 
transgenic parasites [45, 46].
To analyze whether the C-terminal fusion of a heterologous protein to UIS4 affects 
either UIS4 expression or its PVM location, we first generated a transgene reporter line that 
expresses mCherry fused to UIS4. We transfected GIMOPyGAP-fabb/f parasites with a construct 
containing a mCherry::uis4 expression cassette (exp. 2696). This construct targets and 
replaces the hdhfr::yfcu SM in the fabb/f locus of GIMOPyGAP-fabb/f with the mCherry::uis4 
cassette (Figure 2A). Transfection, negative selection with 5-FC, cloning and genotyping 
of transformed parasites was performed using standard technologies [47, 50]. Correct 
integration of the mCherry::uis4 expression cassette in the fabb/f gene in the cloned line 
2696cl1 was verified by Southern analyses of PFG-separated chromosomes and diagnostic 
PCR analysis (Figure 2B).  We next analyzed mCherry::UIS4 expression during the parasite’s 
life cycle by fluorescence microscopy. No mCherry signal was detected in blood stages 
or developing oocysts (Figure 2C), in agreement with the absence of UIS4 expression in 
these stages. In sporozoites, uis4 is transcribed but transcripts are translationally repressed 
[57, 58].  We could indeed detect no mCherry signals in >80% of live, freshly isolated 
sporozoites. However, in sporozoites kept for longer periods in RPMI1640 culture medium, 
weak mCherry signals were visible, with >50% of the sporozoites weakly mCherry-positive 
as early as 1 hour after isolation (Figure 2C). mCherry expression was clearly detected 
in cultured liver stage parasites, predominantly located at the periphery of the parasites 
(Figure 2D), consistent with UIS4 localization in the PV/PVM [57]. Although we did not 
further analyze the exact location of mCherry::UIS4 in the PV, our results demonstrate that 
the fusion protein mCherry::UIS4 is only expressed in liver stages and is mainly located 
at the periphery of the parasite during liver stage development. In addition, our results 
indicate that the fusion of UIS4 to mCherry does not affect the development of sporozoites 
into mature liver stages. Parasites lacking expression of UIS4 display a strongly retarded 
liver stage maturation [56, 59]; in contrast, mCherry::UIS4-expressing parasites display 
normal liver stage development, as shown both in vitro analysis of liver stage maturation 














Figure 2. Introduction of the mCherry::uis4 fusion gene into GIMOPyGAP-fabb/f and analysis of 
mCherry::UIS4 expression in sporozoites and liver stages. (A) Schematic representation of 
the introduction of the mCherry::uis4 expression cassette into the genome of GIMOPyGAP-fabb/f (line 
2868cl1). Construct pL2154 contains the uis4 coding DNA sequence (CDS) fused to mCherry which is 
flanked by the uis4 promoter and 3’-UTR regions. This construct is integrated into the modified fabb/f 
locus of GIMOPyGAP-fabb/f, that contains the hdhfr::yfcu selectable marker (SM) cassette, by double cross-
over homologous recombination at the homology regions (HR1, HR2). Negative selection with 5-FC 
selects for parasites that have the SM cassette replaced by the mCherry::uis4 expression cassette. 
Location of primers used for PCR analysis and sizes of PCR products are shown. (B) Diagnostic PCR (left 














infected with mCherry::uis4 sporozoites (Figure 2E).  All mice infected with mCherry::uis4 
sporozoites did not develop a blood stage infection as expected based on the introduction 
of the transgene expression cassette into the fabb/f gene locus, resulting in the absence of 
FabB/F expression and late liver stage developmental arrest.
Generation of four adjuvant GAPs expressing putative immunomodulatory 
proteins fused to UIS4 
To generate adjuvant GAP that express putative immunomodulatory proteins we selected 
the following four adjuvants: (i) nontoxic cholera toxin B subunit from Vibrio cholerae (CTB), 
(ii) heat shock protein Gp96 of mice (Gp96), (iii) heat shock protein X from Mycobacterium 
tuberculosis (HspX) and (iv) the TLR5 binding region of Salmonella typhimurium flagellin 
(amino acids 89–96; FliC). We fused the coding sequence of these genes to the uis4 gene 
of P. yoelii under control of the 5’-promoter and 3’-transcriptional terminator  sequences 
of uis4 and the expression cassettes were introduced into the fabb/f gene locus of 
GIMOPyGAP-fabb/f parasites by GIMO transfection. We transfected GIMOPyGAP-fabb/f parasites with 
the four adjuvant constructs that are designed to replace the hdhfr::yfcu SM in the fabb/f 
locus of GIMOPyGAP-fabb/f (Figure 3A, B) with the adjuvant transgene. Transfection, negative 
selection with 5-FC, cloning and genotyping of transformed parasites was performed using 
standard technologies [47, 50]. Correct integration of the transgene expression cassette 
into the fabb/f gene was verified by Southern analyses of PFG-separated chromosomes 
and diagnostic PCR analysis for the following transgenic GAP lines, CTB::UIS4 (2690cl1), 
Gp96::UIS4 (2692cl2), HspX::UIS4 (2694cl1), FliC::UIS4 (2698cl2) (Figure 3C). These 
of construct pL2154 in in parasites of line 2696cl1. PCR shows the absence of the hdhfr::yfcu SM 
marker and the presence of the mCherry::uis4 fusion gene. 5’ integration PCR (5’-int; primers p9/
p10), 3’ integration PCR (3’-int; primers p13/p14), hdhfr::yfcu (SM; primers p7/p8), mCherry::uis4 
(CDS; primers p11/p12). Primer locations and product sizes are shown in A and primer sequences in 
Table S1). Hybridization of PFG-separated chromosomes with a mixture of two probes (the hdhfr probe 
and a control probe recognizing p25 gene on chromosome 5) shows the removal of the SM cassette 
marker from the fabb/f locus on chromosome 11 in 2696cl1 parasites. (C) Analysis of mCherry::UIS4 
expression in live blood and mosquito parasite stages by fluorescence microscopy. No mCherry signal 
was detected in blood stages and oocysts. Left panel: a representative schizont of the negative blood 
stages is shown and an oocyst-containing midgut of an A. stephensi mosquito. Right panel: no signal 
was detected in >80% of sporozoites that were analyzed directly after isolation (Spz-fresh; upper 
panel). Incubation of sporozoites in RPMI 1640 for longer periods (>1 hour) resulted in weak mCherry 
signals in >50% of the ‘activated’ sporozoites (Spz-act; lower panel). H: Hoechst; BF: bright field; M: 
merged. BS and Spz; Scale bar: 2 µm. (D) Analysis of mCherry::UIS4 expression in live, cultured liver 
stages. Representative images of maturing liver schizonts, showing mCherry signals, mainly located at 
the periphery of the parasite. H: Hoechst; BF: bright field; M: merged. Scale bar: 10 µm. (E) Parasite 
liver loads in mice at 44 hour after infection with 1 × 104 sporozoites of a parent PyGAP (line 2251cl3) 
and the PyGAP expressing UIS4::mCherry (line 2696cl1). Parasite liver loads in mice were determined 
by measuring in vivo luciferase activity and depicted as relative light units (RLU). The left panel shows 















Figure 3. Introduction of four adjuvant-expression cassettes into GIMOPyGAP-fabb/f and genotype 
analysis of the adjuvant GAPs. (A) Schematic representation of the introduction of the adjuvant-
expression cassette into the genome GIMOPyGAP-fabb/f (line 2868cl1). The construct contains the uis4 
coding DNA sequence (CDS) fused to the adjuvant which is flanked by the uis4 promoter and 3’ UTR 
regions. This construct is integrated into the modified fabb/f locus of GIMOPyGAP-fabb/f, that contains 
the hdhfr::yfcu selectable marker (SM) cassette, by double cross-over homologous recombination at 
the homology regions (HR1, HR2). Negative selection with 5-FC selects for parasites that have the SM 
cassette replaced by the adjuvant expression cassette. Location of primers used for PCR analysis 














adjuvant GAP lines showed wild type blood stage growth as determined during the cloning 
procedure (data not shown).
Sporozoites of 3 adjuvant GAPs, CTB::UIS4, HspX::UIS4 and FliC::UIS4, are 
infectious to mice and develop into maturing liver stages
The four adjuvant GAP lines were infectious to mosquitoes and produced wild type-like 
numbers of oocysts. All lines produced salivary gland sporozoites, with three lines 
(Gp96::UIS4; HspX::UIS4, FliC::UIS4) producing sporozoite numbers that were comparable 
to sporozoite numbers produced by the parent PyGAP, whereas  CTB::UIS4 produced 
lower numbers of sporozoites (Figure 4A). Sporozoites of three of the four adjuvant  GAP 
(CTB::UIS4; HspX::UIS4, FliC::UIS4) were infective to mice, as shown by in vivo imaging 
of parasite liver loads after infection of mice with adjuvant GAP sporozoites (Figure 4B). 
However, no hepatic infection was detected in mice infected with Gp96::UIS4 sporozoites 
(Figure 4B and Figure 5B). The normal liver parasite liver loads of CTB::UIS4; HspX::UIS4 
and FliC::UIS4 parasites, as visualised by in vivo imaging of the liver 44h after infection and 
shown by the presence of developing schizonts in in vitro cultures of infected hepatocytes 
(Figure 4C) demonstrate that the expression of these adjuvants do not disrupt intrahepatic 
development of the late arresting P. yoelii fabb/f GAP.
Fusion of Gp96 to PVM proteins affects parasite development
The absence of detectable parasites in the liver of mice infected with Gp96::UIS4 
sporozoites may be due to different reasons. Gp96::UIS4 sporozoites may not be able to 
invade hepatocytes, or they may be able to invade but arrest growth soon after invasion. 
Growth arrest may result from either toxicity of Gp96 for the parasite or from a perturbation 
of the correct function of UIS4 (i.e. the formation maintenance of PV/PVM) upon fusion to 
GP96.  Another possibility is that expression of the Gp96::UIS4 results in efficient detection 
and clearance of infected hepatocytes by the immune system. To examine the possible 
toxicity of Gp96  for developing liver stage parasites, we generated a transgenic P. yoelii 
17XNL line (2866cl1) that expressed Gp96 in the cytoplasm of the parasite and was not 
fused to a Plasmodium protein. Gp96 was placed under control of the promoter of the liver 
stage specific gene, lisp2  (Figure S1A) which has been previously used to drive transgene 
expression in the cytoplasm of liver stages [60-62]. The gp96@lisp2 expression cassette 
CTB, Gp96, HspX or FliC fused to uis4 under control of the promoter and 3’-UTR regions of uis4 as 
shown in A. (C) Diagnostic PCR (left panel) and Southern analysis of PFG-separated chromosomes 
(right panel) confirm correct integration of the constructs in parasites of the four different adjuvant 
GAP and the parent PyGAP (line 2668cl1). PCR shows the absence of the hdhfr::yfcu SM marker 
and the presence of the coding DNA sequence (CDS) of the fusion gene. 5’ integration PCR (5’-
int.), 3’ integration PCR (3’-int.). Primer locations are shown in A and primer sequences in Table S1). 
Hybridization of PFG-separated chromosomes with a mixture of two probes (the hdhfr probe and 
a control probe recognizing p25 gene on chromosome 5) confirms the removal of the SM cassette 














Figure 4. Analysis of mosquito and liver stage development of the four adjuvant GAP. (A) Oocyst and 
sporozoite production in A. stephensi of the four adjuvant GAP and the parent PyGAP (line 2251cl3). 
Oocyst and sporozoite numbers were determined at day 8 and day 14, respectively, after mosquito 
infection. (B) Parasite liver loads in mice 44 hour after infection with 1 × 104 sporozoites of a parent 
PyGAP (line 2251cl3) and the four adjuvant GAP. Parasite liver loads were determined by measuring 
in vivo luciferase activity and depicted as relative light units (RLU). The left panel shows images of 
real time in vivo imaging of luciferase-expressing liver stage parasites in mice at 44 h after injection 
of sporozoites. (C) Analysis of development of liver stages in in vitro cultures of infected hepatocytes. 
Representative images of maturing GFP-expressing liver schizonts of three adjuvant GAP are shown. 














Figure 5. Analysis of protective immunity induced by immunization of mice with sporozoites of 
the adjuvant GAP. (A) The time line shows immunization of BALB/c mice with adjuvant GAP sporozoites 
(a single dose of 2.5 × 104) and challenge 14 days later with 3 × 103 wild type (PyWT; line 1971cl1) 
sporozoites. Challenged mice were monitored for blood-stage infections from day 18 onwards to 
determine the prepatent period. (B) Parasite liver loads in mice at 44 hour after immunization with 2.5 
× 104 sporozoites of a parent PyGAP (line 2251cl3) and the four adjuvant GAP and after challenge of 
the immunized mice with 3 × 103 wild type sporozoites (PyWT; line 1971cl1). Parasite liver load were 
determined by measuring in vivo luciferase activity and depicted as relative light units (RLU). The upper 
panel shows images of real time in vivo imaging of luciferase expressing liver stage parasites in mice 
at 44 h after sporozoite injection. (C) Survival curves (Kaplan-Meier analysis) illustrating the prepatent 
period (day at which a parasitemia of 0.5–2% is observed) and the Log-Rank (Mantel-Cox) Test was 
used to compare groups of mice. Data shown correspond to groups of 5 mice.  Significance values: 
naïve vs PyGAP *p = 0.027; naïve vs CTB::GAP *p = 0.027; naïve vs gp96::GAP **p = 0.007; naïve vs 
HspX::GAP p = 0.065; naïve vs FliC::GAP p = 0.065). 
was introduced into a novel P. yoelii 17XNL GIMO line (GIMOPys1; 2828cl2), which has 
a hdhfr::yfcu SM under control of the P. yoelii hsp70, introduced into the silent s1 locus 
of the 1971cl1 line (Figure S2). The gp96@lisp2 parasites (line 2866cl1) exhibit normal 
development throughout the parasite’s life cycle, including its liver stage development 
and the time to patency in the blood after sporozoite inoculation is comparable to that 
of WT parasites (Figure S1C). These observations indicate that expression of Gp96  in 
the  cytoplasm is not toxic for the parasite. This suggests that fusion of Gp69 to UIS4 
compromises the essential function of UIS4 at the PVM, resulting in the absence of 
liver stage development, comparable to mutants lacking expression of UIS4 [56, 59]. 
Previously we have fused transgenes, such as ovalbumin and mCherry, to another PVM 
protein HEP17/EXP1  [45, 63], which is expressed on the PVM of both blood- and liver-
stage parasites and is essential for blood stage development. We therefore attempted 
to generate a transgenic line that express Gp69 fused to HEP17/EXP1  and, as a control, 
a transgenic line where FliC was fused to HEP17/EXP1.  In seven independent transfection 
experiments we were unable to select for parasites that contained a gp96::hep17/exp1 
expression cassette integrated into the fabb/f locus, whereas we were able to select 
parasites where the FliC::hep17/exp1 expression cassette had integrated into the fabb/f 
locus (line 2587m1cl1) of the parental GIMO GAP line 2567cl1 (Figure S3). Combined, 
our observations indicate that fusion of Gp96 to Plasmodium PVM proteins is lethal to 
the parasite. 
Analysis of protective immunity induced by immunization of mice with 
sporozoites of the adjuvant GAP 
To analyze protective immunity induced by immunization with adjuvant GAP sporozoites, 
we used a recently developed ‘sub-saturating’ immunization regiment in BALB/c mice using 
GAP-sporozoites (ΔPyFabBF-GFP-Luccon) [22]. This ‘sub-optimal’ immunization regiment 




























WT parasites as determined by a delay of blood-stage prepatency. In this protocol (Figure 
5A) mice are immunized with a single dose of 2.5 × 104 GAP sporozoites and  challenged 
14 days later with 3 × 103 wild type P. yoelii sporozoite (Py-GFP-Luccon; PyWT). A single 
immunization with this parasite dose results in a maximum of one day delay in prepatent 
period in immunized mice compared to naïve mice and none of the mice are completely 
protected. Since the blood stage multiplication rate is approximately 10× per 24 h, a one 
day delay in the prepatent period represents a ~90% reduction of liver infection, and this 
protocol was used to determine 10-fold increase in GAP vaccine potency after the addition 
of an adjuvant [22]. 
We used this protocol to analyze protective immunity of the four adjuvant GAP, 
CTB::UIS4; Gp96::UIS4, HspX::UIS4, FliC::UIS4. Groups of 5 mice were immunized with 
a single dose of 2.5 × 104 adjuvant GAP sporozoites and challenged 14 days later with 
3 × 103 WT sporozoites. Parasite liver loads were determined by in vivo imaging at 44 hours 
after injection of sporozoites, both after immunization and after challenge. In addition, 
the time to blood stage patency (prepatent period) after challenge was determined to be 
4-7 days after WT sporozoite challenge. As a control we immunized mice with sporozoites 
of the non-adjuvanted P. yoelii fabb/f GAP (line 2251cl3).
Parasite liver loads of all groups of mice immunized with the adjuvant-GAPs, except 
for the Gp96::UIS4,  were comparable to liver loads of mice immunized with the parent 
P. yoelii fabb/f GAP (Figure 5B). The absence of Gp96::UIS4 parasites in the liver at 44h 
after immunization was expected based on the absence of liver stage development 
Gp96::UIS4-expressing parasites (see previous section above). After challenge with WT 
sporozoites 14 days after immunization, the parasite liver load of mice immunized with 
CTB::UIS4, Gp96::UIS4 and the control GAP were significantly reduced compared to naïve 
mice infected with the same parasite dose (Figure 5C). Although parasite liver loads of 
HspX::UIS4 and FliC::UIS4 immunized mice were reduced compared to those of naïve 
mice, this reduction was not significant. Despite the variation in the parasite liver loads 
after WT sporozoite challenge all adjuvant GAP immunized mice became patent with a 1-2 
day delay compared to the naïve mice, but all groups of adjuvant GAP-immunized mice 
had a prepatent period that was similar to that of P. yoelii fabb/f GAP-immunized mice (at 
day 5-6). These observations indicate that the four adjuvant GAP had a similar or lower 
than 10-fold increased potency when compared to the parent, non-adjuvanted GAP. 
DISCUSSION
In this study we generated four different transgenic GAPs engineered to express 
the potential immunomodulatory proteins CTB, Gp96, HspX and FliC, shown to act as 
adjuvants in other vaccine studies [35-43]. These proteins have been shown to interact 
with innate immune pattern recognition receptors on antigen presenting cells (APC)  that 
can both trigger cytokine production to limit infection and directing adaptive immune 














are thought to stimulate different Toll-like receptors (TLRs), which can not only improve 
antibody and CD4+ T cell responses but also promote the cross-presentation of vaccine 
antigens directing the immune response towards the formation of cytotoxic (CD8+) T cells. 
Parasite antigen-specific  CD8+ T cells are considered of particular importance in detection 
and clearance of Plasmodium-infected hepatocytes [59, 64]. However, immunization with 
none of the four adjuvant GAP developed in the present study resulted in a significant 
increase in protective efficacy (more than 10-fold) compared to the unmodified 
PyGAP in the P. yoelli-BALB/c model employed in this study to measure enhanced 
protective immunity.
This inability to achieve significantly higher protective immunity with the adjuvant 
GAPs could be due to a number of factors, but is unlikely to be due to a poor expression 
of the adjuvant proteins. These proteins were fused to UIS4, a protein associated with 
the PVM, which surrounds the parasites inside a hepatocyte [57]. UIS4 is strongly expressed 
during Plasmodium liver stage development [65] and is essential for normal development 
of liver stages [57, 58]. Mutants that lack UIS4 expression have a very strong defect in liver 
stage development with only very few parasites developing in hepatocytes 24 hours after 
sporozoite infection [56]. We found that fusion of mCherry to the C-terminus of UIS4 in 
PyGAP parasites did not affect UIS4 expression; mCherry is clearly exported to the PVM/
PV and these transgenic parasite develop into liver schizonts, similarly to the unmodified 
PyGAP. Parasite liver loads 44 hours after injection of three of the four adjuvant GAP 
sporozoites (CTB::UIS4, HspX::UIS4 and FliC::UIS4) were comparable to the parasite liver 
loads achieved after the administration of the same number of non-adjuvanted PyGAP 
sporozoites, indicating that fusion of these adjuvants to UIS4 did not negatively impact 
UIS4 expression. This PyGAP-like liver stage development of adjuvant GAPs was also 
confirmed by microscopy analyses of in vitro infected hepatocytes. In contrast,  we were 
unable to detect liver stage development with the GP96 adjuvant-expressing parasite, 
neither in vivo nor in vitro. By analyzing additional mutants expressing Gp96, either 
expressed in the liver-stage parasite’s cytoplasm or fused to another PVM protein, we 
provide evidence that fusion of this protein to proteins of the PVM interferes with parasite 
development. Therefore, the failure of Gp96::UIS4 sporozoites to establish a liver infection 
appears to be due to the incorrect or absent PVM formation after hepatocyte invasion by 
the parasites. The lack of PVM formation and rapid arrest during liver stage development 
might affect both Gp96 expression and exposure to the immune system, which may 
explain Gp96’s inability to enhance GAP immunogenicity. However, despite the fact that 
Gp96::UIS4 sporozoites arrest early during liver stage development, immunization with 
Gp96::UIS4 sporozoites induced levels of protective immune responses similar to those 
of the late-arresting PyΔfabb/f GAP. This observation was unexpected since it has been 
shown that late-arresting GAP induce stronger protective immunity than early arresting 
parasites [8], and might suggest that protective immunity induced in the P. yoelii/
BALB/c model employed is mainly generated against sporozoite antigens with limited 














to UIS4, a protein expressed only after sporozoite invasion of hepatocytes. While uis4 is 
already transcribed in sporozoites, these transcripts are translationally repressed [57, 58]. 
Translational repression is mediated by sequences inside the open reading frame of uis4 
[57] and we found that transcripts of the uis4 and mCherry fusion were also translationally 
repressed. This suggests that the adjuvants fused to UIS4 are not expressed in sporozoites 
and interact with immune responses only after the intracellular parasite aborts liver 
stage development. 
Our failure to measure enhanced protective immune responses may be due to 
the inability of the selected adjuvants to induce protective immune responses that can 
more effectively detect and destroy developing liver stage parasites. While the precise 
mechanisms of protection mediated by immunization with attenuated sporozoites remain 
unknown, CD8+ T cells and IFN-γ appear to be critical for protective immunity as they 
are thought to play a major role in eliminating infected hepatocytes [59, 66, 67]. Recent 
mechanistic investigations into immunity induced by sporozoite-based immunization 
have shown that protective immune responses encompass diverse and robust immune 
responses that include not only CD8+ but also CD4+ T cells and a significant contribution 
from antibodies against sporozoite antigens [17, 18]. The selected adjuvants are known 
to stimulate TLR 2 (Gp96), TLR 4 (Gp96/CTB/HSPX) and TLR 5 (FliC) on the plasma 
membrane of APCs [37, 39, 41, 44] and the selection was based on the hypothesis 
that when GAP-infected hepatocytes disintegrate and release parasite antigens they 
will also simultaneously release the adjuvant, with parasite antigens being taken up by 
APCs and the released adjuvants stimulating TLRs on the same APC. This would then 
result in increased inflammatory responses against parasite antigens thereby improving 
and increasing cellular and humoral immune responses. It is possible that the adjuvants 
selected do not stimulate the most appropriate adaptive response that would result in 
the recognition and elimination of infected liver cells.
In this study we did not directly measure the effect of the TLR-agonists on different 
immune cell populations in immunized mice and we only measured protective immunity 
by determination of the prepatent period after challenge with WT parasites. One can 
speculate that either the adjuvants did not activate the appropriate immune cells or that 
those that are involved in removal of infected liver cells are activated but this activation is 
not sufficient to result in a more than 10-fold increase in protective immunity (i.e. 1 day or 
more delay in patency).
The failure to measure enhanced protective immune responses may also be due to 
the immunization protocol we employed. In this study we have used the P. yoelli-BALB/c 
immunization protocol which involves immunization with a single dose of sporozoites 
of a late arresting PyGAP followed by a challenge with wild type sporozoites 14 days 
later [22]. The effect of the selected adjuvants on protective immunity may have 
been better observed after prime-boost immunization strategies where the re-call of 
expanded immunological memory responses may enhance protective immunity. Indeed, 














results in an increase of the duration of protective immune response compared to 
non-adjuvanted GAP.
In conclusion, we have tested a set of potential adjuvants and created a panel of adjuvant 
GAPs to assess the possibility of enhancing immunogenicity of GAP. Whilst we were not 
able to detect a higher that 10-fold increase in vaccine potency, we have developed an 
immunization-challenge protocol, as well as a PyGAP GIMO mother line to rapidly create 
adjuvant GAPs, which can be used to evaluate other immunization schedules, additional 
adjuvants and/or novel enhanced GAPs. Manipulation, of the host immune response to 
direct and increase appropriate adaptive immune responses after vaccination is of value 
not only to enhance GAP vaccines but also other vaccines that need to generate immune 
responses to target liver infections.
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Supplementary Figure S1. Generation, genotype and phenotype analysis of a transgenic P. yoelii line 
expressing Gp96 under control of the promoter region of the liver specific lisp2 gene. (A) Schematic 
representation of the introduction of the Gp96-expression cassette into the GIMOPyS1 parasite (line 
2828cl1; see Figure S2). Construct pL2221 contains the Gp96 coding DNA sequence (CDS) flanked by 
the lisp2 promoter region and the 3’ pbdhfr UTR. This construct is integrated into the modified P. yoelii 
s1 locus of GIMOPyS1 that contains the hdhfr::yfcu selectable marker (SM) cassette  by double cross-
over homologous recombination at the homology regions (HR1, HR2). Negative selection with 5-FC 
selects for parasites that have the SM cassette replaced by the Gp96 expression cassette. Location 
of primers used for PCR analysis and sizes of PCR products are shown. (B) Diagnostic PCR (left panel) 
and Southern analysis of PFG-separated chromosomes (right panel) confirm correct integration of 
construct pL2221 in line 2866cl1 parasites. PCR shows the absence of the hdhfr::yfcu marker and 
the presence of the Gp96 CDS. 5’ integration PCR (5’-int; primers p17/p18), 3’ integration PCR (3’-int; 
primers p21/p22), hdhfr::yfcu (SM, primers p15/p16), Gp96 CDS (primers p19/p20). Primer locations 
and product sizes are shown in A, and primer sequences are presented in Table S1). Hybridization 
of PFG-separated chromosomes with a mixture of two probes (the hdhfr probe and a control probe 
recognizing p25 gene on chromosome 5) shows the removal of the SM cassette marker in the s1 
locus on chromosome 12 in 2866cl1 parasites. (C) Oocyst and sporozoite production in A. stephensi 
of the Gp96@lisp2 parasite line and the parent wild type (WT) P. yoelli line (line 1971cl1). Oocyst and 
sporozoite numbers were determined at day 8 and day 14, respectively, after mosquito infection. 
(D) Parasite liver loads in mice at 44 hour after infection with 1 × 104 sporozoites of the Gp96@lisp2 
parasite line (3 mice) and the parent wild type (WT) P. yoelli line (line 1971cl1) (17 mice). Parasite liver 
loads were determined by measuring in vivo luciferase activity and depicted as relative light units 
(RLU; middle panel). The left panel shows images of real time in vivo imaging of luciferase expressing 
liver stage parasites in mice at 44 h after injection of sporozoites. The right panel shows a Kaplan-




























Supplementary Figure S2. Generation and genotype analysis of the P. yoelii GIMO parent line 
(GIMOPys1) for introduction of expression cassettes into the s1 locus. (A) Schematic representation of 
the introduction of the hdhfr-yfcu selectable marker (SM) cassette into the s1 gene locus of the parent 
P. yoelii parasite (line 1971cl1). Construct pL2203 contains the hdhfr-yfcu SM flanked by the hsp70 
promoter region and the 3’ pbdhfr UTR. This construct is integrated into the s1 locus by double 
cross-over homologous recombination at the s1 homology regions (HR1, HR2). Positive selection 
with pyrimethamine selects for parasites that have the s1 coding sequence replaced by the SM 
cassette, thereby creating a GIMO line (2828cl2) for introduction of adjuvant expression cassettes. 
Location of primers used for PCR analysis and sizes of PCR products are shown. (B) Diagnostic PCR 
(left panel) and Southern analysis of PFG-separated chromosomes (right panel) confirm correct 
integration of construct pL2203 in parasites of line 2828cl2. PCR shows the presence of the hdhfr::yfcu 
marker. 5’ integration PCR (5’-int; primers p25/p26), 3’ integration PCR (3’-int; primers p29/p30), 
hdhfr::yfcu (primers p27/p28), s1 (CDS; primers p23/p24). Primer locations and product sizes are 
shown in A and primer sequences in Table S1). Hybridization of PFG-separated chromosomes with 
a mixture of two probes (the hdhfr probe and a control probe recognizing p25 gene on chromosome 
5) shows the presence of the SM cassette marker in the s1  locus on chromosome 12 in two clones of 














Supplementary Figure S3. Introduction of the Flic::hep17 fusion gene into GIMOPyGAP-fabb/f and 
genotype analysis of the FliC::HEP17 parasite line. (A) Schematic representation of the introduction 
of the FliC::hep17 expression cassette into the genome of GIMOPyGAP-fabb/f (line 2567cl1). Construct 
pL2114 contains the flic coding sequence (CDS) fused to the hep17 open reading frame (ORF) which 
is flanked by the hep17 promoter and 3’-UTR regions. This construct is integrated into the modified 
fabb/f locus of GIMOPyGAP-fabb/f by double cross-over homologous recombination at the homology 
regions (HR1, HR2). This locus contains the hdhfr::yfcu selectable marker (SM) cassette with the SM 
under control of the P. berghei eef1α promoter and an mCherry expression cassette with mCherry 
under control of the hsp70 promoter. Negative selection with 5-FC selects for parasites that have 
the SM cassette replaced by the FliC::hep17 expression cassette. Location of primers used for PCR 
analysis and sizes of PCR products are shown. (B) Diagnostic PCR (left panel) and Southern analysis 














parasites of line 2587m1cl1. PCR shows the absence of the hdhfr::yfcu SM marker and the presence of 
the FliC CDS. 5’ integration PCR (5’ int; primers p33/p34), 3’ integration PCR (3’ int; primers p37/p38), 
hdhfr::yfcu (SM; primers p31/p32), FliC (CDS; primers p35/p36). Primer locations and product sizes 
are shown in A and primer sequences in Table S1). Hybridization of PFG-separated chromosomes with 
a mixture of two probes (the hdhfr probe and a control probe recognizing p25 gene on chromosome 5) 
shows the removal of the SM cassette marker from the fabb/f locus on chromosome 11 in 2587m1cl1 
parasites. (C) Schematic representation of (unsuccessful) attempts to introduction of the Gp96::hep17 
expression cassette into the genome of GIMOPyGAP-fabb/f (line 2567cl1). Construct pL2115 contains 
the Gp96 coding sequence (CDS) fused to the hep17 open reading frame (ORF) which is flanked by 
the hep17 promoter and 3’ UTR regions. This construct aims at integration into the modified fabb/f 
locus of GIMOPyGAP-fabb/f by double cross-over homologous recombination at the homology regions 
(HR1, HR2). This locus contains the hdhfr::yfcu selectable marker (SM) cassette with the SM under 
control of the P. berghei eef1α promoter and an mCherry expression cassette with mCherry is under 
control of the hsp70 promoter. Negative selection with 5-FC aims at selecting for parasites in which 
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Vaccination with live, attenuated sporozoites provide strong protective immunity against 
malaria infection in both mice and humans. Using rodent models of malaria it has been 
shown that attenuated parasites that arrest late into liver-stage development provide 
superior immunity to those that arrest early. It is essential that attenuated-parasite vaccines 
cannot establish a pathogenic blood infection. We attempted to create rodent malaria 
mutants that show complete growth arrest during late liver-stage development by deleting 
different combination of two genes from the Plasmodium berghei parasite genome. 
The genes lisp1, lisp2, mei2 and palm, were selected as they encode proteins that play an 
important role in the final maturation of the parasite’s liver-stages. We showed that three 
genetically attenuated parasites (GAPs), Δlisp1Δlisp2, Δmei2Δlisp1 and Δlisp1Δpalm, 
produced blood-stage infections in mice after infection with 5 × 104 sporozoites. In 
contrast no blood-stage infections were observed in mice infected with 5 × 104 or 2-3 
× 105 Δmei2Δlisp2 and Δmei2Δpalm sporozoites. However, after a high dose of 5 × 105 
sporozoites of either mutant, some mice developed a blood infection. The Δmei2Δlisp2 
and Δmei2Δpalm mutants replicate and arrest late into liver-stage development as shown 
in vitro by the presence of large intrahepatic stages that express the merozoite proteins 
MSP1 and AMA1, and in vivo through the detection of high parasite liver-loads 44 hours 
after infection. We compared the immunogenicity of Δmei2Δlisp2 and Δmei2Δpalm late-
arresting GAPs (LA-GAPs) with that of an early-arresting GAP (Δb9Δslarp) in both BALB/c 
and C57BL/6 mice. Our results showed no significant differences exists in the induction 
of protective immunity between the two late-arresting GAPs and that the LA-GAPs were 
not significantly more protective than the early-arresting GAP. Overall, our results show 
that two double gene-deletion mutants were highly but not completely attenuated and 
that unexpectedly these LA-GAPs are not significantly more protective than parasites that 













Complete protection against a malaria infection has been demonstrated after immunization 
with live attenuated sporozoites both in rodent models of malaria and in humans [1-3]. 
Such sterile protection against a malaria infection in humans has been obtained after 
immunization with Plasmodium falciparum (Pf) sporozoites, which have been attenuated 
by radiation or administered under chemoprophylaxis [4-6]. A prerequisite for induction of 
protective immunity by whole sporozoite-based (wsp) vaccines is that sporozoites retain their 
capacity to invade liver cells after administration, as heat-killed sporozoites are unable to 
induce strong protective immunity [7, 8]. Vaccination with radiation-attenuated sporozoites 
(Irr-Spz) is currently the most advanced wsp vaccination strategy and is currently under 
evaluation both in the clinic and in the field [2, 9]. A number of studies have demonstrated 
that Irr-Spz vaccination can elicit strong protective immunity in humans [9-11]. However, 
in order to achieve high levels of protection, multiple immunizations with high doses of 
attenuated sporozoites are required [6, 9]. In the context of mass administration of wsp 
vaccines in malaria-endemic countries, multiple immunizations with high sporozoites 
doses have considerable implications for cost of goods due to the complicated production 
of sporozoites. A major challenge is to produce a highly immunogenic live-attenuated 
vaccine, that requires the fewest attenuated sporozoites per dose, and the fewest doses 
to induce sustained sterile protection against a malaria infection.
In rodent models of malaria it has been shown that immunization with sporozoites 
of genetically-attenuated parasites (GAPs) can induce similar, or even better, levels of 
protective immunity compared to Irr-Spz [1, 12-14]. Genetic attenuation of sporozoites is 
based on the deletion of one or multiple genes that play an important role during liver-
stage development, resulting in complete growth arrest of the parasites in the liver and 
thereby preventing the development of a blood-stage infection after immunization with 
GAP sporozoites. An advantage of GAP sporozoites compared to Irr-Sporozoites is that 
homogenous sporozoites populations can be produced with defined genetic identity and 
an attenuation phenotype that can be designed to induce optimal protective immunity. 
Moreover, the use of GAP sporozoites provide manufacturing advantages compared 
to Irr-Spz [1, 13, 14]. Most notably because sporozoites do not need to be irradiated 
before they are vialed and because their production poses little risk to the individuals who 
produce the vaccine as GAP sporozoites are unable to establish a pathogenic blood-stage 
infection. GAP studies in rodent malaria models have been critical for the generation 
of several P. falciparum GAP vaccine candidates, which are currently undergoing clinical 
evaluation [15-19]. Moreover, rodent models of malaria have been used to explore 
different approaches to enhance immunogenicity of wsp vaccines [1, 13, 14]. For example, 
it has been demonstrated that co-administration of adjuvants during immunization with 
attenuated sporozoites can enhance protective immune responses [20-22]. In addition, it 
has been shown that immunization of mice with GAP whose growth is arrested late during 












with GAP that arrest early after invasion of hepatocytes. Specifically, it has been shown that 
late-arresting GAP (LA-GAP) induce greater numbers of a broader range of CD8+ T cells, 
which results in increased protection against a malaria infection compared to immunization 
with early-arresting GAPs [12], most probably due to a greater number and repertoire 
of antigens expressed by LA-GAP. This may also explain the high degree of protective 
immunity observed when humans are immunized by fully infectious sporozoites under 
chemoprophylactic treatment with chloroquine [5, 23]. In this immunization approach, 
liver-stage development progresses normally but the merozoites that are released from 
the liver and infect erythrocytes are killed by chloroquine. This wsp approach induces 
sterile protection against parasite challenge but requires approximately 60-fold fewer 
cumulative sporozoites numbers than immunization with Irr-Spz which arrest early during 
liver-stage development [24]. A prerequisite for a GAP vaccine for humans use, is that 
the GAP sporozoites are unable to establish a potentially pathogenic blood-stage infection 
which requires that parasite growth is completely arrested during development in the liver. 
Consequently, multiple gene deletions in the same GAP are considered necessary, each 
governing independent but essential processes during liver-stage development [25]. 
Currently, three P. falciparum GAPs have been developed for clinical evaluation, all of 
which are early-arresting GAPs, that halt development soon after hepatocyte invasion 
[26-28]. In these GAPs either two or three genes, which encode proteins that play a vital 
role in early liver-stage development, have been deleted. Three of the selected proteins, 
P52, P36 and B9 are all members of the so-called 6-Cys gene family and all participate in 
the formation and maintenance of the parasitophorous vacuole (PV) inside the infected 
hepatocyte [29, 30] and the fourth protein, SLARP/SAP1, is involved in the regulation of 
gene expression [31, 32]. In contrast to the creation of early-arresting GAPs, the generation 
of safe LA-GAPs has been challenging. Although several genes have been identified that 
encode proteins that play an important role during late liver-stage development, deletion 
of those genes did not result in complete growth arrest in rodent models of malaria. 
Examples include multiple proteins involved in type II fatty acid synthesis pathways (FAS 
II, i.e. Fab proteins) [33, 34], a transcription factor with AP2 domain(s) (AP2-L) [35], biotin-
protein ligase 1 (HCS1) [36] and proteins involved in formation and egress of merozoites 
from liver-schizonts, i.e. liver merozoite formation protein (PALM) [37], putative liver stage 
protein 1 (LISP1) [38], liver-specific protein 2 (LISP2; also known as sequestrin) [29, 39] and 
ZIP domain-containing protein (ZIPCO) [40]. Only the deletion of  the genes encoding 
FabB/F [33] and MEI2-like RNA-binding protein (PlasMei2; hereafter referred to as mei2) 
have been reported to result in complete growth arrest in the rodent parasite P. yoelii [41]. 
However, studies in P. falciparum have shown that parasites lacking FabB/F expression are 
unable to complete mosquito stage development [42]. 
In an effort to identify GAPs that arrest late into liver-stage development and are unable 
to establish a blood infection, we investigated whether deleting combinations of genes 
that have been shown to have a role in late liver-stage development, could synergize to 












genes, mei2-palm or mei2-lisp2, had the strongest attenuation phenotype in P. berghei 
and both Δmei2Δlisp2 and Δmei2Δpalm parasites were arrested in growth late during 
liver-stage development. Our observation of the strong attenuation of Δmei2Δlisp2 is in 
line with a recent study where a similar phenotype was observed for the equivalent genetic 
deletion in P. yoelii [43]. However, we show that infection with high doses of Δmei2Δlisp2 
and Δmei2Δpalm sporozoites can result in ‘breakthrough’ blood infections. Moreover, 
unexpectedly, mouse immunization studies indicated that there was no improvement in 
protective immunity generated by LA-GAPs compared to an early-arresting GAP, which 
arrests soon after hepatocyte invasion. We discuss the implications of these findings both 
in the context of LA-GAP vaccine development and why late-arresting parasites do not 
provoke higher protective immunity despite the presence of much greater antigen load 
and diversity.
MATERIALS AND METHODS
Experimental animals and wild type and transgenic P. berghei lines
Female OF1, BALB/c ByJ and C57BL/6 mice (6-7 weeks; Charles River Laboratories, France) 
were used. All animal experiments of this study were approved by the Animal Experiments 
Committee of the Leiden University Medical Center (DEC 12042 and 14207) and Instituto 
de Medicina Molecular (IMM Lisboa). The Dutch Experiments on Animal Act and Animal 
Care Committee of IMM Lisboa (ACCiMM) are established under European guidelines (EU 
directive no. 86/609/EEC regarding the Protection of Animals used for Experimental and 
Other Scientific Purposes). All experiments were performed in accordance with relevant 
guidelines and regulations. Four P. berghei (Pb) lines were used: i) the reference ‘wild 
type’ PbANKA parasite line 676m1cl1 (PbANKA-GFP-Luccon; mutant RMgm-29; www.
pberghei.eu) which contains the fusion gene gfp-luc gene under control of the constitutive 
eef1α promoter integrated into the neutral 230p gene locus (PBANKA_0306000) and ii) 
the parent line PbANKA parasite line 1868cl1 (PbANKA-mCherryhsp70+Luceef1α; line RMgm-
1320; www.pberghei.eu) which contains the fusion gene mcherry gene under control of 
the strong hsp70 promoter and luciferase gene under control of the constitutive eef1α 
promoter integrated into the neutral 230p gene locus (PBANKA_0306000). Both lines does 
not contain a drug-selectable marker. Also, two previously generated of early-arresting 
GAP mutant parasite lines (in P. berghei ANKA background) were used Δslarp (1839cl3; 
mutant RMgm-1140; www.pberghei.eu) and Δb9Δslarp (1844cl1; mutant RMgm-1141; 
www.pberghei.eu).
Generation of marker-free mei2 and lisp1 single gene-deletion mutants
The mei2 (PBANKA_1122300) and lisp1 (PBANKA_1024600) genes were deleted in P. 
berghei by standard methods of transfection [44] using gene-deletion plasmids that were 
obtained from PlasmoGEM (Wellcome Trust Sanger Institute, UK). For deletion of mei2, 












(pL2204) were used (http://plasmogem.sanger.ac.uk/) [45]. Both constructs contain 
the hdhfr::yfcu selectable marker (SM) cassette with the P. berghei eef1α promoter region 
and 3’ terminal sequence of pbdhfr. Before transfection, the constructs were linearized by 
digesting with NotI. Parasites of line 1868cl1 were transfected with constructs pL2206 (exp. 
2834) and pL2204 (exp. 2832) using standard transfection technologies and transformed 
parasites selected by positive selection with pyrimethamine [44]. Selected parasites were 
cloned by limiting dilution and mutants 2834cl2 and 2832cl3 were used for genotype 
analysis and to generate the SM-free gene deletion mutants. To remove the hdhfr::yfcu SM 
cassette from the genomes of 2834cl2 and 2832cl3, these parasites were selected (negative 
selection) by treatment of infected mice with 5-Fluorocytosine (5-FC) as described [46]. This 
treatment selects for parasites that have undergone homologous recombination between 
the two 3’-UTR of pbdhfr untranslated regions present in the integrated constructs pL2206 
and pL2204, flanking the hdhfr::yfcu cassette and thereby removing the SM [47]. Selection 
and cloning of the parasites resulted in the SM-free single gene-deletion mutants Δmei2 
(2834cl2m1cl1) and Δlisp1 (2832cl3m0cl1) that were used to generate the double gene-
deletion mutants (see next section).
 Generation of double gene-deletion mutants
Parasites of Δmei2, which contains a disrupted plasmei2 gene and is SM-free, was 
used to delete the following genes in independent transfection experiments: lisp1 
(PBANKA_1024600), lisp2 (PBANKA_1003000) and palm (PBANKA_0101100). In 
addition, parasites of Δlisp1, which contains a disrupted lisp1 gene and is SM-free, 
was used to delete the following genes in independent transfection experiments: lisp2 
(PBANKA_1003000) and palm (PBANKA_0101100). To delete the lisp1, palm and lisp2 
genes, the gene-deletion constructs PbGEM-334115 (pL2204), PbGEM-266100 (pL2205) 
(http://plasmogem.sanger.ac.uk/) [45] and pL1462 (Annoura et al., 2014; http://www.
pberghei.eu/index.php?rmgm=930) were used, respectively. The PlasmoGEM constructs 
were obtained from Wellcome Trust Sanger Institute, UK. The PlasmoGem constructs 
contain the hdhfr::yfcu SM and pL1462 contains the dhfr gene of Toxoplasma gondii flanked 
by the pbdhfr promoter region and the 3’-UTR of pbdhfr. Transfection with linearized 
constructs, positive selection of transfected parasites with pyrimethamine and cloning of 
selected parasites were performed as described [44]. This resulted in the 5 following lines/
clones: Δmei2Δlisp2 (line 2900cl3), Δmei2Δlisp1 (line 2901cl1), Δmei2Δpalm (line 2903cl3), 
Δlisp1Δlisp2 (line 2961cl1) and Δlisp1Δpalm (line 2961cl1) that were used for genotype 
and phenotype analyses (see next sections). 
Genotyping single- and double gene-deletion mutants
Correct integration of the constructs and deletion of the genes were verified by Southern 
analyses of Pulsed Field Gel (PFG)-separated chromosomes and diagnostic PCR analysis 












removal of the hdhfr::yfcu SM by negative selection, the PFG-separated chromosomes 
were hybridized with a mixture of two probes: a probe of the hdhfr gene and a ~800 bp 
fragment of the 5′UTR of PBANKA_0508000 located on chromosome 5 [48]. To show 
correct integration of the construct pL1462 containing the tgdhfr SM the PFG-separated 
chromosomes were hybridized with a probe recognizing the 3’-UTR of pbdhfr [44].  PCR 
primers used to confirm correct integration of the constructs are listed in Table S2.
Mosquito infection, analysis of oocysts and preparation and injection of 
sporozoites
Infection of A. stephensi mosquitoes, collection and counting of sporozoites by manual 
dissection of mosquito salivary glands (at day 21 days after feeding) were performed as 
described [22, 26]. Mosquitoes were kept at a temperature of 21°C and 80% humidity. 
Salivary glands were collected in RPMI medium, homogenized and filtered (40 µm Falcon, 
Corning, Amsterdam, NL). The free sporozoites were counted in a Bürker counting chamber 
using phase-contrast microscopy. For intravenous (IV) administration, sporozoites were 
suspended in RPMI-1640 medium and per mouse 200 μl was injected into the tail vein.
Determination of parasite liver load and prepatent period after infection, 
immunization or challenge
Parasite liver loads in live mice, after infection, immunization or challenge, were 
quantified by real time in vivo imaging as previously described [49]. Time and dose 
schedules of immunization and challenge by intravenous injection of sporozoites are 
indicated in the Results section and in the Figures. Parasite liver loads were visualized 
and quantified by measuring luciferase activity of parasites in whole bodies of mice at 
44, 56 and 65 h after injection of sporozoites using the IVIS Lumina II Imaging System 
(Perkin Elmer Life Sciences, Waltham, USA). During measurements mice were anesthetized 
using the isofluorane-anesthesia system (XGI-8, Caliper Life Sciences, Hopkinton, USA). 
D-luciferin was dissolved in PBS (100 mg/kg; Caliper Life Sciences, USA) and 60 µl injected 
subcutaneously in the neck. Measurements were performed within 8 min after the injection 
of D-luciferin. Quantitative analysis of bioluminescence of whole bodies was performed by 
measuring the luminescence signal intensity (RLU; relative light units) using the ROI (region 
of interest) settings of the Living Image® 4.5.5 software. Mice were monitored for blood-
stage infections by Giemsa-stained blood smears made at day 4 to 30 after infection or 
challenge. The prepatent period (measured in days after sporozoites challenge) is defined 
as the day when a blood-stage infection with a parasitemia of 0.5–2% is observed [48]. 
Analysis of liver stage development in-vitro 
Sporozoites were isolated from salivary glands of infected A. stephensi mosquitoes 21 days 
after an infectious blood meal as described above. The human-hepatoma cell line Huh7 












(5 × 104) were added to monolayers of Huh7 cells on coverslips in 24 well plates (with 
a confluency of 80–90%) in ‘complete’ RPMI supplemented with 10% (vol/vol) fetal bovine 
serum (FBS), 2% (vol/vol) penicillin-streptomycin, 1% (vol/vol) GlutaMAX (Invitrogen), and 
maintained at 37°C with 5% CO2. At 24, 48 and 72 hours after infection, nuclei were 
stained with Hoechst 33342 at a final concentration of 10 µM and live imaging of mCherry-
expressing parasites and liver-stage size were measured using Leica LAS X software by 
determining the area of the parasite at its greatest circumference using the mCherry-
positive area (µm2). The following exposure times: Alexa 488/FITC: 0.7 s; mCherry: 0.7 s; 
Hoechst 0.136 s (1x gain) were used. 
 For immunofluorescence analyses of liver-stages, the infected cells at 24, 48 and 
72 h post infections were fixed with 4% paraformaldehyde in PBS for 30 min and cells 
were permeabilized with 1% Triton X-100 in PBS for 30 min at RT. The infected cells 
were incubated overnight at 4°C with the rabbit anti-P. yoelii MSP1 [50] and rat anti-P. 
falciparum AMA1 [51] as a primary antibodies in 10% fetal calf serum in PBS, washed 3 
times with PBS at RT, followed by incubation for 1 h with secondary conjugated antibodies 
anti-rabbit IgG Alexa Fluor®488 (Invitrogen) or anti-rat IgG FITC (Thermofisher). Nuclei 
were stained with the DNA-specific dye Hoechst-33342 at a final concentration of 10 μM 
(Sigma, The Netherlands) for 30 min at RT. Fixed cells were covered with 1-2 drops of 
an anti-fading agent (Vectashield), and a coverslip placed onto of the cells and sealed 
with nail polish. Stained cells were analysed for fluorescence using a Leica fluorescence 
MDR microscope (40x magnification). Pictures were recorded with a DC500 digital camera 
microscope using Leica LAS X software with the following exposure times: Alexa 488/FITC: 
0.7 s; mCherry: 0.7 s; Hoechst 0.136 s (1x gain).
Statistics
All data were analyzed using the GraphPad Prism software package 5.04 (GraphPad 
Software, Inc). For sporozoites number and in-vivo imaging (RLU) analysis, statistical 
analysis was performed using the unpaired Student’s t-test. For the survival analysis, 
statistical analyzes to determine differences in protection after challenge were performed 
using a Kaplan–Meier survival plot, and survival curves were compared using the Log-rank 
(Mantel-Cox) test. Survival was considered as the complete absence of parasites in blood. 
The significance threshold were 0.05 in all analysis.
RESULTS
Generation of five double gene-deletion mutants; removing genes with a 
reported role in late liver-stage development
To screen for genetically attenuated parasites (GAP) that fully arrest growth late during 
liver-stage development we first generated two single gene-deletion mutants lacking 
either plasmei2, hereafter called mei2,  (PBANKA_1122300) or lisp1 (PBANKA_1024600). 












and PbGEM-334115 KO, respectively [45]. These constructs are designed to replace 
the complete open reading frame (ORF) of these genes by the hdhfr::yfcu  selectable 
marker (SM) cassette by double cross-over homologous recombination. The two gene-
deletion mutants, Δmei2 and Δlisp1, were generated in the reference reporter line 
1868cl1, which expresses mCherry and luciferase under control of the constitutive hsp70 
and eef1a promoters, respectively [52]. Transfection followed by positive selection with 
pyrimethamine, cloning and genotyping of transformed parasites was performed using 
standard technologies [44], resulting in isolation of the following cloned lines 2834cl2 
(Δmei2) and 2832cl3 (Δlisp1) (Figure S1, S2). Subsequently, negative selection was applied 
by treating mice with 5-FC that were infected with parasites of the two lines. This selection 
procedure selects for parasites with the hdhfr::yfcu SM cassette removed [53]. Negative 
selection, followed by cloning, resulted in the isolation of the following cloned lines 
that are drug-selectable marker free, 2834cl2m1cl1 (Δmei2) and 2832cl3m0cl1 (Δlisp1) 
(Figure S1, S2). These two lines have been used to create the following five double gene-
deletion mutants Δmei2Δlisp2, Δmei2Δlisp1, Δmei2Δpalm, Δlisp1Δlisp2, and Δlisp1Δpalm 
(Figure S3, S4). To delete lisp2 (PBANKA_1003000) we used the construct reported in 
Annoura et al. [29], which replaces the complete lisp2 ORF by a tgdhfr SM cassette by double 
cross-over homologous recombination. To delete lisp1 and palm (PBANKA_0101100) we 
used the PlasmoGem constructs  PbGEM-334115 KO and PbGEM-266100 KO, respectively 
[45]. These constructs are designed to replace the complete ORF by the hdhfr::yfcu SM 
cassette. Transfection followed by positive selection with pyrimethamine, cloning and 
genotyping of transformed parasites were performed using standard technologies [44], 
resulting in isolation of the five cloned lines Δmei2Δlisp2 (2900cl3), Δmei2Δlisp1 (2901cl1), 
Δmei2Δpalm (2903cl3), Δlisp1Δlisp2 (2961cl1), and Δlisp1Δpalm (2963cl1) (Figure S3, S4). 
Parasites of all five lines showed normal, wild type (WT) blood-stage growth as determined 
during the cloning procedure (data not shown). In addition, they all produced salivary 
gland sporozoites in A. stephensi mosquitoes in numbers that that were in the range of 
WT P. berghei ANKA parasites (Table S1). 
Screening double gene-deletion mutants for liver-stage growth arrest and 
absence of blood infections 
To screen for complete liver-stage growth arrest, we infected C57BL/6 mice with 5 × 104 
sporozoites of the five double gene-deletion mutants and the single gene-deletion mutant 
Δmei2. C57BL/6 mice were selected as they are highly susceptible to infection of the liver 
by P. berghei sporozoites. In this screen the single gene-deletion mutant Δlisp2 and Δpalm 
were not included since P. berghei mutants lacking these genes have been analyzed 
previously for breakthrough blood infections [29, 37]. For Δlisp2 we previously reported 
that 43-100% of Swiss mice infected with 5 × 104 sporozoites developed blood infections, 
although with a delay in prepatent period of 2-3 days compared to mice infected with 












that 20% of C57BL/6 mice infected with 105 sporozoites developed blood infections, with 
a delay in prepatent period of 4-8 days compared to mice infected with the same number 
of WT parasites.
 We first determined parasite liver loads in mice infected with 5 × 104 Δmei2, 
Δmei2Δlisp2, Δmei2Δpalm, Δmei2Δlisp1, Δlisp1Δlisp2 and Δlisp1Δpalm sporozoites by in 
vivo imaging at 44 hours (h) after injection (Figure 1A). As an early-arresting GAP control 
we also infected mice with the same number of Δslarp sporozoites. We could measure 
parasites in the liver at 44 h in the 6 lines. At this time point the control parasites, Δslarp, 
that arrest early after invasion of hepatocytes are not detectable by in vivo imaging 
(Figure 1A). At 44 h post infection mice infected with the double gene-deletion mutants 
Δmei2Δpalm and Δmei2Δlisp1 have lower parasite liver loads compared to mice infected 
with either WT or the single gene-deletion mutant Δmei2 (Figure 1A).
Some mice infected with 5 × 104 Δmei2Δlisp1, Δlisp1Δlisp2 and Δlisp1Δpalm 
sporozoites developed blood infections, specifically 50%, 100% and 30% of the mice, 
respectively (Table 1, Figure 1A). These mice that established a blood-stage infection had 
a delay to blood-stage patency, but while Δlisp1Δlisp2-infected mice were delayed 2-3 
days longer than in WT infected mice, ΔmeiΔlisp1 and Δlisp1Δpalm were delayed by 5-9 
days (Table 1, Figure 1A). Mice infected with 5 × 104 Δmei2Δlisp2, Δmei2Δpalm and Δmei2 
sporozoites did not develop blood infections (Table 1, Figure 1A). The absence of blood 
infections in mice infected with the single gene-deletion Δmei2 was unexpected since 50% 
of the mice infected with the double gene-deletion mutant Δmei2Δlisp1 developed blood 
infections. Next we infected mice with higher doses of sporozoites (2-5 × 105) with these 
three (Δmei2Δlisp2, Δmei2Δpalm and Δmei2) mutants. At a dose of 2 × 105 sporozoites 3 
out of 10 mice infected with Δmei2 sporozoites developed blood infections with a long 
prepatent period of 12-14 days, demonstrating that parasites lacking only mei2 do not 
completely arrest in the liver (Table 1). No mice developed blood infections when infected 
with 2-3 × 105 Δmei2Δlisp2 and Δmei2Δpalm sporozoites. However, at the highest dose, 
5 × 105 sporozoites, we observed blood infections in one out of ten mice infected with 
Δmei2Δlisp2 and one out of three mice infected with Δmei2Δpalm, with prepatent periods 
of 12 and 14 days (Table 1). These observations indicate that all five double gene-deletion 
mutants are not completely attenuated in the rodent parasite P. berghei.
Analysis of liver-stage development of two double gene-deletion mutants 
with the strongest attenuation phenotype
Next we analyzed in more detail the late liver-stage development of Δmei2Δlisp2 and 
Δmei2Δpalm, the mutants with the strongest attenuation phenotype. First we analyzed 
the persistence of attenuated parasites in the liver by in vivo imaging. In WT-infected mice 
luminescence signals in livers decrease between 48 h and 52 h, as merozoites are released 
from infected hepatocytes and enter the blood circulation and at 60 h luminescence signals 












Figure 1. Parasite development in the liver and attenuation-phenotype after infection of C57BL/6 mice 
with sporozoites of different gene-deletion mutants. (A) The time line shows infection of C57BL/6 mice 
with sporozoites of gene-deletion mutants, determination of parasite liver load by in vivo imaging and 
determination of the prepatent period of blood infection. Left: Parasite liver loads in mice (n=6) at 
44 h after intravenous injection of 5 × 104 sporozoites of WT and 7 gene deletion mutants. Parasite 
liver loads were determined by measuring in vivo luciferase activity and depicted as relative light 












Table 1. Development of blood stage infections in C57BL/6 mice infected intravenously with a single 
dose of sporozoites (sporozoites) of different parasite mutants.  
Parasite line or mutant
No. of sporozoites  
per dose ( × 104) No. of mice patenta
No. of days to 
patencyb
WT 5 3/3 5
Δmei2 5 0/6 n.a.
20 3/10 9 - 10




Δmei2Δlisp1 5 3/6 12 - 14
Δmei2Δpalm 5 0/6 n.a.
30 0/5 n.a.
50 1/3 9
Δlisp1Δlisp2 5 6/6 7 - 8
Δlisp1Δpalm 5 2/6 10 - 13
a The number of mice that developed a blood stage infection
b The time of blood stage parasitemia between 0.5-2% WT - wild type; n.a. – not applicable
Δmei2Δlisp1 *p = 0.04). n.s. – not significant. Right: The Kaplan-Meier curves illustrate the prepatent 
period (day at which a parasitemia of 0.5–2% is observed). Data are shown of groups of 6 mice. 
Significance values [Log-Rank (Mantel-Cox) test]: WT vs Δmei2Δlisp2, Δmei2Δpalm, Δmei2Δlisp1, 
Δlisp1Δlisp2, Δlisp1Δpalm **p = 0.004.  (B) The time line shows infection of C57BL/6 mice with 
sporozoites of gene-deletion mutants and determination of parasite liver load by in vivo imaging. 
The graph shows parasite liver loads in mice (n=6) at different hours (h) after intravenous injection of 
5 × 104 sporozoites (44, 56 and 65 h) of 3 gene-deletion mutants. Parasite liver loads were determined 
by measuring in vivo luciferase activity and depicted as relative light units (RLU). Significance values 
(unpaired two-tailed t test): *p < 0.05; **p < 0.01; ***p < 0.001. n.s. – not significant.
cells and distributed across all organs [54]. In contrast, in mice infected with Δmei2 and 
Δmei2Δpalm parasites can still be detected in the liver at 56 and 65 h, without luminescent 
parasites in the blood circulation, although the mice had lower liver loads compared to 
44 h (Figure 1B). Specifically, liver loads at 56 h in Δmei2- and Δmei2Δpalm-infected mice 
had decreased 2-5 fold compared to 44 h and in both groups of mice we could not detect 
liver signals in 4 out of the 6 mice at 65 h. In contrast, in Δmei2Δlisp2-infected mice no 
parasites could be detected in the liver at both 56 and 65 h (Figure 1B). These observation 












infected hepatocytes are lost or removed  after 44 h, Δmei2Δpalm infected hepatocytes 
can persist up to 65 h.
Next we analyzed Δmei2Δlisp2 and Δmei2Δpalm development in cultured Huh7 
hepatoma cells.  We measured the size parasites within a hepatocyte at 24, 48 and 72 h. 
At 24 and 48 h little or no differences were observed between the size of WT parasites 
and Δmei2Δlisp2 and Δmei2Δpalm parasites (Figure 2) However, at 72 h the liver-stages 
of both mutants were significantly larger than WT liver-stages, with a mean size of 1399 
µm2 for Δmei2Δlisp2 and 1191 µm2 for Δmei2Δpalm compared to  507 µm2 or 630 µm2 
for WT parasites at 48 and 72 h, respectively (Figure 2). These observations may suggest 
that, in vitro, liver-stages of Δmei2Δlisp2 and Δmei2Δpalm can continue growing and/or 
dividing. However, in vivo we could not detect Δmei2Δlisp2 parasites in mice livers after 56 
h (Figure 1B). To examine the developmental progress of Δmei2Δlisp2 and Δmei2Δpalm 
during late liver-stage development, we examined the expression of two merozoite 
genes, msp1 and ama1, which are expressed late during liver-stage development. In P. 
berghei blood-stages the merozoite surface membrane protein MSP1 is expressed in early 
schizonts [55]  whereas the micronemal protein AMA1 is expressed in late schizonts [51]. In 
rodent Plasmodium parasites we have previously measured MSP1 expression in infected 
hepatocytes at 44 h using anti-MSP1 antibodies [56]. By immunofluorescence analyses using 
anti-MSP1 and anti-AMA1 antibodies, we found that both Δmei2Δlisp2 and Δmei2Δpalm 
liver-schizonts expressed MSP1 and AMA1 at 72 h, and this staining was comparable to 
72 h WT liver-schizonts (Figure 3). These observations indicate that the increase in size of 
parasites inside the hepatocytes at these later time points of development is associated 
with the expression of merozoite antigens, including antigens that are expressed later into 
schizont development (i.e. AMA1). 
Analysis of immunogenicity of two double gene-deletion mutants with the 
strongest attenuation phenotype
We compared the immunogenicity of the late-arresting GAPs (LA-GAPs), Δmei2Δlisp2 and 
Δmei2Δpalm, with protective immunity of an early-arresting GAP (Δb9Δslarp), using similar 
immunization protocols that have been used to compare immunogenicity of a mid-to-late 
arrester GAP with the early-arresting Δb9Δslarp GAP [57]. First, we immunized BALB/c 
mice using an immunization scheme employing single doses of 1,200 (high), 800 (medium), 
or 400 (low) sporozoites, followed by a challenge with 104 GFP-luciferase expressing WT 
sporozoites 3 weeks after immunization (Figure 4A). At 44 h after challenge, we measured 
parasite liver loads in the immunized mice by in vivo imaging. In mice immunized with 
Δmei2Δlisp2 and Δb9Δslarp, we were only able to detect liver-stage parasites in one 
Δb9Δslarp immunized animal. In contrast, 2 out of 5 mice in each of the Δmei2Δpalm 
LA-GAP immunization groups, WT liver-stage parasites could be detected in the liver at 
44 h (Figure 4B). 
All mice immunized with medium or high doses of the two LA-GAP sporozoites showed 












Figure 2. Size of liver-stage parasites of gene-deletion mutants at different time points after infection of 
hepatocytes. Upper panel: Representative images of live parasite at different time points after infection 
of Huh7 hepatocytes with sporozoites of two gene-deletion mutants, showing mCherry expression. 
Liver-stages express cytoplasmic mCherry (under control of the constitutive hsp70 promoter). Liver-
stage size was measured by determining the area of the parasite at its greatest circumference (green 
circles) using the mCherry-positive area (µm2). Nuclei of parasites and hepatocytes were stained with 
Hoechst (blue). Lower panel: Size of liver stages, determined as described above; at least 20 parasites 
were measured at each time point. Significant differences (unpaired two-tailed t-test): *p < 0.05; 
***p < 0.001;  ****p < 0.0001. n.s. – not significant. Scale bar: 10 μm.
induced complete protection at these higher doses (Figure 4C and Table 2). After the low 
dose immunization, all 5 mice immunized with LA-GAP Δmei2Δlisp2 were protected, 
whereas 2 mice developed a blood infection  after Δmei2Δpalm GAP immunization 
and 1 mouse after immunization with the early-arresting GAP (Figure 4C). As expected, 
challenging naive BALB/c mice with 10,000 WT sporozoites resulted in detectable parasite 
liver loads and all 5 mice developed blood infections with a prepatent period of 5 days 
(Figure 4B,C). As summarized in Table 2, there was no significant difference in protective 












Figure 3. Expression of merozoite proteins MSP1 and AMA1  in liver stages of gene-deletion mutants 
at 72 hours after infection of hepatocytes. Representative images of fixed liver-stages at 72 hours 
after infection of Huh7 hepatocytes with sporozoites of two gene-deletion mutants, showing MSP1 
and AMA1 expression. Liver-stages express cytoplasmic mCherry (under control of the constitutive 
hsp70 promoter). Parasites are stained with anti-MSP1 (α-MSP1; green; Alexa-488) and anti-AMA1 
antibodies (α-AMA1; green; FITC) and the nuclei of the parasite and hepatocyte are stained with 
Hoechst (blue). Scale bar: 10 μm.
to the early-arresting GAP. Interestingly, all high- and mid-dose Δmei2Δpalm immunized 
mice did not develop a WT blood-stage infection despite the detectable presence of 
WT parasites in some mice at 44 h after challenge. This indicates that WT parasites were 
cleared late from the liver in the Δmei2Δpalm immunized mice.   
We performed a second immunization experiment in BALB/c mice, aimed to identify 
potential differences in maintenance and duration of protection between the two LA-GAPs 
and the early-arresting GAP. In this experiment BALB/c mice were immunized with a single 
dose of 800 sporozoites and challenged 6 weeks later with 3 × 103 parasites. As a control, 
we challenged immunized mice with 3 × 103 sporozoites at weeks 6. In the repeat 
early challenge experiment, we again detected no parasite liver loads at 44 h after WT 
challenge in the LA-GAP Δmei2Δlisp2 and the early-arresting GAP immunized mice, but 
we detected higher WT-parasite liver loads at 44 h in the LA-GAP Δmei2Δpalm immunized 
mice (Figure 5A). These higher parasite liver load in LA-GAP Δmei2Δpalm immunized mice 
is comparable to what we observed in the first experiment (Figure 4A). Unexpectedly, in 
this experiment all immunized mice challenged after 3 weeks developed blood infections, 
although with a prepatent period delay of 2-4 days compared to naïve mice (Figure 5A; 
Table 2). This was unexpected since in the first experiment all mice that were immunized 
with a dose of 800 sporozoites were completely protected against WT challenge at 3 
weeks. The difference between the two experiments is that the first experiment was 
performed in Leiden (The Netherlands) whereas the second experiment was performed in 
Lisbon (Portugal). In both laboratory the same BALB/c mice were used (BALB/c ByJ strain 












Figure 4. Analysis of protective immunity induced by immunization of BALB/c ByJ mice with 
sporozoites) of gene-deletion mutants (challenge of mice after 3 weeks; Leiden experiment). (A) 
The time line shows immunization of BALB/c  mice with sporozoites of gene-deletion mutants, 
challenge of mice with wild type (WT) sporozoites,  determination of WT parasite liver load by in 
vivo imaging and determination of the prepatent period of blood infection. (B) Parasite liver loads 
in mice (n=5) at 44 h after challenge of the immunized mice with 1 × 104 WT sporozoites. Parasite 
liver loads were determined by measuring in vivo luciferase activity and depicted as relative light 
units (RLU). (C) The Kaplan-Meier curves illustrate the prepatent period (day at which a parasitemia 
of 0.5–2% is observed). Data are shown of groups of 5 mice.  Significance values [Log-Rank (Mantel-
Cox) test]: Naive vs Δb9Δslarp, Δmei2Δlisp2 and Δmei2Δpalm **p < 0.005. No significant differences 













Figure 5. Analysis of protective immunity induced by immunization of BALB/c ByJ mice with sporozoites 
of gene-deletion mutants (challenge of mice after 3 and 6 weeks; Lisbon experiment).  (A) The time 
line shows immunization of BALB/c mice with sporozoites of gene-deletion mutants, challenge of 
mice with wild type (WT) sporozoites after 3 weeks,  determination of WT parasite liver load by in 
vivo imaging and determination of the prepatent period of blood infection. Left: Parasite liver loads 
in mice (n=3) at 44 h after challenge of the immunized mice with 1 × 104 WT sporozoites. Parasite 
liver loads were determined by measuring in vivo luciferase activity and depicted as relative light units 












0.5–2% is observed). Data are shown of groups of 3 mice.  Significance values [Log-Rank (Mantel-Cox) 
test]: significant longer prepatent period of Δb9Δslarp and Δmei2Δlisp2 immunized mice compared 
to naive, non-immunized and Δmei2Δpalm immunized mice *p = 0.02.  (B) The time line shows 
immunization of BALB/c mice with sporozoites of gene-deletion mutants, challenge of mice with 
wild type (WT) sporozoites after 6 weeks,  determination of WT parasite liver load by in vivo imaging 
and determination of the prepatent period of blood infection. The graph shows Kaplan-Meier 
curves illustrating the prepatent period (day at which a parasitemia of 0.5–2% is observed). Data are 
shown of groups of 5 mice.   Significance values [Log-Rank (Mantel-Cox) test]:  Naïve vs Δb9Δslarp 
**p = 0.008; Naïve vs Δmei2Δlisp2 *p = 0.04; Naïve vs Δmei2Δpalm **p = 0.008. No significant 
differences between mice immunized with early-arresting Δb9Δslarp and mice immunized with 
Δmei2Δlisp2 and Δmei2Δpalm.
Table 2. Protective immunity after challenge with 103 wild type sporozoites of BALB/c mice immunized 
with early-arresting GAP (Δb9Δslarp) or LA-GAPs (Δmei2Δlisp2, Δmei2Δpalm) sporozoites.
Mouse strain Parasite line
No. of doses and 
sporozoite number ( × 103)
No. of mice 
patenta
No. of days to 
patencyd
BALB/c ByJ Δmei2Δlisp2 1 x 0.4 0/5b n.a.
(experiment in Leiden) 1 x 0.8 0/5b n.a.
1 x 1.2 0/5b n.a.
Δmei2Δpalm 1 x 0.4 2/5b 7
1 x 0.8 0/5b n.a.
1 x 1.2 0/5b n.a.
Δb9Δslarp 1 x 0.4 1/5b 7
1 x 0.8 0/5b n.a.
1 x 1.2 0/5b n.a.
Naïve − 5/5b 5
BALB/c ByJ Δmei2Δlisp2 1 x 0.8 3/3b 4 - 5
(experiment in Lisbon) 1 x 0.8 5/5c 4 - 16
Δmei2Δpalm 1 x 0.8 3/3b 7
1 x 0.8 4/5c 6 - 16
Δb9Δslarp 1 x 0.8 3/3b 6 - 7
1 x 0.8 4/5c 6
Naïve − 3/3b 4
− 2/2c 4
a The number of mice that developed a blood stage infection
b Mice were challenged with 1 x 104 WT sporozoites 21 days after immunization
c Mice were challenged with 3 x 103 WT sporozoites 42 days after immunization
d The time of blood stage parasitemia between 0.5-2%
n.a. – not applicable
 In the delayed challenge study, performed using 3 × 103 WT sporozoites at 6 weeks 
after immunization, we observed that most early-arresting or LA-GAP immunized mice 
develop a blood-stage infection (Figure 5B; Table 1); however, the prepatent periods are 
considerably delayed from 2-12 days compared to naïve mice. However, no significant 












and the early-arresting GAP immunized mice (Figure 5B). Only 2 mice were protected 
after delayed challenge, one in the group immunized with the early-arresting GAP and 
one in the group of LA-GAP Δmei2Δpalm immunized mice (Figure 5B). Combined these 
observations indicate the absence of large differences in immunogenicity between 
the LA-GAP and early-arresting GAP in the BALB/c model used.
Next we immunized C57BL/6 mice as these mice are known to be a more stringent 
model for inducing protective immunity against P. berghei liver-stages [58]. The C57BL/6 
mice were immunized three times at weekly intervals either with 104 (high) or 103 (low) 
sporozoites (Figure 6A). Two weeks after the final immunization mice were challenged with 
104 WT sporozoites. In the groups of mice immunized with the low dose of 103 sporozoites, 
all mice, except one (immunized with LA-GAP Δmei2Δlisp2), developed blood infections 
(Figure 6B, Table 3). Most immunized but unprotected mice developed a 2-4 days delayed 
blood-stage infection compared to naïve mice, regardless of the GAP used. There were 
no significant differences in the prolongation of the prepatent period between the mice 
immunized with 103 (low) sporozoites of the LA-GAPs or the early-arresting GAP. 
In the groups of mice immunized with the high dose of 104 sporozoites, 5 out of 7 mice 
were protected from infection when mice were immunized with the LA-GAP Δmei2Δlisp2 
and 6 out of 8 mice were protected from infection when mice were immunized with the early-
arresting GAP. However, after high dose immunization with the LA-GAP Δmei2Δpalm only 
one mouse was protected and the remainder had a 2-3 days delay to blood-stage patency 
compared to naive mice. With the high sporozoites dose (104) immunization Δmei2Δpalm 
immunized mice have significant shorter prepatent periods compared to Δmei2Δlisp2 
and the early-arresting GAP whereas no differences exist between mice immunized with 
Δmei2Δlisp2 and the early-arresting GAP (Figure 6B).
DISCUSSION
In this study we generated five different double gene-deletion mutants, removing genes 
that have been shown to play a role in late liver-stage parasite development, in order to 
create fully arrested LA-GAPs. Three out of five mutants, Δmei2Δlisp1, Δlisp1Δlisp2 and 
Δlisp1Δpalm led to breakthrough blood infections in mice after infection with a (low) dose 
of 5 × 104 sporozoites. In all these mutants lisp1 was one of the two deleted genes. LISP1 
has been reported as not playing a role in liver-schizont maturation or in the formation 
of the merozoites, but rather as being involved in the release of liver merozoites [38]. 
Parasites lacking LISP1 expression display a 10-15 fold reduction in the number of 
merozoites released from hepatocytes and ensuing capacity to generate a blood-stage 
infection in mice [38]. In our study 50% of the mice infected with the double gene-deletion 
mutant Δmei2Δlisp1 developed blood-stage infections after inoculation with 5 × 104 
sporozoites. This was unexpected since the same number of sporozoites of the Δmei2 
single gene-deletion mutant did not lead to a blood-stage infection. This could be due 












mice with blood-stage infections would have been detected. However, while the single-
gene deletion mutants lacking either lisp2, lisp1 or palm are known to be only partially 
arrested in the liver [29, 37, 38], it has been reported that P. yoelii mutants lacking mei2 
have a very strong attenuation phenotype and blood infections were only observed in 
mice infected with very high doses of sporozoites [41, 43]. Therefore,  it is possible that 
the deletion of lisp1 (a gene responsible for parasite release from hepatocytes) in addition 
to mei2 (which appears to affect parasite nuclear division and merozoite formation) could 
have resulted in parasites that are retained within the infected hepatocyte for a longer 
period of time, allowing for some infectious merozoites to form and give gave rise to 
the blood-stage infections.
The combination of deleting mei2 with either lisp2 or palm resulted in mutants 
that showed the strongest attenuation phenotype. The additive effect on the level of 
attenuation of combining lisp2 or palm with mei2 was demonstrated when mice were 
infected with 2 × 105 sporozoites. In these experiments we were unable to detect blood-
Figure 6. Analysis of protective immunity induced by immunization of C57BL/6 mice with sporozoites 
of gene-deletion mutants. (A) The time line shows immunization of C57BL/6 mice with 3 doses 
of sporozoites of gene-deletion mutants, challenge of mice with wild type (WT) sporozoites, 
determination of WT parasite liver load by in vivo imaging and determination of the prepatent period 
of blood infection. The graph shows the parasite liver loads in mice (n =7 - 8) at 44 h after challenge 
of the immunized mice with 1 × 104 WT sporozoites. Mice were immunized with 3 doses of either 
104 or 103 sporozoites.  Parasite liver loads were determined by measuring in vivo luciferase activity 
and depicted as relative light units (RLU). Significance values (unpaired two-tailed t test): Naive vs 
1,000 Δb9Δslarp *p = 0.017; Naive vs 1,000 Δmei2Δlisp2 **p = 0.008; Naive vs 1,000 Δmei2Δpalm 
**p = 0.001; Naive vs 10,000 Δmei2Δpalm ***p = 0.0002). (B) The Kaplan-Meier curves illustrate 
the prepatent period (day at which a parasitemia of 0.5–2% is observed). Data are shown of groups 
of 7 - 8 mice.  Significance values [Log-Rank (Mantel-Cox) test]: Naive vs Δb9Δslarp, Δmei2Δlisp2 and 
Δmei2Δpalm ***p < 0.001.
Table 3. Protective immunity after challenge with 103 wild type sporozoites of C57BL/6 mice immunized 
with early-arresting GAP (Δb9Δslarp) or LA-GAPs (Δmei2Δlisp2, Δmei2Δpalm) sporozoites.
Mouse strain Parasite line
No. of doses and sporozoite 
number ( × 103)
No. of  
mice patenta
No. of days to 
patencyc
C57BL/6 Δmei2Δlisp2 3 x 1.0 7/8b 4 - 6
3 x 10 2/7b 6 - 8
Δmei2Δpalm 3 x 1.0 8/8b 4 - 8
3 x 10 7/8b 6
Δb9Δslarp 3 x 1.0 8/8b 4 - 7
3 x 10 2/8b 6
Naïve − 5/5b 4
a The number of mice that developed a blood stage infection 
b Mice were challenged with 1 x 104 WT sporozoites 21 days last after immunization























stage infections after infection with either Δmei2Δlisp2 or Δmei2Δpalm, whereas 30% 
of the mice established a blood-stage infection when infected with the same number 
of Δmei2 sporozoites. The additive effect on attenuation of combining lisp2 and mei2 
was also recently reported in P. yoelii, where Δmei2Δlisp2 infected mice did not establish 
blood-stage infections, following injection of up to 5 × 105 sporozoites, whereas 3 out 
of 30 mice infected with 2 × 105 sporozoites of the P. yoelii Δmei2 mutant did produce 
blood-stage infections [43]. The additive effects may be explained by the different roles 
the three proteins have on the full maturation of parasite liver-stages. MEI2 is predicted 
to be a RNA binding protein and is located in distinct cytoplasmic structures reminiscent 
of RNA-storage ‘P-bodies’ [41]. P. yoelii liver-stage schizonts lacking this protein exhibited 
an abnormal DNA segregation phenotype and failed to form merozoites [41]. PALM is 
a Plasmodium apicoplast protein and its absence in rodent parasites affects merozoite 
formation in late liver-schizonts, with reduced merozoite segregation and merosome 
formation [37]. LISP2 has been shown to be specifically expressed during parasite liver-
stages and is present in the parasitophorous vacuole (PV) that surround the parasites 
and also in the cytoplasm of infected hepatocytes. Absence of this protein also results 
in reduced and delayed merozoite formation, as observed for mutants lacking MEI2 and 
PALM [59], and although all three proteins affect correct merozoite formation, their distinct 
cellular localization indicates that may play diverse roles in different biological processes. 
Given that P. yoelii mutants lacking both mei2 and lisp2 [43] did not result 
in a breakthrough blood infection even after 5 × 105 sporozoites, our observed 
a breakthrough blood infection in one out of ten mice infected with 5 × 105 P. berghei 
Δmei2Δlisp2 sporozoites was unexpected. However, differences in attenuation phenotype 
between identical P. yoelii and P. berghei gene-deletion mutants have been reported in 
previous studies. For example, P. yoelli mutants lacking the gene encoding β-ketoacyl-
ACP synthase II gene (fabb/f) show a much stronger attenuation phenotype [33] than 
P. berghei mutants lacking the orthologous fabb/f gene [34, 56]. Interestingly, while 
both P. berghei and P. yoelii lacking fabb/f show varying degrees of attenuation in liver-
stage development, P. falciparum parasites lacking this gene are unable to complete 
development in the mosquito [60]. Further, while a complete attenuation phenotype has 
been reported for P. yoelii parasites lacking two genes, p52 and p36, encoding proteins 
critical for the formation and maintenance of the PV [28], P. berghei parasites lacking these 
genes are not completely attenuated and these mutants can develop blood infections 
[56]. This discrepancy in attenuation between different Plasmodium species was further 
demonstrated by the observation that P. falciparum sporozoites lacking p52 and p36 could 
produce a blood infection in humans [19]. Specifically, in a phase I clinical study where 
volunteers were exposed to bites of 200 infected mosquitoes, one out of six volunteers 
became blood-stage positive. 
Currently, only two genetically attenuated P. falciparum mutants have been generated, 
informed by studies performed in rodent malaria models, which have advanced into 












and consist of 2 or 3 gene-deletions; in these parasites slarp has been deleted in 
combination with either b9 [26] or with p52 and p36 [19]. Recently, a clinical safety study 
has been performed in human volunteers using the P. falciparum GAP lacking  slarp, p52 
and p36. Ten out of ten volunteers exposed to the bites of 150-200 triple gene-deletion 
GAP infected mosquitoes remained blood-stage negative [18]. The limited number of 
methods to rapidly and cost-effectively test the attenuation and protective efficacy of P. 
falciparum GAPs limits the direct down-selection of P. falciparum GAPs, and presently 
very few studies have been performed in humans that can confirm the predictive value of 
rodent models in assessing the attenuation level of GAPs that lack certain genes or gene 
combinations. Rodent Plasmodium parasites take about 2 days to complete liver-stage 
development while this process takes a week in P. falciparum. Thus, the deletion of liver-
stage specific genes may result in different levels of attenuation in different Plasmodium 
species. Therefore, while the deletion of mei2 in combination with either palm or lisp2 
results in very strong, but incomplete, attenuation in rodent parasites, additional studies 
in P. falciparum are required to investigate if deletion of the same combination of genes 
results in complete attenuation in P. falciparum. 
We have examined the development of the two GAPs with the strongest late-arrest 
attenuation phenotype, Δmei2Δlisp2 and Δmei2Δpalm, and compared the phenotypes 
to that of an early-arresting GAP (i.e. Δb9Δslarp). The P. berghei early-arresting GAP, 
Δb9Δslarp, has been analysed in different studies [26, 57]. This GAP lacks the expression 
of the  SLARP/SAP1 protein which is involved in gene expression in sporozoites [26, 31] 
and the B9 protein that is located in the PV, [29]; this GAP aborts development soon after 
hepatocyte invasion. The P. berghei Δb9Δslarp GAP is able to generate strong protective 
immunity against WT P. berghei challenge in both BALB/c and C57BL/6 mice [26]. In 
the present study we have shown, in vitro, that Δmei2Δlisp2 and Δmei2Δpalm liver-stage 
parasites develop into large dividing schizonts that express both early and late merozoite 
proteins, MSP1 and AMA1. Surprisingly, mature schizonts of both mutants develop into 
significantly larger parasites than WT liver-schizonts. This may suggest that these parasites 
continue growing and/or replicating aberrantly and may therefore express more antigens 
than WT parasites at late stages of development. A remarkable difference between 
the two LA-GAPs is the difference in their persistence in the liver as detected by in vivo 
imaging of luminescence signals, which indicate that Δmei2 and Δmei2Δpalm parasites 
may persist longer than Δmei2Δlisp2 parasites. Additional studies are required to identify 
the mechanisms underlying the enlargement of Δmei2Δlisp2 and Δmei2Δpalm liver-
schizonts. Despite its enhanced development in vitro, the LA-GAP Δmei2Δlisp2 cannot be 
detected in vivo in the liver at 56 h post infection, whereas Δmei2 and Δmei2Δpalm GAPs 
can still be detected up to 65 h post infection. The faster disappearance of parasites from 
the liver may result from different factors; Δmei2Δlisp2 liver-schizonts may more rapidly 
rupture in vivo, resulting in release of the non-infectious merozoites or the liver-schizonts 
may disintegrate faster and thereby losing luminescence signals. It is also possible that 












factors. Again, additional investigation is required to unravel the mechanisms underlying 
differences in persistence and clearance of LA-GAPs in the liver. 
In one study by Butler et al. [12] employing rodent malaria models, it was found that late-
arresting GAPs induce stronger protective immune responses compared to early-arresting 
GAPs. It is presumed that this increase in immunogenicity arises from the greater amount 
and repertoire of antigens present in LA-GAP compared to early-arresting parasites [12]. It 
was shown that immunization with late-arresting GAP (LA-GAP) induced greater numbers 
of a broader range of CD8+ T cells compared to early-arresting parasites. Butler et al. 
compared the immunogenicity of a P. yoelii LA-GAP lacking expression of FabB/F with an 
P. yoelii GAP lacking expression of slarp/sap1 and with radiation attenuated parasites, both 
of which arrest early after hepatocyte invasion. The higher levels of protective immunity 
induced by LA-GAP were observed in both BALB/c, Swiss Webster and C56BL/6 mice [12]. 
Based on the results of the Butler study, we anticipated that immunization of mice 
with two LA-GAPs generated in this study would also result in significantly enhanced 
protective immunity compared to the early-arresting GAP, in both BALB/c and in 
C57BL/6 mice. All the more so since the LA-GAPs Δmei2Δlisp2 and Δmei2Δpalm appear 
to continue development at late liver-stages that may result in even more antigens per 
parasite. Therefore, our observations that protective immunity induced after Δmei2Δlisp2 
and Δmei2Δpalm immunization is not significantly different compared to Δb9Δslarp 
immunization, neither in C57BL/6 nor in BALB/c mice, was highly unexpected. 
The difference between our study and the Butler study might be explained by 
differences between the early-arresting GAPs or the LA-GAPs used in the different studies. 
However, differences in immunogenicity of the early-arresting GAP seems unlikely, since 
in both studies the early-arresting GAP lack the slarp/sap1 gene, which would result in 
both mutants having a similar arrest phenotype and, likely, antigen profile. With respect 
to differences in the LA-GAP used, we do show that the Δmei2Δlisp2 and Δmei2Δpalm 
mutants develop in very large schizonts expressing proteins that include proteins expressed 
late into liver-stage development. In the Butler study an LA-GAP was used that lacks 
the fabb/f gene; rodent parasites lacking this gene arrest during the maturation of liver-
schizonts [33, 56] and it has not been reported whether these parasites are enlarged or 
persist longer in mouse livers than WT parasites. It is therefore surprising that Δmei2Δlisp2 
and Δmei2Δpalm do not induce better protective immune responses than early-arresting 
parasites, since they are likely to express the same (if not more) antigens as those found 
in parasites lacking fabb/f. 
Another possible explanation for the differences in immunogenicity between LA-GAP 
and early-arresting GAP observed in ours and the Butler study, is the use of GAPs that 
are generated in different rodent Plasmodium species. We used P. berghei to create our 
GAPs whereas Butler et al. generated the GAP lacking fabb/f in P. yoelii. Differences in 
T- or B-cell epitopes of antigens of these two species may influence the immunogenicity 
of parasites in different mouse strains. Moreover, it has been shown that these two rodent 












differences in memory CD8+ T cell-mediated immunity against liver-stage antigens [61]. It 
is also interesting to note that we observed differences in immunogenicity of our LA-GAPs 
in BALB/c mice in two different laboratories. Specifically, while in the Leiden laboratory 
were able to generate full protection in BALB/c mice after immunization with a single dose 
of 800 LA-GAPs sporozoites, none of the BALB/c mice were protected using the same 
LA-GAP dose in the Lisbon laboratory. In both laboratory the same BALB/c mice were used 
(BALB/c ByJ strain obtained from Charles River, France).
Combined, our observations indicate that (1) additional gene-deletion GAPs may need 
to be screened to identify GAPs that completely arrest during late liver-stage development 
and (2) the hypothesis that the greater the amount and diversity of antigens in a LA-GAPs 
the more likely it is to generate stronger protective immunity, requires reconsideration. 
Additional studies are required to define what immune mechanisms contribute to 
the induction, maintenance and deployment of adaptive immune response after LA-GAP 
immunization and the role of different rodent malaria parasites and different mouse 
strains in inducing protective immune responses. Using different Plasmodium species 
and employing different immunization protocols it might be possible to unveil these 
processes. These studies have important implications for the development of LA-GAPs for 
the human parasite P. falciparum. However, only by clinically evaluating of both the safety 
and the immunogenicity of LA-GAP will we be able to draw conclusions on the benefits of 
using LA-GAP compared to early-arresting GAP for vaccination. 
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Supplementary Figure S1. Generation and genotype analysis of the selectable marker free P. berghei 
single gene-deletion mutant Δmei2. (A) Schematic representation of the introduction of the hdhfr-
yfcu selectable marker (SM) cassette into the Δmei2 gene locus of the parent P. berghei parasite (line 
1868cl1). Construct pL2206 contains the SM flanked by the eef1α promoter region and the 3’-UTR 
of pbdhfr. This construct is integrated into the mei2 locus by double cross-over homologous 
recombination at the mei2 homology regions (HR1, HR2). Positive selection with pyrimethamine 
selects for parasites that have the mei2 coding sequence replaced by the SM cassette, resulting in 
parasite line 2834cl2. To remove the SM cassette from the genome of 2834cl2 parasites were selected 
(negative selection) by treatment of infected mice with 5-Fluorocytosine (5-FC). This treatment selects 
for parasites that has undergone homologous recombination between the two 3’-UTR of pbdhfr 
untranslated regions present in the integrated constructs pL2206, flanking the SM cassette and 
thereby removing the SM. This creates the SM free P. berghei Δmei2 single gene-deletion mutant 
(2834cl2m1cl1). Location of primers (p) used for PCR analysis and sizes of PCR products are shown. 
Details of primers are shown Table S2. (B) Diagnostic PCR (left panel) and Southern analysis of PFG-
separated chromosomes (right panel) confirm correct integration of construct pL2206 in parasites of 
line 2834cl2. PCR shows the presence of the hdhfr::yfcu SM (primers p3/p4); 5’ integration PCR (5’-int; 
primers p1/p2); mei2 open reading frame PCR (ORF; primers p5/p6). Primer locations and product 
sizes are shown in A and primer sequences in Table S2. Hybridization of PFG-separated chromosomes 
(chr.) with a mixture of two probes (the hdhfr probe and a control probe recognizing p25 gene on 
chromosome 5) shows the presence of the SM cassette marker in the mei2 locus on chromosome 11 
in two clones of the 2834 line and the absence of the SM in the mei2 locus on chromosome 11 in SM 























Supplementary Figure S2. Generation and genotype analysis of the selectable marker free P. berghei 
single gene-deletion mutant Δlisp1. (A) Schematic representation of the introduction of the hdhfr-yfcu 
selectable marker (SM) cassette into the lisp1 gene locus of the parent P. berghei parasite (line 1868cl1). 
Construct pL2204 contains the SM flanked by the eef1α promoter region and the 3’-UTR of pbdhfr. 
This construct is integrated into the lisp1 locus by double cross-over homologous recombination at 
the lisp1 homology regions (HR1, HR2). Positive selection with pyrimethamine selects for parasites 
that have the lisp1 coding sequence replaced by the SM cassette, resulting in parasite line 2832cl3. 
To remove the SM cassette from the genome of 2834cl2 parasites were selected (negative selection) 
by treatment of infected mice with 5-Fluorocytosine (5-FC). This treatment selects for parasites that 
has undergone homologous recombination between the two 3’-UTR of pbdhfr untranslated regions 
present in the integrated constructs pL2204, flanking the SM cassette and thereby removing the SM. 
This creates the SM free P. berghei Δ lisp1 single gene-deletion mutant (2832cl3m0cl1). Location 
of primers (p) used for PCR analysis and sizes of PCR products are shown. Details of primers are 
shown Table S2. (B) Diagnostic PCR (left panel) and Southern analysis of PFG-separated chromosomes 
(right panel) confirm correct integration of construct pL2204 in parasites of line 2832cl3. PCR shows 
the presence of the hdhfr::yfcu SM (primers p3/p4); 5’ integration PCR (5’-int; primers p1/p2); lisp1 
open reading frame PCR (ORF; primers p5/p6). Primer locations and product sizes are shown in A and 
primer sequences in Table S2. Hybridization of PFG-separated chromosomes (chr.) with a mixture of 
two probes (the hdhfr probe and a control probe recognizing p25 gene on chromosome 5) shows 
the presence of the SM cassette marker in the lisp1 locus on chromosome 10 in three clones of 
























Supplementary Figure S3. Generation and genotype analysis of the double gene-deletion mutants 
Δmei2Δlisp1, Δmei2Δlisp2 and Δmei2Δpalm. (A) Schematic representation of the introduction of 
the selectable marker (SM) cassettes (hdhfr::yfcu or tgdhfr) into the lisp2, lisp1 and palm gene loci of 
the single-gene deletion mutant Δmei2 (2834cl2m1cl1). To delete the lisp2, lisp1 and palm genes, 
the gene-deletion constructs pL1462, pL2204, and pL2205 were used, respectively. pL2204 and 
pL2205 constructs contain the hdhfr::yfcu SM flanked by the eef1α promoter region and the 3’-UTR 
of pbdhfr and pL1462 contains the dhfr gene of Toxoplasma gondii flanked by the pbdhfr promoter 
region and the 3’-UTR of pbdhfr. These constructs integrate by double cross-over homologous 
recombination at the homology regions (HR1, HR2) of lisp2, lisp1 and palm. Positive selection with 
pyrimethamine selects for parasites that have the lisp2, lisp1 and palm coding sequences replaced 
by the SM cassettes of the different constructs, resulting in parasite lines 2900cl3 (Δmei2Δlisp2), 
2901cl1 (Δmei2Δlisp1) and 2903cl3 (Δmei2Δpalm), respectively. Location of primers (p) used for 
PCR analysis and sizes of PCR products are shown. Details of primers are shown Table S2. chr. – 
chromosomes. (B) Diagnostic PCR (left panel) and Southern analysis of PFG-separated chromosomes 
(right panel) confirm correct integration of constructs pL2204, pL2205 and pL1462 in parasites of 
Δmei2 (2834cl2m1cl1). PCR shows the presence of the tgdhfr SM (primers p13/p14); the hdhfr::yfcu 
SM (primers p3/p4); 3’ integration of lisp2 PCR (3’-int; primers p15/p16); 5’ integration of lisp1 PCR 
(5’-int; primers p9/p10); 3’ integration of lisp1 PCR (3’-int; primers p11/p12); 5’ integration of palm 
PCR (5’-int; primers p17/p18); 3’ integration of palm PCR (3’-int; primers p19/p20). Primer locations 
and product sizes are shown in A and primer sequences in Table S2. Hybridization of PFG-separated 
chromosomes with a mixture of two probes (the hdhfr probe and a control probe recognizing p25 gene 
on chromosome 5) shows the presence of the SM cassette in the lisp1 and palm locus on chromosome 
10 and 1 in three clones of the 2901 and 2903 lines, respectively. For the three clones of line 2900, 
hybridization with the 3′-UTR pbdhfr probe recognizes the integrated construct on chromosome 10, 
the reporter mCherry-Luccon construct on chromosome 3, and the endogenous dhfr gene located on 























Supplementary Figure S4. Generation and genotype analysis of the double gene-deletion mutants 
Δlisp1Δlisp2, and Δlisp1Δpalm. (A) Schematic representation of the introduction of the selectable 
marker (SM) cassettes (hdhfr::yfcu or tgdhfr) into the lisp2 and palm gene loci of the single-gene 
deletion mutant Δlisp1 (2832cl3m0cl1). To delete the lisp2 and palm genes, the gene-deletion 
constructs pL1462 and pL2205 were used, respectively. Construct pL1462 contains as SM the dhfr 
gene of Toxoplasma gondii flanked by the pbdhfr promoter region and the 3’-UTR of pbdhfr. Construct 
pL2205 contains the hdhfr::yfcu SM flanked by the eef1α promoter region and the 3′-UTR of pbdhfr. 
These constructs integrate by double cross-over homologous recombination at homology regions 
(HR1, HR2) of lisp2 and palm. Positive selection with pyrimethamine selects for parasites that have 
the lisp2 and palm coding sequences replaced by the SM cassettes, resulting in parasite lines 2961cl1 
(Δlisp1Δlisp2) and 2963cl1 (Δlisp1Δpalm), respectively. Location of primers (p) used for PCR analysis 
and sizes of PCR products are shown. Details of primers are shown Table S2. chr. – chromosomes. 
(B) Diagnostic PCR (left panel) and Southern analysis of PFG-separated chromosomes (right panel) 
confirm correct integration of constructs pL1462 and pL2205 in parasites of Δlisp1 (2832cl3m0cl1). 
PCR shows the presence of the tgdhfr SM (primers p13/p14); hdhfr::yfcu SM (primers p3/p4); 
(3’ integration of lisp2 PCR (3’-int; primers p15/p16); 5’ integration of palm PCR (5’-int; primers p17/
p18); 3’ integration of palm PCR (3’-int; primers p19/p20). Primer locations and product sizes are 
shown in A and primer sequences in Table S2. Hybridization of PFG-separated chromosomes with 
a mixture of two probes (the hdhfr probe and a control probe recognizing p25 gene on chromosome 
5) shows the presence of the SM cassette marker in the lisp2 locus on chromosome 10 in three 
clones of the 2961 line. For the three clones of 2963 line, hybridization with the 3′-UTR pbdhfr probe 
recognizes the integrated construct on chromosome 1, the reporter mCherry-Luccon construct on 
chromosome 3, the endogenous dhfr gene located on chromosome 7 and the integrated lisp1 gene 
deletion construct after SM excision on chromosome 10.
Supplementary Table S1. Sporozoite production in A. stephensi mosquitoes fed with different P. berghei 
gene-deletion mutants
Parasite line / mutant
Sporozoite no. (× 103)a
Mean ± sd
WT 20.8 ± 4.2
Δmei2 15.4 ± 3.4
Δmei2Δlisp2 14,9 ± 7.7
Δmei2Δpalm 11 ± 2.9
Δmei2Δlisp1 14 (1 exp.)
Δlisp1 n.d.
Δlisp1Δlisp2 17.3 (1 exp.)
Δlisp1Δpalm 27.3(1 exp.)
a Mean number of sporozoites per mosquito
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The transmission-blocking vaccine candidate Pfs48/45 from the human malaria parasite 
Plasmodium falciparum is known to be difficult to express in heterologous systems, either 
as full-length protein or as correctly folded protein fragments that retain conformational 
epitopes. In this study we express full-length Pfs48/45 in the rodent parasite P. berghei. 
Pfs48/45 is expressed as a transgene under control of the strong P. berghei schizont-
specific msp1 gene promoter (Pfs48/45@PbMSP1). Pfs48/45@PbMSP1 schizont-infected 
red blood cells produced full-length Pfs48/45 and the structural integrity of Pfs48/45 
was confirmed using a panel of conformation-specific monoclonal antibodies that bind 
to different Pfs48/45 epitopes. Sera from mice immunized with transgenic Pfs48/45@
PbMSP1 schizonts showed strong transmission-reducing activity in mosquitoes infected 
with P. falciparum using standard membrane feeding. These results demonstrate that 
transgenic rodent malaria parasites expressing human malaria antigens maybe used as 














Efficient and conformationally-accurate expression of Plasmodium proteins in heterologous 
systems, such as yeast or bacteria, is frequently problematic resulting in misfolded or 
incorrectly modified proteins, which are often poorly expressed [1, 2]. This hampers 
the screening of Plasmodium antigens in immunization studies for their suitability as 
vaccine candidate antigens. Preclinical evaluation of Plasmodium antigens often involves 
immunizing rodents with recombinant Plasmodium proteins followed by an examination 
of induced immune responses, either in vivo using rodent models of malaria or in vitro by 
performing functional assays with human malaria parasites incubated with immune sera 
[3]. Multiple factors contribute to inefficient expression of Plasmodium proteins, such as 
the high AT content of Plasmodium genes, large size and often unique protein structure (i.e. 
encoding repeated stretches of amino acids) and unique post-translational modifications 
[1, 4]. This is particularly evident for cysteine-rich proteins where correct folding depends 
on accurate formation of disulfide bridges to form domains specific for Plasmodium 
proteins [5-7]. Transgenic rodent malaria parasites (RMP) expressing human malaria 
parasite (HMP) proteins are increasingly used to evaluate and rank order candidate malaria 
vaccines before investing in scalable manufacture to support advancement to clinical 
testing [3]. Such transgenic RMP have been used in preclinical assays to evaluate vaccine 
potential of HMP proteins, both in vivo where mice are immunized with HMP antigens and 
subsequently challenged with transgenic RMP expressing the cognate HMP or in in vitro 
assays where immune sera or antibodies are evaluated for inhibition of parasite growth or 
invasion. Both the functional complementation of RMP genes by the HMP orthologs [3] 
and analysis of HMP expression using antisera, provide evidence for correct expression of 
functional HMP proteins in transgenic RMP [8]. Based on these studies, we reasoned that 
transgenic RMP can be used as expression systems to more efficiently express, screen, 
validate and down-select HMP antigens as potential novel malaria vaccine candidates 
[2, 9]. Further, the expression of conformationally-accurate Plasmodium proteins could 
be used to generate epitope-specific monoclonal antibodies, which in turn can be used 
to better characterize the vaccine antigen. The use of RMP would circumvent many of 
the above-mentioned problems associated with expression in heterologous expression 
systems including, but not limited to, peculiarities of post-translational modifications 
and Plasmodium-specific domains involved in protein trafficking and cellular location. As 
a proof of concept, we generated transgenic P. berghei (Pb) parasites that express full 
length Pfs48/45 from P. falciparum (Pf). The Pfs48/45 protein is expressed in Plasmodium 
gametocytes and gametes [10, 11] and contains multiple cysteine-rich domains with 
multiple disulfide bonds [12-14]. These constitute distinct conformational B cell epitopes 
that can be recognized by several monoclonal antibodies some of which have transmission-
blocking (TB) activity [15]. Pfs48/45 becomes exposed on the surface of gametes once 
the parasite is taken up in blood meal by a mosquito and here the antigen can be targeted 












immunization studies has been problematic in most commonly used expression systems, 
mainly due to incorrect or insufficient protein folding, which is dependent on the correct 
formation of disulfide bridges in this cysteine-rich protein [17, 18]. The limited reactivity 
of recombinant Pfs48/45 with monoclonal antibodies against conformational epitopes of 
Pfs48/45 has indicated this misfolding [19, 20]. 
MATERIAL AND METHODS
Experimental animals and parasites
Female OF1 and C57Bl/6 mice (6 to 8 weeks old; Charles River/Janvier) and Wistar rats 
(HsdCpb:WU; 175-199 gr, Harlan Netherlands BV) were used.  All animal experiments of 
this study were approved by the Animal Experiments Committee of the Leiden University 
Medical Center (DEC 12042, 12043). The Dutch Experiments on Animal Act is established 
under European guidelines (EU directive no. 86/609/EEC regarding the Protection of 
Animals used for Experimental and Other Scientific Purposes). All experiments were 
performed in accordance with relevant guidelines and regulations. The following reference 
lines of the ANKA strain of P. berghei (Pb) were used in this study: line cl15cy1 (Janse et al., 
2006) and line GIMOpbANKA (1596cl1; RMgm-687 in www.pberghei.eu; referred to as PbWT). 
The GIMOpbANKA (1596cl1) was generated in the cl15cy1 parent line and this line expresses 
a fusion of a drug resistance gene hdhfr (human dihydrofolate reductase) and a drug 
sensitivity gene yfcu (yeast cytosine deaminase and uridyl phosphoribosyl transferase), 
the so called positive-negative selectable marker (SM), constitutively expressed by the P. 
berghei eef1α promoter stably integrated into the 230p locus [21]. 
Generation and genotyping of the transgenic parasite line, Pfs48/45@
PbMSP1
To introduce the Pfs48/45 gene (PF3D7_1346700) into the redundant p230p gene locus 
(PBANKA_0306000) of the Pb genome, we generated DNA construct pL1706. The basic 
gene insertion construct pL0046 was used, which contains the 5’ and 3’ 230p targeting 
regions, the tgdhfr/ts selectable marker (SM) cassette and an mCherry expression cassette 
under the control of the eef1α promoter with 3’ terminal sequence of pbdhfr/ts. The eef1α 
promoter was replaced by the msp1 promoter (PBANKA_0831000) using AflII and 
BamHI digestion. The msp1 promoter was amplified from genomic Pb ANKA DNA using 
primers 6145 and 6146. In addition the mCherry coding sequence (CDS) was replaced by 
the Pfs48/45 CDS using BamHI and SgrAI digestion. The Pfs48/45 CDS  was amplified from 
genomic DNA of the Pf NF54 strain using primers 5583 and 5584. This resulted in construct 
pL1706.  In order to introduce the expression construct in the genome of the parent GIMO 
PbANKA line (1596cl1) , we next removed the tgdhfr/ts SM by digestion of the plasmid 
with SbfI and  AflII. The ends of the linearized constructs were then rendered blunt using 
Klenow enzyme treatment, and re-ligated. This final construct (pL1707) were analyzed 
via restriction digestions to confirm correct assembly. Before transfection, the construct 












Parasites of line 1596cl1 were transfected with this construct (exp. 1807) using standard 
transfection technologies and transformed parasites selected by negative selection with 
5-fluorocytosine (5-FC) [21, 22]. Selected parasites were cloned by limiting dilution. 
Three independent clones have been obtained after the cloning and correct integration 
of the construct was confirmed by Southern Analysis of PFG-separated chromosomes 
(data not shown).  Mutant 1807cl2 was used for further genotype and phenotype analysis. 
Correct integration of the construct into the p230p gene locus was performed by diagnostic 
PCR-analysis and Southern analysis of pulsed field gel (PFG) separated chromosomes 
as described previously [23]. For Southern analysis, PFG-separated chromosomes were 
hybridized to a mixture of two probes, one recognizing hdhfr and one control probe, 
recognizing the p25 gene on chromosome 5 [22].
Western and IFA analyses of Pfs48/45 expression
Transgenic schizonts were obtained from short-term overnight cultures of infected blood 
obtained by cardiac puncture from rats or mice as previously described [24]. Leucocytes 
were removed from the infected blood using Plasmodipur filters before the parasites were 
put into short-term overnight culture. Schizonts from the short-term cultures were purified 
using Nycodenz gradient centrifugation, resulting in parasite populations consisting of 
>90% schizonts [24]. 
For Western analysis, purified schizont preparations were extracted in 25 mM Tris-HCl, 
pH 8.0, 150 mM NaCl, 1.0% sodium deoxycholate, and 1 mM phenylmethylsulfonyl 
fluoride. Insoluble debris was removed by centrifugation at 13,000 g for 5 min at room 
temperature (RT) and the supernatant was used for Western analysis [15].  Parasite proteins 
were separated by electrophoresis on a 12% SDS-PAGE gel and transferred to Hybond 
ECL nitrocellulose membrane (Amersham Biosciences) for 2 h at 200 mAh. Membranes 
were blocked for non-specific binding in phosphate-buffered saline (PBS) with 0.1% Tween 
20 (PBST) containing 3% skim milk (Elk, Campina, The Netherlands) overnight at 4°C. 
Blots were hybridized with 4 anti-Pfs48/45 monoclonal antibodies that recognize Pfs48/45 
epitopes I, IIb, III and V (antibodies 85RF45.1, 85RF45.2b, 85RF45.3, 85RF45.5) [14]. 
One microgram of protein was loaded in each lane and for reduced reaction, the DTT 
was added at final concentration of 10 mM [25]. After incubation with the monoclonal 
antibodies the membranes were washed with PBST and incubated for 1 hour at RT with 
horseradish peroxidase (HRP)-conjugated goat anti-rat IgG secondary antibody (Sigma-
Aldrich) and developed in Amersham ECL Western Blotting Detection Kit according to 
the manufacturer’s instructions (GE Healthcare). As a loading control, the membranes were 
also incubated with rabbit anti-P. yoelii MSP1 antibody [26], followed by incubation with 
HRP-conjugated goat anti-rabbit IgG secondary antibody (GE Healthcare).
The amount of Pfs48/45 protein in total schizont extract was estimated by quantitative 
Western blot analysis. Protein extracts of the schizont and gametocyte lysates (see above) 
and R0.10C recombinant protein were quantified using PierceTM BCA protein assay kit 












a serial dilution series (50, 25, 12.5, 6 and 3 ng) of the recombinant P. falciparum P48/45 
fused to GLURP R0 domain (R0.10C)  was loaded on the gel. Proteins were separated 
by electrophoresis and transferred  to nitrocellulose membrane as described above and 
the blot was probed with antibody 85RF45.1 (1:2000 dilution) as the primary antibody. 
The X-ray film was exposed to the membrane for 30 sec and developed using HQ 
350XT X-ray Film Processor. The optical intensity (or Optical Densitometry (OD) values) 
of the signals were quantified with a BioRad GS-800™ Calibrated Densitometer using 
Quantity One software (Bio-Rad). 
For immunofluorescence analyses (IFA), schizonts-infected red blood cells (RBC) were 
collected from short-term overnight cultures of infected mice blood described above [24]. 
The schizont-infected RBC were washed 3 times in PBS and 5 µl of packed cells resuspended 
in 1 ml PBS. 15-20 µl of this suspension was placed in a well of a 10-well black cell-line 
diagnostic microscope slide (Thermo Scientific) and allowed to air dry. The slides were fixed 
with 4% paraformaldehyde in PBS for 30 min and cells were permeabilized with 1% Triton 
X-100 in PBS for 30 min at RT. The slides were incubated overnight at 4°C with the four 
different rat anti-Pfs48/45 antibodies and rabbit anti-MSP1 antibody (described above) in 
10% fetal calf serum in PBS, washed 3 times with PBS at RT, followed by incubation for 1 
hour with secondary conjugated antibodies anti-rabbit IgG Alexa Fluor®488 (Invitrogen) 
or anti-rat IgG Alexa Fluor®594 (Invitrogen). Nuclei were stained with the DNA-specific 
dye Hoechst-33342 at a final concentration of 10 µM (Sigma, The Netherlands) for 30 min 
at RT. Fixed cells were covered with 1-2 drops of an anti-fading agent (Vectashield), and 
a coverslip placed onto of the cells and sealed with nail polish. Stained cells were analysed 
for fluorescence using a Leica fluorescence MDR microscope (100x magnification). Pictures 
were recorded with a DC500 digital camera microscope using Leica LAS X software with 
the following exposure times: Alexa: 0.7 s; Hoechst 0.136 s; bright field 0.62 s (1x gain).
Immunization with schizont-extracts and purification of IgG from 
immunized mice
For generation of the schizont-extracts for immunization, 10 Wistar rats were infected 
with either PbWT (c15cy1) or Pfs48/45@PbMSP1 parasites and at a parasitemia of 1-3% 
infected blood was collected by cardiac puncture. Leucocyte removal,  short-term 
overnight culture of infected RBC and Nycodenz gradient purification of schizonts was 
performed as described above. Purified schizont-infected RBC were divided into samples 
containing 1.1 × 109 schizont-infected RBC cells. The cells were pelleted by centrifugation 
(450 g, 8 minutes) and stored at −80°C after removal of the supernatant. 
Groups of 10 C57BL/6 mice were immunized with either PbWT (c15cy1) or Pfs48/45@
PbMSP1 schizonts by intravenous injection of 1 × 108 schizont-infected red blood cells 
(in 200 µl RPMI). Mice were immunized a total of four times, at 2 week intervals. Before 
injection, schizonts were subjected to 3 freeze (dry ice) - thaw (RT) cycles, to ensure 
parasites were killed. Fourteen days after the last immunization blood was collected from 












min). Serum was stored at −20°C until further analysis. IgG was purified from the pooled 
serum from 10 mice, by protein G affinity chromatography (Pierce, Rockford, IL) according 
to the manufacturer’s instructions and adjusted to a final concentration of 4 mg/ml in 
phosphate-buffered saline (PBS). 
Standard Membrane Feeding Assay (SMFA)
IgG purified from sera obtained from immunized mice was assessed for transmission 
reducing (TR) activity in SMFA as previously described [27, 28] using P. falciparum (Pf) 
gametocytes. Briefly, Pf gametocyte cultures (16 to 18 days old) of P. falciparum NF54 
(originally provided by Steve Hoffman, Sanaria, Rockville, MD) were adjusted to 0.15 to 0.2% 
stage V gametocytemia at 50% hematocrit. Sixty microliters of a test sample (with a defined 
concentration of purified mouse IgG) in 1x PBS was mixed with 100 µl of the gametocyte 
mixture, and the final mixture was immediately fed to 50 female Anopheles stephensi 
(Nijmegen strain, 3 to 6 days old) mosquitoes through a membrane-feeding apparatus. 
Mosquitoes were kept for 8 days and dissected (20 per sample) to count the number of 
oocysts. As assay controls both malaria-naïve human sera and an anti-Pf25 monoclonal 
antibody (4B7; [29]) were used to establish background and complete inhibition of oocyst 
formation, respectively.  Significance of inhibition (% inhibition in oocyst intensity) was 
determined by the zero-inflated negative binomial model described previously [28].
RESULTS AND DISCUSSION
In this study the coding sequence of the gene encoding Pfs48/45 (PF3D7_1346700) 
was introduced into the redundant P. berghei p230p gene locus (PBANKA_0306000) 
[3, 21, 30]. The Pfs48/45 gene was placed under control of 1.3 kb of the promoter region of 
the schizont-specific Pb msp1 gene (PBANKA_0831000). This promoter was chosen since 
msp1 is one of the highest transcribed genes in developing Pb schizonts [31] and the Pb 
schizont stage can be easily produced and purified in large quantities [24]. The transgenic 
parasite (Pfs48/45@PbMSP1) was generated by the method of GIMO transfection and 
selection [21]. Using this method transgenes can be rapidly introduced into the p230p 
gene locus in a GIMOpbANKA parent line by replacing the positive-negative selectable 
marker expression cassette by the transgene expression cassette (Supplementary M&M 
and Figure 1A). Correct replacement of the selectable marker cassette and insertion of 
the Pfs48/45 expression cassette in a cloned line of Pfs48/45@PbMSP1 (1807cl2) was 
confirmed by diagnostic PCR and Southern analysis of chromosomes separated by 
pulsed-field gel electrophoresis (Figure 1B). Analysis of the growth rate of transgenic 
Pfs48/45@PbMSP1 parasites during the cloning period demonstrated normal growth 
of blood stages, comparable to wild type (WT) PbANKA parasites (i.e. all mice (n=3) 
achieved a 0.5-2% parasitemia on day 8, after inoculation with a single infected red 
blood cell). To obtain transgenic schizonts, parasites were cultured overnight using 












We confirmed expression of Pfs48/45 in the transgenic schizonts by Western and 
immuno-fluorescence analysis using four anti-Pfs48/45 monoclonal antibodies 85RF45.1 
(45.1), 85RF45.2b (45.2b), 85RF45.3 (45.3), and 85RF45.5 (45.5). Three of these (45.1, 
45.2b and 45.3) recognize conformational epitopes (epitopes I, IIb and III respectively) in 
the C terminal region of Pfs48/45 [14]. 
In Western analysis all the antibodies recognize a protein of the expected size (48 kDa) 
in protein extracts from Pfs48/45@PbMSP1 schizonts and WT Pf gametocytes but not in 
extracts from a Pb line that does not express Pfs48/45 (i.e. GIMOpbANKA line 1596cl1). As 
a positive control, recombinant protein that contains a fragment of P. falciparum Pfs48/45 
fused to the GLURP R0 domain (R0.10C) was included and as expected a 150 kDa band 
was present after probing with monoclonal antibodies 45.1, 45.2b and 45.3 but was 
not present after probing with 45.5 (Figure 1C) [32]. We next examined the presence of 
Pfs48/45 epitopes using the anti-Pfs48/45 antibodies by immuno-fluorescence assay (IFA) 
(Figure 1D). All antibodies recognized Pfs48/45 produced in the Pfs48/45@PbMSP1 
schizonts and did not react with proteins of WT Pb schizonts (Figure 1C and 1D). These 
results demonstrate that transgenic Pb schizonts can effectively express full length 
Figure 1. Generation, genotype and phenotype analyses of Pfs48/45@PbMSP1, a transgenic P. 
berghei parasite expressing P. falciparum P48/45 in schizonts. (A) Schematic representation of 
the introduction of the Pfs48/45-expression cassette into the GIMOpbANKA parasite (line 1596cl1). 
Construct pL1707 contains the Pfs48/45 gene flanked by the msp1 promoter region and the 3’ pbdhfr 
UTR. This construct is integrated into the modified P. berghei 230p locus of GIMOpbANKA that contains 
the hdhfr::yfcu selectable marker (SM) cassette  by double cross-over homologous recombination 
at the homology regions (230p; grey boxes). Negative selection with 5-FC selects for parasites that 
have the SM cassette replaced by the Pfs48/45 expression cassette. Location of primers used for PCR 
analysis and sizes of PCR products are shown. (B) Diagnostic PCR (upper panel) and Southern analysis 
of PFG-separated chromosomes (lower panel) confirm correct integration of construct pL1707 in line 
1807cl2 parasites. PCR shows the absence of the hdhfr::yfcu marker and the presence of the Pfs48/45. 
5’ integration PCR (5’ int; primers p5/p6), 3’ integration PCR (3’ int; primers p7/p8), hdhfr::yfcu (primers 
p1/p2), Pfs48/45 (primers p3/p4). Primer locations and product sizes are shown in A and primer 
sequences in Table S1). Hybridization of PFG-separated chromosomes with a mixture of two probes 
(the hdhfr probe and a control probe recognizing p25 gene on chromosome 5) shows the removal of 
the SM cassette marker in the 230p locus on chromosome 3 in 1807cl2 parasites. (C) Western  analysis 
of Pfs48/45 expression in protein extracts of purified gametocytes of P. falciparum (Pf Gam), purified 
schizonts of wild type P. berghei (1596cl1) and purified schizonts of Pfs48/45@PbMSP1 (1807cl2). As 
a positive control, recombinant P. falciparum P48/45 fragment fused to GLURP R0 domain (R0.10C) 
was included (expected molecular size is 150 kDa). Blots were stained with 4 different anti-Pfs48/45 
antibodies (45.1-3, 45.5) that recognize different epitopes. Anti-PyMSP1 antibody staining was used 
as a loading control. (D) Immuno-fluorescence analyses of Pfs48/45 expression in purified schizonts 
of Pfs48/45@PbMSP1 (1807cl2), and  the reference parent P. berghei GIMO line (i.e. WT; 1596cl1). 
Fixed parasites were stained with four different rat anti-Pfs48/45 mAbs (45.1-3, 45.5) and rabbit anti-
PyMSP1 antibody followed by secondary conjugated  antibodies anti-rabbit IgG Alexa Fluor ® 488 
(green) or anti-rat IgG Alexa Fluor ® 594 (red). Nuclei stained with the DNA-specific dye Hoechst 
33342 (H). All pictures were recorded with the same exposure/gain times; anti-rabbit IgG Alexa Fluor 
® 488 (green) 0.7 s; anti-rat IgG Alexa Fluor ® 594 (red) 0.6s; Hoechst (blue) 0.136 s; bright field 0.62 












Pfs48/45, which retains a number of conformational epitopes. Pfs48/45, like MSP1, contains 
a GPI anchor and is present at the plasma membrane of Pf gametocytes/gametes [33]. 
The immuno-fluorescence analyses indicate that Pfs48/45 was located in the cytoplasm 












fluorescence signals obtained with anti-MSP1 antibodies, which stain MSP1 at the merozoite 
plasma membrane in mature schizonts (Figure 1D). Possible reasons for this observation is 
that GPI attachment may be different between rodent and human Plasmodium parasites, 
or that the attachment of Pfs48/45 onto P. berghei merozoites would require the presence 
of other Plasmodium proteins normally present in gametocytes/gametes.
In order to estimate the proportion of Pfs48/45 present in the protein lysates of Pfs48/45@
PbMSP1 schizonts we performed a quantitative Western Blot analysis. Densitometry analysis 
of signals obtained after probing known amounts of Pfs48/45@PbMSP1 protein schizont 
lysates and a dilution series of recombinant Pfs48/45 with anti-Pfs48/45 monoclonal 45.1, 
revealed that the intensity of the schizont lysate signals corresponds to less than 1 ng of 
recombinant Pfs48/45 (Supplementary Figure S1), indicating that is between 0.25 - 0.12% 
of the total schizont lysate is Pfs48/45 (Figure 2A).
Next, we examined if Pfs48/45@PbMSP1 transgenic schizont lysate could be used to 
raise sera that could block Pf transmission in mosquitoes, presumably by Pfs48/45 specific 
antibodies. Two groups of 10 C57BL/6 mice were immunized 4 times (2 week interval) with 
lysates of 1x108  schizonts of either Pfs48/45@PbMSP1 or WT (c15cy1) parasites (Figure 
2B). Purified schizonts were inactivated by three rounds of freezing on dry ice followed 
by thawing at room temperature before immunization and schizont lysates were injected 
intravenously. Two weeks after the final immunization, serum was collected from all animals 
and a serum pool made for each group. Total IgG was isolated from the pooled sera 
and tested for transmission-reducing activity (TR activity) in standard membrane feeding 
assays (SMFA) using Pf gametocytes (Supplementary M&M). Pf gametocytes were fed 
to A. stephensi mosquitoes in the presence of IgG obtained from mice immunized with 
Figure 2. Quantification of Pfs48/45 protein in Pfs48/45@PbMSP1 schizont lysate and transmission 
reducing (TR) activity of IgG isolated from mice immunized with Pfs48/45@PbMSP1 schizont lysates. 
A. Pfs48/45@PbMSP1 schizont lysates (500 & 250 ng), P. falciparum gametocytes (Pf Gam.; 500 
ng) and P. berghei WT schizont lysate (PbWT; 500 ng) were analyzed in Western blot analysis using 
anti-Pfs48/45 monoclonal 85RF45.1 (1:2000). Densitometry analysis was performed on signals after 
probing Pfs48/45@PbMSP1 schizont lysate (500 ng) and a dilution series (50, 25, 12.5, 6 and 3 ng) of 
recombinant Pfs48/45 (r48/45; R0.10C) with antibody 45.1. The Table shows the calculated Pfs48/45 
protein content (ng) and the percentage of Pfs48/45 protein in parasite samples; see Supplementary 
Figure S1 for determination of Pfs48/45 in samples. *quantification performed after subtraction 
of background (b/g) Optical Densitometry (OD) values and **quantitation based on regression 
curve calculations (see Supplementary Figure S1). B. Timeline showing the immunization  of mice 
with extracts of Pfs48/45@PbMSP1 and PbWT schizont lysates and collection of sera for isolation 
of IgG that is tested for TR activity in standard membrane feeding assays (SMFA) of P. falciparum 
gametocytes to Anopheles stephensi mosquitoes (see C). C. Left panel: First SMFA with IgGs from 
mice immunized with purified schizonts of Pfs48/45@PbMSP1 and PbWT. TR activity was determined 
by the mean number of oocysts 8 days after feeding, and significance of inhibition was determined 
by the zero-inflated negative binomial model described previously [28]. Right panel: Second SMFA 
with serially diluted IgGs. IgG from mice immunized with purified schizonts of Pfs48/45@PbMSP1 was 
titrated resulting in the concentrations shown in the Figure. Significant TR activity was detected until 












schizonts of either Pfs48/45@PbMSP1 or WT. In the first experiment, IgG (1500 µg/ml) from 
Pfs48/45@PbMSP1-immunized mice showed 99.8% inhibition in oocyst density (p=0.001) 
compared to the IgG obtained from WT immunized (Figure 2C). Next, TR activity was 
determined in SMFA using a dilution series of the IgG obtained from Pfs48/45@PbMSP1-












was still observed at a concentration of 187 µg/ml (p=0.014) compared to the control IgG 
(Figure 2C). The quantitative Western blot analysis (Figure 2A) indicated that is between 
0.25-0.12% of the total Pfs48/45@PbMSP1 schizont lysate was Pfs48/45 and therefore 
it is likely that the majority of the IgG from the immunized mice is not directed against 
Pfs48/45. The failure to induce TR activity of IgG of mice immunized with WT schizont lysate 
indicates that the small proportion of anti-Pfs48/45 antibodies are mediating the TR activity 
after Pfs48/45@PbMSP1 schizont lysate immunization. The strong TR activity mediated by 
the total IgG isolated from Pfs48/45@PbMSP1 immunized mice (Figure 2C), indicates that 
Pfs48/45 expressed in P. berghei can induce antibodies with potent TR activity.     
Combined, our proof-of concept studies demonstrate that transgenic Pb schizonts 
can be used as a system to produce a difficult to express HMP protein that is correctly 
folded and retains conformational epitopes of the native protein. This opens possibilities 
to use this expression system to evaluate the immunogenicity of other difficult to express 
antigens or specific domains of these parasites. Studies using sera obtained from mice 
immunized with Pf proteins expressed by transgenic Pb parasites could be used to rank-
order novel vaccine candidate antigens, not only in TB studies but also for blood-stage 
antigens using blood stage growth inhibition assays (GIA) or sporozoite-antigens using 
inhibition of sporozoite invasion (ISI) assays [3]. Moreover, the expression in transgenic 
schizonts of HMP proteins with affinity tags will allow for the purification of these HMP 
proteins from whole parasite lysate preparations and immunization with purified protein 
will mean that all of the raised immune response is due to the target antigen and will 
permit a more detailed analyses of antigen immunogenicity, for example to examine and 
clone potent inhibitory and cross-reactive B-cells/antibodies after rodent immunization 
[34]. The creation of transgenic parasites that express antigens from multiple life-cycles 
that can induce potent immune responses is also of interest to the development of whole 
organism vaccines [35]. For example, genetically attenuated sporozoite vaccines could 
be further modified to induce immune responses against multiple life cycle stages by 
expression in sporozoites and liver stages antigens of blood- or transmission–stages to 
produce a multi stage-vaccine.
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Supplementary Figure S1. Quantification of Pfs48/45 protein in Pfs48/45@PbMSP1 schizont lysate 
by Western blot analyses as shown in Figure 2A. Densitometry and regression curve analysis was 
performed on signals after probing Pfs48/45@PbMSP1 schizont lysate (500 ng) and a dilution series 
(50, 25, 12.5, 6 and 3 ng) of recombinant Pfs48/45 fusion protein (r48/45; R0.10C) with antibody 
45.1. Regression analysis based on the dilution series of recombinant Pfs48/45 fusion (R0.10C). 
Optical densitometry (OD) values of signals before and after *background (b/g) subtraction and 
the calculated protein content and the percentage of Pfs48/45 protein of the total amount of protein 
in the P. falciparum gametocyte (Pf Gam), P. berghei WT schizont (PbWT) and Pfs48/45@PbMSP1 
schizont lysates. ** To calculate the amount and percentage of Pfs48/45 in the protein samples we 
adjusted for the proportion of Pfs48/45 (approximately 35%) in the recombinant protein R0.10C 































































































































































































































































































































































































































In this thesis we describe a set of studies, performed using rodent models of malaria, 
aimed to identify methods to improve vaccines consisting of live attenuated sporozoites, in 
particular genetically attenuated parasites (GAP) vaccines. Studies in rodents and humans 
have shown that immunization with live-attenuated sporozoites can generate protective 
immunity, however induction of sterile protection in humans has required immunization 
with multiple vaccine doses and each dose consisting of relatively high numbers of 
sporozoites [1, 2]. Increasing the immunogenicity of whole sporozoite (wsp) vaccines can 
both reduce the number of sporozoites per dose and the number of vaccine doses. In 
the studies described in this thesis we attempted to increase GAP immunogenicity by: 
(i) adding adjuvants during GAP immunization; (ii) introducing genes encoding putative 
immunomodulatory proteins in the GAP genome to create ‘self-adjuvanting’ parasites; (iii) 
generating GAPs that arrest late into liver-stage development (LA-GAP) to increase antigen 
load and diversity during immunization; and (iv) exploring possibilities to genetically 
modify parasite to express vaccine antigens from different life cycle stages, in order to test 
the ability of parasites to induce immune responses against multiple life cycle stages and 
to inform the creation of a ‘multi-stage’ GAP vaccine.
IMPROVING GAP IMMUNIZATION BY THE ADDITION 
OF IMMUNOSTIMULATORY MOLECULES (CHAPTER 3)
While the precise mechanisms of protection mediated by immunization with attenuated 
sporozoites remain unknown, T cells appear to be critical for protection and in particular 
CD8+ T cells are thought to play a major role in eliminating infected hepatocytes. Early 
rodent studies using sporozoites attenuated by irradiation (Irr-Spz) have demonstrated 
a vital role for CD8+ T cells [3, 4]. Recent mechanistic investigations into protective immune 
responses induced by immunization with attenuated sporozoites have demonstrated 
diverse and robust immune responses that encompasses both CD8+ and CD4+ T cells, 
as well as a significant contribution from antibodies [5, 6]. Nonetheless, CD8+ T cells 
are considered to be the main effector cells in eliciting protection after sporozoites 
immunization [7].
Cancer immunotherapies have employed antibodies that target proteins on the surface 
of T cells, as treatment with these antibodies have been shown to restore, expand and 
enhance the function of tumor-reactive T cells. The antagonistic antibodies targeting 
CTLA-4 and PD-1 have been used to block inhibitory signals to T cells [8, 9], while agonistic 
antibodies targeting CD27, OX40 and 4-1BB on CD4+ and CD8+ T cells have been used 
to increase costimulatory signals [10-12]. These immunostimulatory antibodies have been 
shown to improve the control of tumors and this was associated with an increase in tumor-
specific T cell function [13]. 
 We show that treatment of mice with an agonistic antibody against the T cell 
costimulatory molecule OX40 enhances protective immunity after immunization with GAP 










and CD8+ T cell subsets, in both the liver and the spleen. In addition α-OX40 treatment 
induced the production of effector cytokine-producing T cells in the liver and spleen. 
Previously it has been shown that targeting OX40 increases the magnitude of T cell 
responses and improves T cell functionality [14, 15]. OX40 is transiently expressed on 
T cells following cognate interactions between T cell receptors (TCRs) and antigen-major 
histocompatibility (MHC) complexes on antigen presenting cells (APCs) [15]. While OX40 
is expressed on both activated CD4+ and CD8+ T cells, OX40 expression on CD4+ T cells 
is greater than CD8+ T cells and consequently α-OX40 treatment is expected to exert its 
greatest effect on CD4+ T cells [15-17]. Our analyses of T cell responses in mice immunized 
with a single dose of GAP parasites, showed an increase in total WBC numbers in the livers 
and an increase in CD4+ effector (CD44hiCD11ahi) T cells in both liver and spleen of α-OX40 
treated mice compared to untreated mice. While protective immunity after sporozoite 
immunization is thought to largely dependent on the killing infected hepatocytes by CD8+ 
T cells and IFN-γ [18-20], adoptive transfer of CD4+ T cells from GAP-immunized C57BL/6 
mice was able to provide sterile protection to 50% of naïve animals against a WT infection, 
indicating an important role for CD4+ T cells in GAP induced immunity [19]. In addition, 
protective immunity induced by sporozoites of a P. yoelii GAP, similar to the one used 
in our study, was dependent not only on CD8+ T cells but also CD4+ T cells [21]. Since 
enhancement of CD4+ T cell responses by OX40 stimulation may lead to an increase in 
humoral immunity we examined total IgG responses generated in mice after prime-boost 
GAP immunization, either with or without α-OX40 treatment. These studies revealed that 
anti-sporozoite antibodies were generated after GAP immunization and significantly more 
IgG was generated in mice immunized with GAP plus α-OX40 treatment compared to 
mice immunized with only GAP. This observation indicates that the increase in CD4+ T cells 
after α-OX40 treatment may directly contribute to B cell maturation/activation. It is known 
that CD4+ T cell help is necessary for an effective CD8+ T cell memory response against 
non-inflammatory antigens, such as tumor cells and certain pathogens that may not carry 
sufficient danger signals [22]. Indeed, we explored the possibility of adding immune-
modulatory (danger) signals into a late arresting GAP in order to increase T cells responses 
(Chapter 4). Mice depleted of CD4+ T cells during immunization with sporozoites failed 
to exhibit a robust CD8+ T cell expansion and were not protected against challenge 
[23, 24]. Murray et al. found that CD4+ T cell help was also necessary to induce protection 
after immunization with GAP sporozoites [21]. Together, our results indicate that improving 
CD4+ T cell activation enhances protective immunity against malaria. 
Future studies 
Additional studies are required to determine if CD4+ T cell stimulation and expansion after 
anti-OX40 treatment acts only to improve humoral responses targeting sporozoites or 
also enhances CD8+ T cell responses against infected liver cells. Also how the expansion 










protection requires further investigation. If this method of adjuvant treatment can be 
applied to human GAP vaccines could be determined by performing small controlled 
human malaria infection (CHMI) studies. However, the use of adjuvants with human 
malaria vaccines may be difficult to deploy in the field due to costs, applicability or side-
effects and therefore these pre-clinical studies in rodent models not only provide useful 
information of the largely unknown mechanisms underlying protective immunity but are of 
importance to select the most appropriate adjuvant to advance further. Although α-OX40 
treatment is currently in clinical trials for cancer immunotherapy, the use of antibody-based 
α-OX40 treatment for vaccines for the developing world may be unrealistic as they are 
likely to be too expensive. Other (protein based) agents that can stimulate costimulatory 
responses, including agonists of OX40 are being developed as potential adjuvants 
in vaccine development. For example, combination therapy using the protein ligand 
of OX40, OX40L, fused to a cancer vaccine have been shown to reduce breast cancer 
metastasis, by enhancing antigen specific CD4+ and CD8+ T cell responses and inhibiting 
immunosuppressive Treg responses [25]. The co-administration of proteins like OX40L 
which are likely to be cheaper and easier to produce, may therefore be more practical 
and feasible approaches to pursue. In conclusion, this study demonstrates how specific 
immune response to vaccination coupled with activation of costimulatory molecules on 
the surface of T cells, can enhance protective immunity after sporozoite immunization and 
merits further investigation to see if such approaches not only increase the magnitude 
but also the breadth of an immune responses after vaccination. Moreover, knowing that 
both formation of parasite-antigen specific CD4 and CD8 T cell responses play a role in 
the reduction of sporozoites and elimination of infected hepatocytes, we created and 
analysed GAPs that encoded immunostimulatory proteins. These so called ‘adjuvant 
GAPs’ studies are described below (Chapter 4). 
IMPROVING GAP IMMUNOGENICITY BY CREATING 
‘SELF-ADJUVANTING’ PARASITES THAT ALSO 
EXPRESS PUTATIVE IMMUNOMODULATORY 
MOLECULES (CHAPTER 4)
GAP immunization in combination with exogenous adjuvants provides useful information 
about mechanisms underlying protective immunity. Induction of protective immune 
responses by GAP immunization is dependent on sporozoites migrating to the liver and 
invading hepatocytes. However, the administration of adjuvants at the site of GAP injection 
will result in systemic distribution of the adjuvant which will therefore be considerably 
diluted at the sites where parasite antigens are taken up by antigen presenting cells (APCs), 
i.e. the liver, spleen or proximal lymph nodes [26]. In order to maximize the adjuvant effect, 
i.e. the increase of the number of APCs that have both taken up parasite antigen and have 
received adjuvant induced stimulatory signals to enhance their function, it is important 










We therefore, explored the possibility of creating GAPs that were engineered to express 
immunomodulatory proteins in sporozoites and liver stages, so called ‘adjuvant GAPs’.
Four different proteins were selected with known adjuvant activity: nontoxic cholera 
toxin B (CTB) sub-unit, mouse heat shock protein Gp96, Mycobacterium heat shock 
protein X (HspX) and Salmonella flagellin (FliC), shown to act as adjuvants in other vaccine 
studies [28-36]. The selected adjuvant molecules are thought to stimulate different Toll-like 
receptors (TLRs), which can not only improve antibody and CD4+ T cell responses but 
also promote the cross-presentation of vaccine antigens directing the immune response 
towards the formation of cytotoxic (CD8+) T cells. Parasite antigen-specific CD8+ T cells are 
considered of particular importance in detection and clearance of Plasmodium-infected 
hepatocytes [19]. However, immunization with none of the four adjuvant GAP developed 
in the present study resulted in a significant increase in protective efficacy (more than 
10-fold) compared to the unmodified PyGAP in the P. yoelli-BALB/c model employed in 
this study to measure enhanced protective immunity. 
This inability to achieve significantly higher protective immunity with the adjuvant 
GAPs could be due to a number of factors, but is unlikely to be due to a poor expression of 
the adjuvant proteins. These proteins were fused to UIS4, a protein associated with the PVM, 
which surrounds the parasites inside a hepatocyte [37]. UIS4 is strongly expressed during 
Plasmodium liver stage development [38]. Our failure to measure enhanced protective 
immune responses may be due to the inability of the selected adjuvants to induce 
protective immune responses that can more effectively detect and destroy developing 
liver stage parasites. 
The selected adjuvants are known to stimulate TLR 2 (Gp96), TLR 4 (Gp96/CTB/HSPX) 
and TLR 5 (FliC) on the plasma membrane of APCs [30, 32, 34, 39] and the selection was 
based on the hypothesis that when GAP-infected hepatocytes disintegrate and release 
parasite antigens they will also simultaneously release the adjuvant, with parasite antigens 
being taken up by APCs and the released adjuvants stimulating TLRs on the same APC. 
This would then result in increased inflammatory responses against parasite antigens 
thereby improving and increasing cellular and humoral immune responses. It is possible 
that the adjuvants selected do not stimulate the most appropriate adaptive response that 
would result in the recognition and elimination of infected liver cells. In this study we did 
not directly measure the effect of the TLR-agonists on different immune cell populations 
in immunized mice and we only measured protective immunity by determination of 
the prepatent period after challenge with WT parasites. One can speculate that either 
the adjuvants did not activate the appropriate immune cells or that those that are involved 
in removal of infected liver cells are activated but this activation is not sufficient to result in 
a more than 10-fold increase in protective immunity (i.e. 1 day or more delay in patency). 
Future studies
The failure of the adjuvant GAPS to greatly enhance protective immune responses may 










yoelli-BALB/c immunization protocol which involves immunization with a single dose of 
sporozoites of a late arresting PyGAP followed by a challenge with wild type sporozoites 
14 days later [40]. In future studies, the effect of the selected adjuvants on protective 
immunity may have been better observed after prime-boost immunization strategies 
where the re-call of expanded immunological memory responses may enhance protective 
immunity in different strains of mice. Indeed, such strategies might also be used to 
examine if immunization with the adjuvant GAP results in an increase of the duration 
of protective immune response compared to non-adjuvanted GAP. Whilst we were not 
able to detect a higher that 10-fold increase in vaccine potency, we have developed an 
immunization-challenge protocol, as well as a PyGAP GIMO mother line to rapidly create 
adjuvant GAPs, which can be used to evaluate other immunization schedules, additional 
adjuvants and/or novel enhanced GAPs. Novel adjuvant GAPs could be tested that encode 
other immunomodulatory molecules that have been characterized to enhance both anti-
microbial and tumor vaccines. In our study we focused on adjuvants that interact with TLRs 
on the APC cell surface; in case of take-up of GAP-infected hepatocytes by APC this may 
be an issue since both the adjuvant and parasites are intracellular within the phagosome of 
the APC. In this case, adjuvant signaling would be better if it were to trigger cytoplasmic 
pattern recognition receptors (PPRs) either inside the APC or, indeed, the infected cell. For 
example,  the C-terminus of flagellin has a NAIP5 ligand that would potentially activate 
intracellular sensing pathways, which could activate hepatocyte death and/or inflammatory 
cytokine production and perhaps increase the adjuvant potency [41, 42]. In Chapter 5 we 
only used the FliC portion of Salmonella flagellin that has been demonstrated to interact 
with TLR5 on the surface of APCs. In future studies we could therefore create and analyze 
a new adjuvant GAP that encodes full length flagellin to expand the adjuvant potential 
of this molecule. Manipulation, of the host immune response to direct and increase 
appropriate adaptive immune responses after vaccination is of value not only to enhance 
GAP vaccines but also other vaccines that need to generate immune responses to target 
liver infections.
THE GENERATION AND CHARACTERIZATION OF 
NOVEL LATE ARRESTING GAP (LA-GAP) (CHAPTER 5)
In contrast to the creation of early arresting-GAP, the generation of safe LA-GAPs have 
been challenging. Several genes have been identified that encode proteins that play an 
important role during late liver-stage development, deletion of those genes did not result 
in complete growth arrest in rodent models of malaria. A prerequisite for a GAP vaccine for 
humans use, is that the GAP sporozoites are unable to establish a potentially pathogenic 
blood-stage infection which requires that parasite growth is completely arrested during 
development in the liver.
We tested whether dual deletion of a variety of genes, with a role in late liver stage 










genetically attenuated rodent malaria parasites (GAPs) by deleting combinations of two 
genes from the parasite genome and screened for complete growth arrest during late 
liver development. The genes we selected for further investigation were: lisp1, lisp2, mei2 
and palm as they have been shown to encode proteins that have been shown to play an 
important role for final-stages of liver stage maturation/development [43-47]. 
We found that three GAPs, Δlisp1Δlisp2, Δmei2Δlisp1 and Δlisp1Δpalm, could produce 
blood infections in mice after infection with 5 × 104 sporozoites. In contrast no blood 
infections were observed in mice infected with Δmei2Δlisp2 and Δmei2Δpalm 5 × 104 or 
2-3 × 105 sporozoites. However, after a high dose of 5 × 105 sporozoites of either mutant, 
some mice developed a blood infection. Given that P. yoelii mutants lacking both mei2 and 
lisp2 [48] did not result in a breakthrough blood infection even after 5 × 105 sporozoites, 
it was unexpected that we observed a breakthrough blood infection in one out of ten 
mice infected with 5 × 105 P. berghei Δmei2Δlisp2 sporozoites. However, differences in 
attenuation phenotype between identical P. yoelii and P. berghei gene-deletion mutants 
have been reported in previous studies. For example, P. yoelli mutants lacking the gene 
encoding β-ketoacyl-ACP synthase II gene (fabb/f) show a much stronger attenuation 
phenotype [49] than P. berghei mutants lacking the orthologous fabb/f gene [50, 51].
We have examined the development the two GAPs with the strongest late-arrest 
attenuation phenotype, Δmei2Δlisp2 and Δmei2Δpalm and compared the phenotypes to 
that of an early-arresting GAP (i.e. Δb9Δslarp). The additive effect on the level of attenuation 
of combining lisp2 or palm with mei2 is demonstrated when we infected mice with 2 × 105 
sporozoites. In these experiments we were unable to detect blood-stage infections after 
infection with either Δmei2Δlisp2 or Δmei2Δpalm, whereas 30% of the mice established 
a blood-stage infection when infected with the same number of Δmei2 sporozoites.
The Δmei2Δlisp2 and Δmei2Δpalm mutants replicate and arrest late into liver-stage 
development as shown in vitro by the presence of large intrahepatic stages that express 
the merozoite proteins MSP1 and AMA1, and in vivo through the detection of high 
parasite liver-loads 44 hours after infection. Surprisingly, mature schizonts of both mutants 
develop into significantly larger parasites than WT liver-schizonts. This may suggest that 
these parasites continue growing and/or replicating aberrantly and may therefore express 
more antigens than WT parasites at late stages of development.
We compared the immunogenicity of Δmei2Δlisp2 and Δmei2Δpalm late-arresting 
GAPs (LA-GAPs) with immunogenicity of an early-arresting GAP (Δb9Δslarp). Immunization 
studies in both BALB/c and C57BL/6 mice showed that there were no significant differences 
in the induction of protective immunity between the two late-arresting GAPs. Moreover, 
the LA-GAPs were not significantly more protective than the early-arresting GAP. In one 
study in rodent models reported by Butler et al. [52] it was found that late-arresting 
GAPs induce stronger protective immune responses compared to early-arresting GAPs. 
It is presumed that this increase in immunogenicity arises from the greater amount and 
repertoire of antigens present in LA-GAP compared to early-arresting parasites [52]. It 










of a broader range of CD8+ T cells compared to early-arresting parasites. The difference 
between our study and the Butler study might be explained by differences between 
the early-arresting GAPs or the LA-GAPs used in the different studies. However, differences 
in immunogenicity of the early-arresting GAP seems unlikely, since in both studies 
the early-arresting GAP lack the slarp/sap1 gene, which would result in both mutants 
having a similar arrest phenotype and, likely, antigen profile. With respect to differences 
in the LA-GAP used, we do show that the Δmei2Δlisp2 and Δmei2Δpalm mutants develop 
in very large schizonts expressing proteins that include proteins expressed late into liver-
stage development. In the Butler study an LA-GAP was used that lacks the fabb/f gene; 
rodent parasites lacking this gene arrest during the maturation of liver-schizonts [49, 51] 
and it has not been reported whether these parasites are enlarged or persist longer in 
mouse livers than WT parasites and it has not been reported whether these parasites are 
enlarged or persist longer in mouse livers than WT parasites. It is therefore surprising that 
Δmei2Δlisp2 and Δmei2Δpalm do not induce better protective immune responses than 
early-arresting parasites, since they are likely to express the same (if not more) antigens as 
those found in parasites lacking fabb/f. 
Another possible explanation for the differences in immunogenicity between LA-GAP 
and early-arresting GAP observed in ours and the Butler study, is the use of GAPs that 
are generated in different rodent Plasmodium species. We used P. berghei to create our 
GAPs whereas Butler et al. generated the GAP lacking fabb/f in P. yoelii. Differences in 
T- or B-cell epitopes of antigens of these two species may influence the immunogenicity 
of parasites in different mouse strains. Moreover, it has been shown that these two rodent 
Plasmodium species differentially regulate key immune-effector pathways resulting in 
differences in memory CD8+ T cell-mediated immunity against liver-stage antigens [53].
Future studies
Currently, only two genetically attenuated P. falciparum mutants have been generated, 
informed by studies performed in rodent malaria models, which have advanced into 
clinical studies. Both of these P. falciparum GAPs arrest early after hepatocyte invasion and 
consist of 2 or 3 gene-deletions; in these parasites slarp has been deleted in combination 
with either b9  [54] or with p52 and p36 [55]. Recently, a clinical safety study has been 
performed in human volunteers using the P. falciparum GAP lacking  slarp, p52 and p36. 
Ten out of ten volunteers exposed to the bites of 150-200 triple gene-deletion GAP-
infected mosquitoes remained blood-stage negative [56]. The limited number of methods 
to rapidly and cost-effectively test the attenuation and protective efficacy of P. falciparum 
GAPs limits the direct down-selection of P. falciparum GAPs, and presently very few studies 
have been performed in humans that can confirm the predictive value of rodent models 
in assessing the attenuation level of GAPs that lack certain genes or gene combinations. 
Rodent Plasmodium parasites take about 2 days to complete liver-stage development while 
this process takes a week in P. falciparum. Thus, the deletion of liver-stage specific genes 










while the deletion of mei2 in combination with either palm or lisp2 results in very strong, 
but incomplete, attenuation in rodent parasites, additional studies in P. falciparum are 
required to investigate if deletion of the same combination of genes results in complete 
attenuation in P. falciparum. 
Based on the results of the Butler study, we anticipated that immunization of mice 
with two LA-GAPs generated in this study would also result in significantly enhanced 
protective immunity compared to the early-arresting GAP, in both BALB/c and in 
C57BL/6 mice. All the more so since the LA-GAPs Δmei2Δlisp2 and Δmei2Δpalm appear 
to continue development at late liver-stages that may result in even more antigens per 
parasite. Therefore, our observations that protective immunity induced after Δmei2Δlisp2 
and Δmei2Δpalm immunization is not significantly different compared to Δb9Δslarp 
immunization, neither in C57BL/6 nor in BALB/c mice, was highly unexpected. 
Combined, our observations indicate that (1) additional gene-deletion GAPs may need 
to be screened to identify GAPs that completely arrest during late liver-stage development 
and (2) the hypothesis that the greater the amount and diversity of antigens in a LA-GAPs 
the more likely it is to generate stronger protective immunity, requires reconsideration. 
Additional studies are required to define what immune mechanisms contribute to 
the induction, maintenance and deployment of adaptive immune response after LA-GAP 
immunization and the role of different rodent malaria parasites and different mouse 
strains in inducing protective immune responses. Using different Plasmodium species 
and employing different immunization protocols it might be possible to unveil these 
processes. These studies have important implications for the development of LA-GAPs for 
the human parasite P. falciparum. However, only by clinically evaluating of both the safety 
and the immunogenicity of LA-GAP will we be able to draw conclusions on the benefits of 
using LA-GAP compared to early-arresting GAP for vaccination. 
GENERATION OF TRANSGENIC PARASITES 
EXPRESSING ANTIGENS FROM OTHER LIFE CYCLE 
STAGES (CHAPTER 6)
In order to establish if transgenic parasites can express additional proteins and if these 
antigens are able to provoke immune responses we examined if P. berghei blood-stage 
schizonts could be used express the P. falciparum transmission blocking vaccine candidate 
antigen, Pfs48/45. The transmission-blocking vaccine candidate Pfs48/45 from the human 
malaria parasite Plasmodium falciparum is known to be difficult to express in heterologous 
systems, either as full-length protein or as correctly folded protein fragments that retain 
conformational epitopes [57, 58]. The Pfs48/45 protein is expressed in Plasmodium 
gametocytes and gametes [59, 60] and contains multiple cysteine-rich domains with 
multiple disulfide bonds [44, 61, 62]. These constitute distinct conformational B cell 
epitopes that can be recognized by several monoclonal antibodies some of which have 










thought to contribute to difficulties of expression of this protein in heterologous expression 
systems [64].
We expressed Pfs48/45 as a transgene under control of the strong P. berghei schizont-
specific msp1 gene promoter (Pfs48/45@PbMSP1). We show that these Pfs48/45@
PbMSP1 schizont-infected red blood cells not only produced full-length Pfs48/45 but also 
that Pfs48/45 retains it structural integrity, as confirmed using a panel of conformation-
specific monoclonal antibodies. We confirmed that this P. berghei expressed Pfs48/45 
could evoke antibody responses, in mice, that reduce P. falciparum development in 
the mosquito. Specifically, we showed that purified IgG isolated from mice immunized 
with transgenic Pfs48/45@PbMSP1 schizont lysate exhibited strong transmission-reducing 
activity in mosquitoes infected with P. falciparum, using standard membrane feeding. 
Quantitative Western blot analysis indicated that only 0.25-0.12% of the total Pfs48/45@
PbMSP1 schizont lysate was Pfs48/45 and therefore it is likely that the majority of 
the IgG from the immunized mice is not directed against Pfs48/45. Further, the failure 
to IgG from mice immunized with WT schizont lysate to block parasite development in 
the mosquito, indicates that the small proportion of anti-Pfs48/45 antibodies are mediating 
the transmission reducing activity after Pfs48/45@PbMSP1 schizont lysate immunization. 
These results demonstrate that transgenic rodent malaria parasites expressing human 
malaria antigens can be used as means to evaluate immunogenicity and functionality of 
difficult to express malaria vaccine candidate antigens. 
Future studies:
The proof-of concept studies in Chapter 6 demonstrate that transgenic P. berghei parasites 
can be used as a system to produce a difficult to express human Plasmodium proteins, 
which are correctly folded and retain the conformational epitopes of the native protein. 
Therefore transgenic rodent malaria parasites can be used as expression systems to more 
efficiently express, screen, validate and down-select human Plasmodium antigens as 
potential novel malaria vaccine candidates.
This P. berghei expression system may therefore be used to evaluate the immunogenicity 
of other difficult to express antigens or specific domains of these parasite antigens. 
Studies using sera obtained from mice immunized with P. falciparum proteins expressed 
by transgenic P. berghei parasites could be used to rank-order novel vaccine candidate 
antigens, not only in transmission-reduction studies but also for blood-stage antigens 
using blood stage growth inhibition assays (GIA) or sporozoite-antigens using inhibition 
of sporozoite invasion (ISI) assays [65]. Moreover, the expression in transgenic schizonts 
of human Plasmodium proteins with affinity tags would allow for the purification of 
these proteins from whole parasite lysate preparations. All of the raised immune 
response Immunization with purified protein would be due to the target antigen, and 
therefore permit a more detailed analyses of antigen immunogenicity, for example to 











Tis study demonstrates that it is possible to express vaccine antigens, from different 
life cycle stages in a genetically modified parasite and thus it opens up possibilities to 
create GAPs that express antigens from multiple life-cycles, so called multi-stage GAP 
vaccine, which could not only protective immune responses against sporozoite and liver 
stages but also to blood- and mosquito-stages. Moreover, this study suggests that it might 
be possible to express vaccine antigens from other Plasmodium strains or species, i.e. P. 
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A number of studies have shown that immunization with live, attenuated sporozoites 
can generate strong protective immunity against malaria infection in humans. The major 
challenge for sporozoite-based vaccines is to produce a highly immunogenic live-
attenuated vaccine, which requires the fewest attenuated sporozoites per dose and 
the fewest doses in order to induce sustained sterile protection against malaria in 
the field. In this thesis, we describe a set of studies performed in rodent models of 
malaria to improve malaria vaccines consisting of sporozoites of genetically attenuated 
parasites (GAPs). We attempted to increase GAP immunogenicity by: (i) adding adjuvants 
during GAP immunization; (ii) introducing genes encoding putative immunomodulatory 
proteins in the GAP genome to create ‘self-adjuvanting’ GAP; (iii) generating GAP that 
arrest late into liver-stage development (known as late-arresting GAPs, or “LA-GAPs”) to 
increase antigen load and diversity during immunization; and (iv) exploring possibilities to 
genetically modify parasite to express vaccine antigens from different life-cycle stages, in 
order to test the ability of GAPs to induce immune responses against multiple life-cycle 
stages and to inform the creation of a ’multi-stage’ GAP vaccine.
We have used well-established rodent malaria models in combination with standard 
and adapted immunization protocols in order to evaluate protective immune responses 
induced by different GAPs and immunization approaches. In addition, we also used 
a variety of well-established genetic modification technologies to create a variety of 
(transgenic) rodent malaria parasite mutants and made use of transgenic parasites that 
express luminescent and fluorescent reporter proteins to analyze parasite development. 
In Chapter 2 we provide a review on the use of transgenic malaria parasites in vaccine 
research, both for testing novel vaccines and for generation of GAP-based vaccines. 
In Chapter 3 we describe studies in which we examine if agonistic OX40 monoclonal 
antibody (OX40 mAb) treatment could be used to improve protective immunity induced by 
immunization with an LA-GAP. In cancer immunotherapies, agonistic antibodies that target 
T cell surface proteins such as CD27, OX40 (CD134) and 4-1BB (CD137) have been used to 
enhance T cell function by increasing co-stimulation. In these studies, we analyze the effect 
of agonistic OX40 monoclonal antibody treatment on protective immunity induced in mice 
immunized with GAP. We show that OX40 stimulation enhanced protective immunity after 
vaccination as shown by an increase in the number of protected mice and delay to blood-
stage infection after challenge with wild-type sporozoites. Consistent with the enhanced 
protective immunity enforced by OX40 stimulation resulted in increased expansion of 
antigen-experienced effector (CD11ahiCD44hi) CD8+ and CD4+ T cells in the liver and 
spleen, and also increased IFN-γ and TNF producing CD4+ T cells in the liver and spleen. 
In addition, GAP immunization plus α-OX40 treatment significantly increased sporozoite-
specific IgG responses. Thus, we demonstrate that targeting T cell costimulatory receptors 






GAP immunization in combination with exogenous adjuvants provides useful 
information about mechanisms underlying protective immunity. However, the use of 
such adjuvants in populations where malaria is endemic may be difficult due to cost-of-
goods, applicability or side-effects. Due to the limitations of co-injecting adjuvants with 
attenuated sporozoites, we describe in Chapter 4 studies where we explored the possibility 
of creating GAPs that express immunomodulatory proteins in sporozoites and liver stages, 
so-called ‘self-adjuvanting GAPs’. We selected four TLR agonists that can increase and 
direct adaptive immune responses and have the ability to improve cross-presentation of 
antigens as has been demonstrated in other animal and/or human studies. The selected 
adjuvant proteins are: (i) nontoxic cholera toxin B subunit from Vibrio cholerae; (ii) heat 
shock protein Gp96 of mice; (iii) heat shock protein X from Mycobacterium tuberculosis; 
and (iv) the TLR5 binding region of Salmonella typhimurium flagellin. The genes encoding 
the ‘adjuvant’ proteins were fused to a Plasmodium gene expressed in liver stages, uis4. 
UIS4 is located at the parasitophorous vacuole membrane (PVM) in infected hepatocytes. 
We fused the adjuvant proteins to a PVM protein, as it has been shown that ovalbumin 
(OVA) fused to proteins located in the PV/PVM induce stronger T cell responses than 
ovalbumin expressed in the cytoplasm of transgenic parasites. To facilitate the generation 
of multiple ‘self-adjuvanting’ lines in P. yoelii LA-GAP, we generated a GIMO locus in the P. 
yoelii fabb/f gene locus, thereby creating a novel P. yoelii GIMO GAP mother line. This 
line was used for the rapid introduction of the adjuvant fusion-transgenes into the P. yoelii 
genome without retention of a drug-selectable marker (SM). The four adjuvant GAPs were 
analysed for protective immunity using the P. yoelli-BALB/c screening model for assessing 
protective immunity after GAP immunization. When compared to immunization performed 
with non-adjuvanted P. yoelii  fabb/f GAP, we were unable to observe a significant 
(more than 10-fold) enhancement  in protection  against wild-type P. yoelii  sporozoite 
challenge after immunization with the four adjuvant GAPs. Several possible explanations 
for the inability to achieve significantly higher protective immunity with the adjuvant 
GAPs are discussed in Chapter 4. Whilst we were not able to detect a higher than 10-fold 
increase in vaccine potency, we have developed an immunization-challenge protocol, as 
well as a novel P. yoelii GIMO GAP mother line to rapidly create adjuvant GAPs, which 
can be used to evaluate other immunization schedules, additional adjuvants and novel 
enhanced GAPs. 
In Chapter 5 we explore the creation of novel LA-GAPs.  It has been shown that 
immunization of mice with GAP that arrest late during liver stage development can induce 
higher levels of protective immunity compared to immunization with GAP that arrest early 
after invasion of hepatocytes. Specifically, it has been shown that LA-GAPs induce greater 
numbers of a broader range of CD8+ T cells, which results in increased protection against 
a malaria infection compared to immunization with early-arresting GAP, most probably due 
to a greater number and repertoire of antigens expressed by LA-GAPs. Currently, three 
P. falciparum GAPs have been developed for clinical evaluation and all are early-arresting 






of early arresting-GAPs, the generation of safe LA-GAPs have been challenging. Several 
genes have been identified that encode proteins that play an important role during late 
liver stage development but deletion of those genes did not result in complete growth 
arrest in rodent models of malaria. In order to create an LA-GAP that completely arrests 
late into liver stage development and cannot establish a blood infection, we describe 
studies where we create double gene-deletion mutants using combinations of different 
genes that have a role in late liver stage development and could synergize to create 
fully arrested GAPs. Four genes, lisp1, lisp2, mei2 and palm were selected that encode 
proteins that have been shown to play an important role for final maturation of liver stages. 
We created the following double gene-deletion mutants: Δlisp1Δlisp2, Δmei2Δlisp1, 
Δlisp1Δpalm, Δmei2Δlisp2 and Δmei2Δpalm. We found that three GAPs, Δlisp1Δlisp2, 
Δmei2Δlisp1 and Δlisp1Δpalm, could produce blood infections in mice after infection 
with 5 × 104 spz. In contrast, no blood infections were observed in mice infected with 
5 × 104 or 2-3 × 105 Δmei2Δlisp2 and Δmei2Δpalm spz. However, after a high dose of 
5 × 105 spz of either mutant, some mice developed a blood infection. The Δmei2Δlisp2 
and Δmei2Δpalm mutants replicated and arrested late into liver-stage development as 
shown in in vitro cultures by large intrahepatic stages that express the merozoite proteins 
MSP1 and AMA1, and in vivo where high parasite liver-loads are detected 44 hours after 
infection. We compared the immunogenicity of Δmei2Δlisp2 and Δmei2Δpalm LA-GAPs 
with the immunogenicity of an early-arresting GAP (Δb9Δslarp). Immunization studies 
in both BALB/c and C57BL/6 mice showed that there were no significant differences in 
the induction of protective immunity between the two LA-GAPs. Moreover, the LA-GAPs 
were not significantly more protective than the early-arresting GAP. These studies indicate 
that the hypothesis that the greater the amount and diversity of antigens in an LA-GAP, 
the more likely it is to generate stronger protective immunity, requires reconsideration.
The creation of GAPs expressing vaccine antigens from different parasite life-cycle 
stages could improve GAP vaccine potency by providing stage-transcending immunity. In 
Chapter 6 we created transgenic parasites that express additional antigens, and examined 
if the introduced antigen provoked specific immune responses. Specifically, we generated 
P. berghei parasite that express the P. falciparum transmission-blocking vaccine candidate 
antigen, Pfs48/45. We expressed Pfs48/45 in P. berghei blood stages, as blood stages are 
easier to produce than sporozoites, and next we examined if these blood stage parasites 
could be used to provoke antibody responses against Pfs48/45. In addition to providing 
a template for creating ‘enhanced’ GAPs that express vaccine antigens from multiple 
parasite life-cycle stages, these studies also demonstrate the utility of P. berghei parasites 
as a P. falciparum protein expression system. Efficient and conformationally-accurate 
expression of Plasmodium proteins in heterologous systems, such as yeast or bacteria, 
is frequently problematic resulting in misfolded or incorrectly modified proteins, which 
are often poorly expressed. This hampers the screening of antigens of human malaria 
parasites in immunization studies for their suitability as vaccine candidate antigens. We 






proteins for the production of such proteins would circumvent problems associated with 
expression in heterologous expression systems, including peculiarities of post-translational 
modifications and Plasmodium-specific domains involved in protein trafficking and cellular 
location. Hence, in Chapter 6 we also describe studies where we express full-length 
Pfs48/45 in the rodent parasite P. berghei. Expression of Pfs48/45 for TB immunization 
studies has been problematic in most commonly used expression systems, mainly due to 
incorrect or insufficient protein folding, which is dependent on the correct formation of 
disulfide bridges in this cysteine-rich protein. We expressed Pfs48/45 as a transgene under 
control of the strong P. berghei schizont-specific msp1 gene promoter (Pfs48/45@PbMSP1). 
Pfs48/45@PbMSP1 schizont-infected red blood cells produced full-length Pfs48/45 and 
the structural integrity of Pfs48/45 was confirmed using a panel of conformation-specific 
monoclonal antibodies that bind to different Pfs48/45 epitopes. Sera from mice immunized 
with transgenic Pfs48/45@PbMSP1 schizonts showed strong transmission-reducing activity 
in mosquitoes infected with P. falciparum using standard membrane feeding. These results 
demonstrate that transgenic rodent malaria parasites expressing human malaria antigens 
can be used as a means to evaluate immunogenicity and functionality of difficult-to-











Verschillende onderzoeken hebben laten zien dat immunisatie met levende, verzwakte 
sporozoieten een krachtige, beschermende afweer tegen malaria infecties kan induceren. 
De grootste uitdaging in het toepassen van vaccins gebaseerd op verzwakte sporozoieten 
is het maken van een vaccin dat een duurzame, volledige bescherming tegen een malaria 
infectie kan induceren met zo weinig mogelijk sporozoieten per dosis en zo weinig mogelijk 
doses per vaccinatieregime. 
Dit proefschrift behandeld een reeks van studies uitgevoerd in knaagdiermodellen 
van malaria met als doel om malaria vaccins, die bestaan uit verzwakte sporozoieten 
van genetisch geattenueerde parasieten (GAP), te verbeteren. Wij hebben getracht 
de immunogeniciteit van de vaccins te verhogen door: (i) gebruik te maken van 
immunologische adjuvantia tijdens GAP immunisaties; (ii) introductie van genen coderend 
voor potentiele, immuun-modulerende eiwitten in het genoom van de GAP om zo ‘zelf-
adjuverende’ GAPs te ontwikkelen; (iii) het genereren van GAPs waarvan de ontwikkeling 
in het leverstadium laat tot stilstand wordt gebracht (LA-GAP; Late Arrester GAP) en 
daardoor blootstelling aan meer antigenen te bewerkstelligen gedurende de immunisatie; 
en (iv) het verder genetisch modificeren van GAPs door genen te introduceren coderend 
voor antigenen van diverse ontwikkelingsstadia van de parasiet om te onderzoeken of het 
mogelijk is om een zogenaamd ‘multi-stage’ vaccin te ontwikkelen dat een afweerreactie 
kan opwekken tegen antigenen van diverse ontwikkelingsstadia.
Wij hebben gebruik gemaakt van veelvuldig toegepaste knaagdiermalaria-modellen in 
combinatie met zowel standaard als aangepaste immunisatieprotocollen voor de evaluatie 
van beschermende afweerreacties opgewekt door vaccinaties met de verschillende GAPs 
en immunisatie-strategieën. Daarnaast hebben wij in deze studies een verscheidenheid 
aan moleculaire technieken toegepast om diverse genetisch gemodificeerde malaria 
parasieten te maken en is er gebruik gemaakt van transgene malaria parasieten die 
luminescerende en fluorescerende indicatoreiwitten tot expressie brengen om parasiet-
infecties te analyseren. In Hoofdstuk 2 wordt een overzicht gegeven van het gebruik 
genetisch gemodificeerde malaria parasieten in vaccinonderzoek, zowel voor het testen 
van nieuwe vaccins als voor het maken van GAP vaccins.
In Hoofdstuk 3 beschrijven wij studies waarin wij onderzoeken of behandeling met 
een agonistisch OX40 monoclonaal antilichaam (OX40 mAb) toegepast kan worden om 
de afweer na immunisatie met een LA-GAP te versterken. Agonistische antilichamen 
die reageren met oppervlakte-eiwitten van T cellen zoals CD27, OX40 (D134) en 4-1BB 
(CD137) worden toegepast in immunotherapieën tegen kanker waarin deze antilichamen 
door co-stimulatie de activiteit van T cellen verhogen. In deze studies hebben wij het 
effect van behandeling met OX40 mAb op de afweerreactie geanalyseerd in GAP-
geïmmuniseerde muizen. Wij tonen aan dat stimulatie met OX40 een verhoogde afweer 
induceert. Dit uit zich in een groter aantal beschermde muizen en een uitgestelde infectie 









Overeenkomstig met de verhoogde afweer, laat OX40 stimulatie een verhoogde toename 
zien van effector (CD11ahiCD44hi) CD8+ en CD4+ T cellen  in de lever en milt, alsmede 
een toename van het aantal IFN-γ en TNF producerende CD4+ T cellen in deze organen. 
GAP immunisatie in combinatie met OX40 behandeling laat bovendien een significante 
toename zien van sporozoiet-specifieke IgG reacties. Deze studies laten zien dat stimulatie 
van co-stimulatoire T cel receptoren de effectiviteit van sporozoiet-vaccins kan verbeteren.
GAP immunisatie gecombineerd met toegediende adjuvantia geeft bruikbare 
inzichten in de onderliggende mechanismen die een rol spelen in de totstandkoming 
van een beschermende afweer. Echter, het gebruik van dergelijke adjuvantia in malaria-
endemische gebieden is niet eenvoudig  vanwege de kosten, de minder gemakkelijke 
toediening en eventuele bijwerkingen die de adjuvantia teweeg kunnen brengen. Vanwege 
deze beperkingen, beschrijven wij in Hoofdstuk 4 studies waarin wij de mogelijkheden 
hebben onderzocht om zogenaamde zelf-adjuverende GAPs te ontwikkelen die immuun-
modulerende eiwitten tot expressie brengen. Vier TLR agonists werden geselecteerd op 
hun vermogen adaptieve immuunreacties te sturen en te verhogen en welke in staat zijn 
om kruispresentatie van antigenen te verbeteren zoals eerder is aangetoond in studies in 
proefdieren of mensen. De geselecteerde adjuvant-eiwitten zijn: (i) ‘nontoxic cholera toxin 
B subunit’ van Vibrio cholerae (CTB); (ii) ‘heat shock protein Gp96’ van muizen (Gp96); 
(iii) ‘heat shock protein X’ van Mycobacterium tuberculosis (HspX); en (iv) ‘TLR5 binding 
region’ van Salmonella typhimurium flagellin. De genen coderend voor deze adjuvant-
eiwtten werden gefuseerd met uis4, een gen dat tot expressie komt in het leverstadium. 
UIS4 is gelokaliseerd op het ‘parasitophorous vacuole membrane’ (PVM) in geïnfecteerde 
hepatocyten. De adjuvant-eiwitten zijn gefuseerd met een PVM-membraaneiwit omdat 
eerder is aangetoond dat ovalbumine (OVA), gefuseerd met membraan-eiwitten 
van de PVM, sterkere T cel reacties induceert dan wanneer OVA tot expressie wordt 
gebracht in het cytoplasma van transgene parasieten. Voor het maken van meerdere, 
zelf-adjuverende LA-GAP, werd een GIMO locus gegenereerd in het genoom van een 
LA-GAP van de knaagdier malaria parasiet P. yoelii voor het introduceren van transgenen, 
waardoor een nieuwe P. yoelii GIMO LA-GAP moederlijn werd gecreëerd. Deze lijn is 
gebruikt voor het eenvoudig en snel introduceren van de gefuseerde adjuvant-genen 
zonder dat selectiemarkers in het genoom aanwezig blijven. De vier resulterende zelf-
adjuverende GAP lijnen werden getest op hun vermogen een beschermende afweer te 
induceren in het P. yoelli-BALB/c screening model voor analyse van afweer tegen een 
malaria infectie na GAP immunisatie. Vergeleken met immunisaties uitgevoerd met een 
niet zelf-adjuverende P. yoelii LA-GAP, hebben we geen significante (meer dan 10-voudig) 
verhoging van beschermende afweer tegen een malaria infectie kunnen aantonen na 
immunisatie met de vier zelf-adjuverende GAPs. Verschillende mogelijke verklaringen 
hiervoor worden in Hoofdstuk 4 besproken. Alhoewel wij geen significante verbetering 
van de immunogeniciteit van GAP hebben kunnen bewerkstelligen, hebben wij wel een 
immunisatie-infectie protocol ontwikkeld alsmede een GAP GIMO moederlijn gecreëerd 








worden voor de evaluatie van nieuwe immunisatie-strategieën, additionele adjuvantia en 
nieuwe, verbeterde GAPs. 
In Hoofdstuk 5 onderzoeken wij het maken van nieuwe’ late-arrester’ GAPs (LA-GAPs). 
Er is aangetoond in muizen dat immunisatie met GAP, waarvan de ontwikkeling laat in 
het leverstadium tot stilstand komt (‘late arresters’), een hogere mate van beschermende 
immuniteit opwekt in vergelijking met immunisatie met GAP waarvan de ontwikkeling 
vroeg tot stilstand komt in levercellen. Aangenomen wordt dat LA-GAPs meer antigenen 
tot expressie brengen waardoor zij meer en een grotere verscheidenheid aan CD8 T cellen 
activeren tijdens de immunisatie. Dit resulteert in een verhoogde afweer tegen een infectie 
met malaria in vergelijking met de afweer na immunisatie met GAPs die vroeg in hun 
ontwikkeling in de lever worden geremd. Op dit moment zijn er drie P. falciparum GAPs 
ontwikkeld voor klinische evaluatie van de immunogeniciteit. Alle drie GAPs zijn echter 
GAPs die vroeg in hun ontwikkeling in het leverstadium, kort na invasie van de levercel, 
worden geremd. In tegenstelling tot de ontwikkeling van deze GAPs, is de ontwikkeling van 
LA-GAPs een grote uitdaging gebleken. Verschillende genen, coderend voor eiwitten die 
een belangrijke rol spelen in het late leverstadium,  zijn geïdentificeerd maar uitschakeling 
van deze genen in knaagdiermodellen van malaria heeft niet geresulteerd in een volledige 
remming van de ontwikkeling van de parasiet in de lever. Om een veilige LA-GAP 
te ontwikkelen die laat in zijn ontwikkeling in de levercel volledig tot stilstand komt en 
geen doorbraak kent naar de bloedstadia, beschrijven wij studies waarin wij genetisch 
gemodificeerde parasieten ontwikkelen met dubbele gen-deleties waarbij verschillende 
combinaties van genen worden uitgeschakeld. Vier genen, lisp1, lisp2, mei2 en palm werden 
geselecteerd waarvan bekend is dat ze een rol spelen in de ontwikkeling van de parasiet 
in het late leverstadium. Wij hebben de volgende dubbele gen-deletie mutanten (GAPs) 
gemaakt: Δlisp1Δlisp2, Δmei2Δlisp1, Δlisp1Δpalm, Δmei2Δlisp2 and Δmei2Δpalm. Bij drie 
GAPs, Δlisp1Δlisp2, Δmei2Δlisp1 en Δlisp1Δpalm, hebben we geconstateerd dat infectie 
van muizen met 5 × 104 sporozoieten toch resulteerde in een bloed-infectie in een aantal 
muizen. Twee andere GAPs daarentegen, Δmei2Δlisp2 en Δmei2Δpalm, lieten geen 
infecties van het bloed zien na infectie van muizen met 5 × 104 or 2-3 × 105 sporozoieten. 
Echter, na infectie met een hogere dosis van 5 × 105 sporozoieten bleken beide mutanten 
bloedinfecties te veroorzaken in sommige muizen. Wij vonden dat de ontwikkeling van 
de Δmei2Δlisp2 en Δmei2Δpalm mutanten pas laat geremd werd in leverstadium. Dit werd 
aangetoond door de aanwezigheid van grote, delende leverstadia in levercel kweken, 
die de merozoiet-specifieke eiwitten MSP1 en AMA1 tot expressie brengen en tevens 
door het aantonen van grote aantallen parasieten, in vivo in muizen, in de lever 44 uur 
na infectie. De immunogeniciteit van de Δmei2Δlisp2 en Δmei2Δpalm LA-GAPs werd 
door ons vergeleken met de immunogeniciteit van de GAP Δb9Δslarp die vroeg geremd 
wordt in ontwikkeling na invasie van lever cellen. Immunisatie-studies in zowel BALB/c en 
C57BL/6 muizen hebben aangetoond dat er geen significante verschillen zijn tussen beide 
LA-GAPs met betrekking tot hun vermogen een beschermende immuniteit te induceren. 








vroeg geremd wordt in de lever. Deze studies laten derhalve zien dat de hypothese, 
waarin wordt verondersteld dat de grotere hoeveelheid/diversiteit van antigenen van een 
LA-GAP verantwoordelijk is voor een sterkere afweerreactie in vergelijking met een GAP 
waarvan de ontwikkeling vroeg tot stilstand komt, opnieuw bekeken moet worden.  
Het creëren van GAPs die vaccin-kandidaat antigenen van diverse stadia van de 
levenscyclus van de parasiet tot expressie brengen zou de effectiviteit van het GAP 
vaccin ten goede kunnen komen door hun vermogen een immuniteit op te wekken tegen 
meerdere ontwikkelingsstadia van de parasiet. In Hoofdstuk 6 hebben we transgene 
parasieten ontwikkeld die additionele antigenen tot expressie brengen en hebben wij 
onderzocht of het geïntroduceerde antigeen specifieke immuunreacties opwekte. Meer 
specifiek, wij hebben een transgene lijn gemaakt van de knaagdier malaria parasiet 
P. berghei, die het zogenaamde ‘transmission blocking vaccine antigen’ Pfs48/45 van 
de humane parasiet P. falciparum tot expressie brengt in de bloedstadia. Dit gametocyt-
specifieke antigen werd tot expressie gebracht in de P. berghei bloedstadia omdat 
bloedstadia, in tegenstelling tot sporozoieten, makkelijker te produceren zijn. Vervolgens 
hebben we onderzocht of de transgene bloedstadia gebruikt kunnen worden voor het 
induceren van specifieke immuunreacties tegen Pfs48/45. Deze studies zijn niet alleen een 
voorbeeld voor het maken van geoptimaliseerde GAPs die vaccin antigenen van diverse 
stadia tot expressie brengen, maar laten ook zien dat P. beghei toegepast kan worden 
als expressiesysteem voor P. faciparum antigenen. Efficiënte en conformatie-accurate 
expressie van P. falciparum eiwitten in heterologe systemen, zoals gist of bacteriën, is 
vaak problematisch, resulterend in verkeerd gevouwen of niet goed gemodificeerde 
eiwitten. Dit hindert de screening van eiwitten van humane parasieten als geschikte 
vaccin-kandidaten in immunisatie studies. We hebben verondersteld dat het gebruik van 
transgene knaagdier malariaparasieten als expressiesysteem voor eiwitten van humane 
malariaparasieten de problemen geassocieerd met het gebruik van heterologe 
expressiesystemen zou kunnen omzeilen, inclusief de problemen met betrekking tot post-
translationele modificaties en expressie van Plasmodium specifieke domeinen betrokken 
bij eiwitmigratie en cellulaire lokalisatie. In Hoofdstuk 6 beschrijven we studies waarin 
we het gehele Pfs48/45 eiwit tot expressie brengen in blodstadia van de knaagdier 
malariaparasiet P. berghei. Expressie van Pfs48/45 voor immunisatiestudies in gangbare 
expressiesystemen is moeilijk gebleken, voornamelijk door incorrecte of niet voldoende 
vouwing van het eiwit, wat afhankelijk is van de correcte formatie van zwavelbruggen in dit 
cysteïne-rijke eiwit. We hebben Pfs48/45 als transgen tot expressie gebracht onder controle 
van de sterke, P. berghei schizont-specifieke msp-1 promoter (Pfs48/45@PbMSP1). Rode 
bloedcellen geïnfecteerd met Pfs48/45@PbMSP1 schizonten lieten expressie zien van het 
Pfs48/45 eiwit en de structurele integriteit van Pfs48/45 werd aangetoond met een reeks 
aan conformatie-specifieke monoclonale antilichamen gericht tegen verschillende Pfs48/45 
epitopen. Sera van muizen geïmmuniseerd met transgene Pfs48/45@PbMSP1 schizonten 
lieten, middels standaard membraanvoedingen, een sterk gereduceerde transmissie 








transgene knaagdier malariaparasieten, welke antigenen van humane malariaparasieten 
tot expressie brengen, gebruikt kunnen worden om de immunogeniciteit en functionaliteit 
te evalueren van malaria vaccin kandidaat antigenen, die in heterologe systemen moeilijk 
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